
==== Front
Signal Transduct Target Ther
Signal Transduct Target Ther
Signal Transduction and Targeted Therapy
2095-9907
2059-3635
Nature Publishing Group UK London

39300122
1958
10.1038/s41392-024-01958-2
Review Article
Pyroptosis in health and disease: mechanisms, regulation and clinical perspective
Liu Yifan 12
Pan Renjie 1
Ouyang Yuzhen 13
Gu Wangning 1
Xiao Tengfei 1
Yang Hongmin 1
Tang Ling 1
Wang Hui wanghui@hnca.org.cn

1
Xiang Bo xiangbolin@csu.edu.cn

1
Chen Pan chenpan08@csu.edu.cn

1
1 https://ror.org/025020z88 grid.410622.3 0000 0004 1758 2377 The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410013 China
2 grid.216417.7 0000 0001 0379 7164 Department of Oncology, Xiangya Hospital, Central South University, 87th Xiangya road, Changsha, 410008 Hunan province China
3 grid.216417.7 0000 0001 0379 7164 Department of Neurology, Xiangya Hospital, Central South University, 87th Xiangya road, Changsha, 410008 Hunan province China
20 9 2024
20 9 2024
2024
9 2458 5 2024
14 8 2024
26 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Pyroptosis is a type of programmed cell death characterized by cell swelling and osmotic lysis, resulting in cytomembrane rupture and release of immunostimulatory components, which play a role in several pathological processes. Significant cellular responses to various stimuli involve the formation of inflammasomes, maturation of inflammatory caspases, and caspase-mediated cleavage of gasdermin. The function of pyroptosis in disease is complex but not a simple angelic or demonic role. While inflammatory diseases such as sepsis are associated with uncontrollable pyroptosis, the potent immune response induced by pyroptosis can be exploited as a therapeutic target for anti-tumor therapy. Thus, a comprehensive review of the role of pyroptosis in disease is crucial for further research and clinical translation from bench to bedside. In this review, we summarize the recent advancements in understanding the role of pyroptosis in disease, covering the related development history, molecular mechanisms including canonical, non-canonical, caspase 3/8, and granzyme-mediated pathways, and its regulatory function in health and multiple diseases. Moreover, this review also provides updates on promising therapeutic strategies by applying novel small molecule inhibitors and traditional medicines to regulate pyroptosis. The present dilemmas and future directions in the landscape of pyroptosis are also discussed from a clinical perspective, providing clues for scientists to develop novel drugs targeting pyroptosis.

Subject terms

Molecular medicine
Drug development
Translational research
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) 82173201 U23A20456 82272758 Wang Hui Xiang Bo Chen Pan Key Research and Development of Hunan Province (No.2023DK2001); Natural Science Foudation of Hunan Province (2022JJ70020)Natural Science Foudation of Hunan Province (2024JJ3036); Hunan Cancer Hospital Climb Plan (2023NSFC-B005)Key Research and Development Program of Hunan Province (2022SK2026); Scientific Research Program of FuRong Laboratory (No.2023SK2094)Natural Science Foundation of Hunan Province (2023JJ60120); Hunan Cancer Hospital Climb Plan (ZX2021003)issue-copyright-statement© West China Hospital, Sichuan University 2024
==== Body
pmcIntroduction

Cell death is critical for homeostasis in the human body because it eliminates unwanted cells.1 Among the different cell death types, regulated cell death (RCD) is encoded by genetic information and is accompanied by normal cell senescence.2 The absence of RCD contributes to the initiation and progression of diseases, such as cancer, which is characterized by uncontrolled cell growth and immortality. Apart from immortalization, excessive cell death is also correlated with the development of disease. For example, some neurodegenerative diseases, such as Alzheimer’s disease, are associated with abnormal loss of neurons during the human aging process.3 Therefore, understanding the different RCD modes and methods of reprogramming cell death is vital for disease therapy innovations.

RCD results from complex cellular responses to different stimuli and includes multiple forms, such as apoptosis, necroptosis, pyroptosis, and ferroptosis.4 With the expansion of research on cell death building on previous scientific endeavors. Pyroptosis is regulated by inflammatory caspases, inflammasome formation, and gasdermin aggregation on the membrane, which is induced by pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and pathogen infection. Pyroptosis involves plasma membrane rupture, chromatin condensation, DNA fragmentation, intact nuclei, pore formation, cell swelling, and osmotic lysis. DAMPs such as interleukin (IL)-18, IL-1β, dsDNA, ATP, and high mobility group box 1 (HMGB1) are also released during pyroptosis.5

A holistic understanding of pyroptosis has been achieved after decades of exploration, as shown in Fig. 1. Notably, Kostura et al. and Black et al. first reported a novel enzyme called IL-1β-converting enzyme (ILE).6,7 In 1993, Yuan et al. reported that CED-3 shares similar functions with ILE.8 The ILE-CED3 enzyme family was named caspase in 1996 and is classified into two groups: inflammatory (caspase-1/4/5/11) and apoptotic (caspase-3/6/7, 2/8/9/10).9 The function and signaling pathways related to caspases were explored in subsequent years. However, pyroptosis and apoptosis were not distinguished from one another until later. For example, pyroptosis in infected macrophages was discovered in 1992 but was misclassified as apoptosis.10 Subsequent publications substantiated the pivotal and unique role of caspase-1 in bacterial-induced cell death.11 Several following studies proposed that caspase-1-mediated cell death differs from apoptosis because membrane integrity is destroyed by the inflammatory response.11–13 Later on, additional caspases, such as caspase-4/5/11, were found to be involved in what has now been coined “pyroptosis”.14 The term “pyroptosis” was first proposed in 2001 to describe this proinflammatory cell death type. Subsequently, Martinon et al. proposed the “inflammasome” concept in 2002, and further evidence identifying key components emerged in the following years, including NLRP1-CASP1 and NLRP3-ASC-CASP1.15,16 In addition to caspase-1, the function of caspase-11 in pyroptosis was reported in two studies by the Dixit group.17,18 In 2015, Feng et al. identified the effector proteins and showed that caspase-1/11/4/5 can cleave gasdermin D (GSDMD) to release its N-terminal domain.19 Dixit et al. and Han et al. proposed that GSDMD is an effector protein in pyroptosis.20,21 N-terminal GSDMD can aggregate on the membrane, forming holes that alter the intracellular osmotic pressure and lead to cell swelling until membrane fracture and cytokine release (e.g., IL-1β, IL-18).22 Shao et al. found that caspase-3 recognizes and hydrolyzes gasdermin E (GSDME) to induce pyroptosis.23 Other groups have reported a caspase-8-mediated pyroptosis pathway.24,25 These studies verified the hypothesis that the cell death pattern should not be classified by the caspase type but the substrate hydrolyzed by the caspase. Pyroptosis was classified as RCD in 2018 and is characterized by its reliance on the gasdermin protein family.2 In 2020, the mechanism through which granzyme A cleaves gasdermin B (GSDMB) and granzyme B cleaves GSDME to trigger pyroptosis were also discovered.26,27 Additional structural mechanisms and signaling pathways have been reported more recently.28,29Fig. 1 Milestones of research on the discovery and development of pyroptosis. From 1989 to 2001, pyroptosis was observed in cells, and related molecules such as IL-1β-converting enzyme (ILE) were identified. The inflammasome concept was formed and developed in the following decade. The discovery of GSDMD as an effector protein initiated the quick development of pyroptosis research with canonical, non-canonical, caspase-3/8 or granzyme-mediated pathways reported. Increasing pyroptosis studies related to specific diseases have also been performed in recent years

A close correlation between pyroptosis and disease has also been widely reported, and the gasdermin protein family’s functionality varies across cells.30,31 GSDMA is predominantly expressed within skin and epithelial tissues such as the hair follicle, epidermis, and gastric epithelium, which correlate to skin inflammation and alopecia.32,33 As for the GSDMB, it is widely expressed in the gastrointestinal epithelium, liver, and immune cells, which participates in the initiation and development of asthma and inflammatory bowel disease (IBD).34,35 The granzyme A released by CD8+ T and NK cells can activate GSDMB, leading to the pyroptosis.27 Furthermore, cancer cell pyroptosis was frequently activated by distinct molecular mechanisms relying on GSDMC and GSDME. The signal transduction after the binding of TNFα can activate the caspase-8/GSDMC pathway leading to tumor necrosis.36 In GSDME-expressing tumor cells, the granzyme B released from NK and CD8+ T lymphocytes and chimeric antigen receptor T (CAR-T) cells can cleave and activate caspase-3 and GSDME, triggering pyroptosis.37 Chemotherapy drugs also increase the expression of caspase-3 in GSDME cells, transform apoptosis into pyroptosis, and enhance anti-tumor immunity.23 However, higher GSDME expression level is correlated to unsatisfactory prognosis, indicating that GSDME may also possess the function of regulating cell proliferation rather than pyroptosis.38 Finally, GSDMD is the most widely researched protein of the gasdermin family, which can be activated by caspase-1/3/4/5/11, participating in multiple inflammatory diseases because of the immunogenic cellular content release during the pyroptosis.39 In macrophage and dendritic cells, a hyperactive caspase 1/GSDMD pathway correlates to excessive proinflammatory substance release (IL-1, IL-6, and tumor necrosis factor (TNF)-α) and an uncontrollable inflammatory status such as the cytokine release syndrome.40 From the perspective of treatment, small-molecule drugs targeting inflammasomes have increasingly emerged in the latest decade.41 Nanomaterials targeting the pyroptotic pathway have been increasingly developed and used in disease therapy.42,43 Therefore, as clinical scientists, in this review, we aimed to summarize the recent progress in the mechanism, regulation, and therapeutic perspectives of pyroptosis in disease. The current limitations and clinical dilemmas are also presented to inspire readers to propel further fundamental and clinical translational research.

Molecular mechanisms of pyroptosis

Pyroptosis is a novel type of RCD with lytic and pro-inflammatory features. Pyroptotic and apoptotic cells both exhibit chromatin condensation and DNA fragmentation, but pyroptotic cells are distinguished by cell swelling, pore formation, osmotic lysis, and release of proinflammatory contents.44–49 Other unique forms of RCD, such as necroptosis and ferroptosis, have also recently emerged.50–53 Pyroptosis and necroptosis share the outcome of inflammatory stimuli release and immune responses, but the molecular pathways involved are different.54–57 Although iron can trigger both ferroptosis and iron-induced pyroptosis, ferroptosis is characterized by phospholipid peroxidation as a unique mode of cell death.58–61 A comparison of key aspects of apoptosis, necroptosis, ferroptosis, and pyroptosis, involving inducing factors, biochemical events, cell morphology, and cell release, is summarized in Table 1.Table 1 Comparison between pyroptosis, apoptosis, necroptosis, and ferroptosis

Type	Pyroptosis	Apoptosis	Necroptosis	Ferroptosis	
Inducing factors	ICD, Microbial infection, DAMPs, PAMPs,	TNF-α, FasL, TRAIL, Irradiation, Hypoxia, Heat shock	TNF-α, FasL, TRAIL, Pathogenic infection	Fe2+ overload initiation and ROS generation	
Biochemical events	Assembly of inflammasome, Caspase-dependent GSDM cleavage, IL-18 and IL-1β release	HSPs, P53, Bcl-2 protein, cytochrome c release, formation of DISC, initiator/effector caspase cascade	RIPK1/RIPK3-mediated phosphorylation of MLKL, permeabilization of the lysosomal membrane, mitochondrial damage	iron accumulation, peroxidation of PUFAs, inhibition of Xc-system/GSH/GPX4	
Cell morphology	Cells swelling, pore formation, rupture and bubbling of plasma membranes, Nucleus intact, Chromatin condensation, DNA fragmentation	Cell and nuclear volume reduced, Membrane intact, Formation of apoptotic bodies, Chromatin condensation, DNA fragmentation	Cells swelling, pore formation, rupture of plasma membranes, Cytoplasmic and organelle swelling, chromatin condensation	Cells swelling, pore formation, decreased mitochondria crista, Condensed mitochondrial membrane, Rupture of mitochondrial outer membrane	
Cell release	Cellular content, DAMPs (IL-18, IL-10, IL-1β, HMGB1, ATP, dsDNA)	Usually no release, In certain cases: DAMPs (HMGB1, ATP, dsDNA, calreticulin)	Cellular content, DAMPs (IL-1α, IL-33, IL-6, HMGB1, ATP, HSPs)	DAMPs (KRAS-G12D, HMGB1, 8-OHG, and PGE2)	
Inflammatory response	Yes	No	Yes	Yes	
References	22,47,57,75,109	48,49	54–57	53,58–61	

Characterization of pyroptosis in humans in 2015 revealed that the cleavage of GSDMD is primarily induced by inflammatory caspases, such as caspase-1, -4, -5, and -11.19 This cleavage results in the loss of interaction between the amino-terminal fragment and carboxy-terminal fragment in GSDMD. GSDMD belongs to the gasdermin superfamily, encompassing gasdermin A/B/C/D/E and DFNB59 (Pejvakin, PJVK) in humans and Gsdma1/2/3, Gsdmc1/2/3/4, Gsdmd, Dfna5, and Dfnb59 in mice. GSDME is also known as DFNA5.20,22 Each member comprises two conserved domains: the N-terminal pore-forming domain and the C-terminal repressor domain (PFD and RD), except DFNB59.62–64 Generally, the RD interacts with the PFD to maintain gasdermin oligomerization, suppressing its cytotoxic effect.62,64 However, when the PFD is separated from the RD, it assembles and forms perforations in the cell membrane in response to various internal and external stimuli. This process leads to the release of molecules associated with inflammation and pyroptosis.22,65 Therefore, gasdermin is regarded as an executor of pyroptosis. Several pathways that induce GSDMD cleavage have been identified, as shown in Fig. 2.Fig. 2 Signaling pathways of pyroptosis. In the canonical pathway of pyroptosis, PAMPs, and DAMPs are stimulated by intracellular signaling molecules. They combine with pro-caspase-1 and the adaptor protein ASC to form inflammasomes, leading to the activation of caspase-1. Cleaved caspase-1 then proceeds to cleave GSDMD and pro-IL-1β/IL-18. N-terminal GSDMD forms non-selective pores in the cell membrane, resulting in water influx, cell lysis, and ultimately cell death. Additionally, IL-1β and IL-18 are released through the pores formed by N-terminal GSDMD. In the non-canonical pathway, LPS activates caspase-4/5/11, triggering pyroptosis by cleaving GSDMD. The cleavage of GSDMD also leads to the efflux of K+, facilitating the assembly of the NLRP3 inflammasome and cleavage of pro-IL-1β and pro-IL-18. In the caspase-8-mediated pathway, the inhibition of TAK1 leads to the activation of caspase-8, which cleaves GSDMD, resulting in pyroptosis. Under hypoxic conditions, PD-L1 translocates to the nucleus and, in conjunction with phosphorylated Stat3, regulates the transcription of GSDMC, leading to the conversion of apoptosis to pyroptosis following TNFα-activated caspase-8. In the granzyme-mediated pathway, CAR-T cells rapidly activate caspase-3 in target cells by releasing GzmB. Subsequently, GSDME is activated, causing extensive pyroptosis. GzmA and GzmB from cytotoxic lymphocytes enter target cells through perforin and induce pyroptosis. GzmA hydrolyzes GSDMB, and GzmB directly activates GSDME. The figure was created by Figdraw

Canonical pathway

Canonical pyroptosis is regulated by the integration of inflammasomes, which induce the cleavage of GSDMD and release of inflammatory factors such as IL-18 and IL-1β.66–70 Inflammasomes are activated and assembled to respond to microbial infections and endogenous danger signals, promoting host immune responses and cellular damage. During this process, released cell contents ultimately recruit innate immune cells to the infection site and modulate adaptive immune cells.71–73

The congregation of inflammasomes is initiated when cytosolic pattern recognition receptors (PRRs), known as detectors of inflammasomes, identify PAMPs and DAMPs.30,74,75 The activation of PRRs triggers downstream signaling cascades, leading to the presentation of type I interferons as well as the release of proinflammatory cytokines.71,76–78 Upon detection of bacterial or viral signals, PRRs assemble with pro-caspase-1 and adapter apoptosis-associated speck-like proteins containing a caspase activation and recruitment domain (CARD) (ASC) to form inflammasomes.15,79–81

Most inflammasomes consist of three segments: (i) leucine-rich repeat-containing proteins (NLRs), (ii) ASC, and (iii) pro-caspase-1.40 NLRs are composed of leucine-rich repeats (LRRs), a NACHT nucleotide-binding domain, and either a pyrin or CARD domain (PYD) at the N-terminus, which categorizes them into NLRP or NLRC subtypes, respectively.82–84 NLRC family members possess one or more N-terminal CARDs, as exemplified by NLRC4, whereas NLRP proteins, such as NLRP1 and NLRP3, harbor N-terminal PYDs.78,85,86

Extensive studies have been performed to characterize NLRC4, including ligand detection by NLR family apoptosis inhibitory protein (NAIP), which is the initial step in NLRC4 inflammasome activation.87,88 Additionally, non-NLR proteins, including AIM2 and pyrin, possess inflammasome-forming capacity. ASC, containing PYD and CARD, mediates inflammasome interactions and pro-caspase-1 recruitment.85 Following inflammasome assembly, caspase-1 undergoes autocatalytic cleavage, leading to the generation of active mature enzymes.89 Caspase-1 has a crucial impact on cleaving GSDMD, creating membrane pores, releasing IL-18 and IL-1β, and ultimately generating cell swelling and pyroptosis.90,91 Additionally, caspase-1 drives pro-IL-1β and pro-IL-18 into their mature, active forms.19,65,92

In some cases, inflammasome stimulation leads to cytokine secretion without cell lysis. However, the mechanisms that regulate the phenomenon remain to be further unveiled. Research suggests that the Toll-like receptor adapter SARM may be involved in this process.93

Non-canonical pathway

In non-canonical pyroptosis, human caspase-4/5 (caspase-11 in mice) is activated by the intimate binding of lipopolysaccharides (LPS) to their N-terminal CARDs.94 Upon activation, caspase-4/5/11 cleaves GSDMD, generating an N-terminus that is inserted into the membrane to form pores.95 However, unlike caspase-1, caspase-4/5/11 are unable to cleave pro-IL-1β/IL-18 precursors on their own, and IL-1β/IL-18 release requires engagement of the NLRP3/caspase-1 pathway in specific cellular contexts.96 The processing of GSDMD by caspase-4/5/11 elicits K+ efflux, which leads to NLRP3 inflammasome formation and pyroptotic cell death similar to the classical pathway.19,97–99 Unlike the classical pathway, in non-canonical pyroptosis, only cleavage of pro-IL-1β/IL-18 depends on caspase-1, while cleavage of GSDMD is performed by other activated inflammatory caspases. Pannexin-1 is another critical mediator of non-canonical caspase-11-induced pyroptosis.100 LPS exposure activates caspase-11, which cleaves pannexin-1, leading to ATP efflux that triggers P2X7-mediated pyroptosis. Notably, pannexin-1 deficient mice exhibit endotoxin shock resistance, indicating that K+ channels are selective modulators of non-canonical NLRP3 stimulation.

Additionally, the NLRP3 inflammasome regulates GSDME expression in human T cells. The NLRP3 inflammasome significantly impacts the activation of caspase-8, caspase-3, and GSDME cleavage, ultimately releasing the alarm signal IL-1α in a specific subset of T helper cells targeting Candida albicans. This process is triggered by calcium-licensed calpain maturation of pro-IL-1α after T cell receptor stimulation. The mechanism of GSDME pore formation in T cells for cytokine release depends on the NLRP3 inflammasome.101

Caspase-3/8–mediated pathway

Previously thought to be inert to gasdermin activation, caspase-3, an apoptotic caspase, has been found to lead to chemotherapy-induced GSDME fragmentation in cells with abundant GSDME, resulting in the liberation of pyroptosis-inducing N-termini in tumors.23,102,103 This phenomenon has been observed in paclitaxel- and cisplatin-induced lung cancer cells and lobaplatin-induced colon cancer cells.104,105 Additionally, the Yersinia effector YopJ stimulates caspase-8 to cleave GSDMD by hindering TAK1 in mouse macrophages, further expanding our mechanistic understanding of pyroptosis.24,25

Caspase-8, another apoptosis-related caspase, has also been implicated in pyroptosis. In breast cancer cells, PD-L1 redirects TNF-induced death from apoptosis to pyroptosis. Under hypoxic conditions, activated STAT3 enters the nucleus along PD-L1, amplifying GSDMC transcription. TNF-α then promotes caspase-8-mediated cleavage of GSDMC, generating N-terminal fragments that perforate the membrane and elicit pyroptosis. Macrophage TNF-α-driven tumor cell pyroptotic death requires nuclear PD-L1, caspase-8, and GSDMC in vivo. Furthermore, certain chemotherapies induce caspase-8- and GSDMC-dependent pyroptotic death.36 Caspase-8 is often referred to as a molecular switch because it is critical in determining whether a cell’s fate is apoptosis, necroptosis, or pyroptosis.106

Granzyme-mediated pathway

In 2020, Liu et al. demonstrated that chimeric antigen receptor (CAR) T-cells can quickly engage caspase-3 in target cells through granzyme B release, triggering the caspase-3/GSDME pyroptosis pathway and leading to widespread pyroptotic cell death.37 In addition, granzyme B directly fragments GSDME to stimulate pyroptosis, enhance anti-tumor immunity, and restrict tumor expansion.26 Natural killer and cytotoxic T cells have been observed to eliminate GSDMB+ cells via pyroptosis, with cytotoxicity resulting from granzyme A (GzmA)-mediated GSDMB fragmentation at Lys229/Lys244. Notably, non-aspartic gasdermin processing and pore formation by GzmA redefined our previous understanding and expanded the potential for pyroptosis induction beyond caspases.27 Different splicing variants of GSDMB have distinct functions, with the cleaved N-terminal fragments of only certain isoforms causing pyroptosis.107

Biological functions in health

The large GSDM family is representative of the widespread phenomenon of pyroptosis in mammals, suggesting that pyroptosis is a vital mode of RCD.108 Scientists have investigated the role of pyroptosis in biological processes, and evidence suggests that pyroptosis likely plays a role in combating infections by eliminating intracellular pathogen replication sites and supporting downstream immune responses.

Inflammasomes are PRRs that recognize intracellular and extracellular pathogen ligands. Sensors of pyroptosis respond to components of bacteria and viruses, leading to the secretion of IL-18 and IL-1β through gasdermin-forming pores and plasma membrane rupture with the release of DAMPs, including HMGB1, ATP, and others. These cellular contents subsequently trigger several cellular events, including inflammation, proliferation, and differentiation.22,47,109 According to preliminary studies, IL-18 and IL-1β are critical for innate and adaptive immunity. NK and Th1 cells express IL18R on their surface and are highly sensitive to IL-18, which forms a positive loop with interferon-γ.110 Thus, pyroptosis is vital in the crosstalk between innate and adaptive immunity, inducing an immunostimulatory response against pathogens.111 As a crucial contributor to innate immunity, pyroptosis leads to the generation of pore-induced intracellular traps (PITs), i.e., structures that entrap previously intracellular microbes. PITs facilitate intracellular bacterial clearance by containing the pathogen and producing signals that promote recruitment and uptake by neutrophils.80 Besides, emerging research has suggested that pyroptosis exerts an antagonistic effect on endogenous danger signals, such as oxidative stress, in addition to triggering a microbe-mediated immune response.112,113

Aside from lytic cell death, gasdermins, the key executors of pyroptosis, participate in a wide range of physiological processes, including cell differentiation, tissue homeostasis, mitochondrial homeostasis, immune tolerance, and neutrophil extracellular trap (NET) formation.114–116 GSDMA3 was reported to play a vital role in normal hair follicle differentiation by participating in the Msx2/Foxn1/acidic hair keratin pathway.117 Li et al. reported that in osteoblasts, GSDMD underwent cleavage to generate non-lytic p20 products, which helped prevent bone loss and maintain bone homeostasis.118 Besides, GSDMD was identified as a key factor in the separation of bacteria from the epithelium in the colon owing to its role in goblet cell-mediated mucus layer formation. This biological function of GSDMD depends on its regulation of cortical F-actin disassembly in the process of mucin secretion.114 According to a recent study, the N-terminal domain of Gsdma3 was associated with Hsp90 and targeted mitochondria, thus regulating mitochondrial oxidative stress.115 In intestinal epithelial cells (IECs), GSDMD was cleaved by caspase-3/7 to produce a 13 kD N-terminal fragment upon exposure to dietary antigens. This fragment translocated to the nucleus and stimulated the expression of CIITA and MHCII molecules, which induced type 1 regulatory T (Tr1) cells and enabled immune tolerance of IECs to dietary antigens.119 Moreover, neutrophil proteases catalyze the proteolytic activation of GSDMD during NETosis, affecting nuclear expansion and protease activation via a feed-forward loop.116

Regulatory function of pyroptosis in diseases

Pyroptosis facilitates the clearance of injured or infected cells, comprising a crucial defense against pathogen infection and DAMP stimulation. Persistent pyroptotic cell death can result in ion gradient dissipation, cellular content release, and exaggerated inflammatory responses, contributing to the pathophysiology of various diseases, including cancer. Two diagrams summarize the regulatory mechanisms of the pyroptotic pathway in cancerous and non-cancerous diseases (Figs. 3 and 4).Fig. 3 Regulatory mechanisms of pyroptosis in cancer. Over recent years, a series of molecules have been proven to target different sites of the pyroptosis pathway, thereby influencing the occurrence and progression of various cancers, including lung cancer, gastric cancer, breast cancer, HCC, and colorectal cancer. AZU1 Azurocidin 1, Akt protein kinase B, ASAH2 sphingolipid metabolic enzyme ceramidase, CPSF6 cleavage and polyadenylation factor 6, CHMP3 charged multivesicular body protein 3, DRD2 D2 dopamine receptor, IBSP integrin binding sialoprotein, MUC20v2 MUC20 variant 2, MMP mitochondrial membrane potential, P2X7R P2X7 receptor, PDK1 3-­phosphoinositide-­dependent kinase 1, Sorcin soluble resistance-related calcium-binding protein, TRAF3 tumor necrosis factor receptor-associated factor 3, TCEA3 transcription elongation factor a3, UCP uncoupling protein 1, ZNF Zinc finger protein 148. The figure was created by Figdraw

Fig. 4 Regulatory mechanisms of pyroptotic cell death in non-cancer disease. Research on pyroptosis fosters the pathological process comprehension of systemic diseases and the underlying mechanisms involving numerous proteins, RNAs, and other molecules. ALPK1 alpha‐kinase1, CTSB cathepsin B, HRC histidine-rich calcium-binding protein, HNE 4-hydroxynonena, METTL14 methyltransferase-like 14, NETs neutrophil extracellular traps, PI(4;5)P2 phosphatidylinositol-(4;5)-bisphosphate, PI4P phosphatidylinositol-4-monophosphate, S1PR2 sphingosine-1-phosphate receptor 2, Txnrd3 thioredoxin reductase 3, TRIM29 tripartite motif containing 29. The figure was created by Figdraw

Cancer

Pyroptosis plays a dual role in cancer, exhibiting context-dependent pro- or anti-tumor effects during tumorigenesis, because of its significant impact on inflammation and immunity.120,121 Its divergent functions in cancer are influenced by tumor characteristics, genetic background, host immunity status, and the specific pyroptotic effectors involved, emphasizing the complex interplay between pyroptosis, innate immunity, and the tumor microenvironment.122–126 Below, we summarize the involvement of pyroptosis in a range of cancers, covering lung, gastric, breast, hepatocellular carcinoma (HCC), and colorectal cancer.127–131

Lung cancer

Lung cancer is highly prevalent and a major factor contributing to death worldwide.132 Inflammasomes, the key initiators of the pyroptotic pathway, were highly expressed in various types of lung cancer. Several genes have been implicated in the regulation of inflammasome expression, most notably, NLRP3. In lung cancer cells, long non-coding RNA (lncRNA) LINC00969 promotes resistance to gefitinib via epigenetic inhibition of NLRP3. Mechanistically, LINC00969 binds to both METTL3 and EZH2, transcriptionally modifies the level of H3K27me3 in the region of NLRP3 promoter, and post-transcriptionally regulates the m6A level in NLRP3.127 Inhibition of tumor necrosis factor receptor-associated factor 3 (TRAF3) promotes the progression of lung adenocarcinoma (LUAD) cells and weakens the sensitivity of the cells to paclitaxel, partly through activation of caspase-1-dependent pyroptosis.133 In lung and pancreatic cancer models, β5-integrin upregulated the Src-STAT3-ASAH2 signaling axis, thus reducing ROS production to prevent chemotherapy-induced pyroptosis.134 ANGPTL4, a critical regulatory gene for lipid and glucose metabolism, was found to contribute to gefitinib resistance in non-small cell lung cancer (NSCLC) cells by regulating the NLRP3/ASC/caspase 8 pathway.135 Silencing lncRNA-XIST promotes NLRP3-mediated pyroptosis and NSCLC progression via activating the miR-335/SOD2/ROS pathway.136 Shi et al. downregulated miR-556-5p expression to increase cisplatin sensitivity in cisplatin-resistant NSCLC (CR-NSCLC) tissues. Mechanistically, the downregulation of miR-556-5p contributes to the expression of NLRP3, thereby provoking pyroptosis in cisplatin-treated CR-NSCLC cells.137 NLRP3-independent pyroptotic pathways influence the onset and progression of lung cancer. For example, AMIGO2 attenuated the (caspase-8 and caspase-9)/caspase-3 cascade by initiating the PDK1/Akt (T308) signal axis, attenuating GSDME-mediated pyroptosis, which reduces the innate sensitivity of NSCLC cells to cisplatin.138

Gastric cancer

Gastric cancer is among the primary causes of cancer-related mortality worldwide and is often discovered at an advanced stage when surgical intervention is no longer appropriate.139 MUC20 variant 2 (MUC20v2) protects gastric cancer cells from apoptosis and pyroptosis by maintaining mitochondrial calcium levels and membrane potential homeostasis, which enhances cell survival and chemoresistance.128 LncRNA ADAMTS9-AS2 is a tumor suppressor and sensitizes chemoresistant gastric cancer cells to cisplatin by upregulating the miR-223-3p/NLRP3 signaling axis.140 USP50 enhances bile acid-induced NLRP3-mediated pyroptosis of macrophages, releasing HMGB1 and leading to the genesis of gastric tumor cells through the PI3K/AKT and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways.141 Cleavage and polyadenylation factor 6 (CPSF6) and Helicobacter pylori also regulate pyroptosis in gastric cancer.142,143

Breast cancer

Breast cancer is one of the most prevalent malignancies worldwide.144 In the tumor microenvironment (TIM) of breast cancer, modulation of macrophages to the M1 phenotype by DRD2, a D2 dopamine receptor, leads to NLRP3 inflammasome assembly and subsequent pyroptosis.145 Azurocidin 1 (AZU1), a heparin‑binding protein, was reported to induce pyroptosis by initiating the pNF‑κB/NLRP3/caspase‑1/GSDMD signaling axis in triple-negative breast cancer (TNBC) in vitro.146 Zinc finger protein 148 (ZNF-148) was found to aggravate the progression of breast cancer through induction of miR-335/SOD2/ROS-mediated pyroptosis.147 Mitochondrial protein UCP1 was reported to inhibit TNBC progression by activating caspase-3-mediated pyroptosis.129 In addition, the PD-L1/PD-1 immune checkpoint has been found to engage in the pyroptosis pathway under specific circumstances when PD-L1 translocates to the nucleus, where it enhances GSDMC transcription. Subsequent treatment with TNF-α results in caspase-8-mediated cleavage of GSDMC, leading to pyroptosis and tumor necrosis in breast cancer.36

Hepatocellular carcinoma

HCC is one of the primary causes of cancer-related death, and its prevalence is anticipated to increase globally.148 A recent study found that soluble resistance-related calcium-binding protein (sorcin) impairs the assembly of the NLRP3 inflammasome, thus inhibiting cell pyroptosis and provoking HCC progression.130 A noteworthy association was found in HCC cells between the expression of GSDMD and NEK7. Moreover, NEK7 knockdown elevated pyroptosis-related markers NLRP3, caspase-1, and GSDMD, reducing HCC stimulation of hepatic stellate cells, hinting at NEK7’s considerable role in both tumor progression and cancer-stromal interactions in HCC.149 Additionally, USP48 stabilized GSDME by removing K48-linked ubiquitination at K120 and K189, thereby promoting pyroptotic death in liver cancer cells.150 Additionally, charged multivesicular body protein 3 (CHMP3) contributed to liver cancer via caspase-1-dependent pyroptotic cell death.151

Colorectal cancer

Owing to environmental degradation and population aging, colorectal cancer ranks third globally in terms of frequency of malignant tumors and has emerged as the world’s fourth most deadly cancer.152 IL-17A has been suspected of inducing mitochondrial dysfunction, intracellular ROS generation, and activation of the NLRP3/caspase-4/GSDMD pyroptotic pathway, consequently upregulating the secretion of inflammatory substances and recruiting infiltrating CD8+ T cells to colorectal tumors.131 The highly selective P2X7R antagonist, A438079, was observed to inhibit pyroptosis via the NLRP3/caspase-1 pathway, although it remains unclear whether this inhibition could ultimately prevent colorectal cancer progression.153 Moreover, a recent study revealed that Nrf2 inhibition increases the sensitivity of CRC cells to oxaliplatin by promoting pyroptosis and ferroptosis.154 USP47-driven deubiquitination and stabilization of transcription elongation factor a3 (TCEA3) suppressed pyroptosis of colorectal cancer cells promoted by chemotherapeutic doxorubicin.155

Neurological disorders

Accumulating evidence points to pyroptosis as a critical factor in Alzheimer’s disease (AD), Parkinson’s disease (PD), ischemic stroke, multiple sclerosis (MS), traumatic brain injury, spinal cord injury, epilepsy, and neuropsychiatric and neurodevelopmental diseases.156–162 Below, we summarize the regulation of pyroptosis in a range of neurological diseases.

Alzheimer’s disease

AD is the most common neurodegenerative disease in the elderly and is characterized by cognitive decline. The major neuropathological features of AD include amyloid β (Aβ) plaques and neurofibrillary tangles (NFT), along with neuroinflammation and neuronal loss.163 Accumulating evidence indicates that the regulation of pyroptosis plays a role in the pathology of AD.164 Moonen et al. demonstrated differential activation of the pyroptotic pathway in a cell type-dependent manner in AD cases, implicating pyroptosis activation in neuronal death.165 Recent studies have revealed that β-amyloid could promote NLRP3-caspase-1-GSDMD signaling in neurons, leading to nerve injury in AD.166,167 β-amyloid protein aggregation around ASC fibrils could amplify the inflammatory response, leading to pyroptotic cell death.168 Other neuropathogenic proteins, including tau proteins, can induce NLRP3 inflammasome activation.169 In a vicious cycle, ASC released by microglia binds to β-amyloid, enhancing the formation of β-amyloid oligomers and aggregates, which can be attenuated by the anti-ASC antibody.170 Cholesterol overload in neuronal cells provokes pyroptosis via increasing Aβ‑induced oxidative stress in the mitochondria.171 Overall, neuropathogenic proteins can induce inflammasome formation and proinflammatory cytokine release, exacerbating AD pathology.

Parkinson’s disease

PD is a neurodegenerative disorder featuring misfolding of α-synuclein proteins and Lewy body formation in affected neurons.172 These neuropathogenic protein aggregations lead to the loss of dopaminergic neurons in the substantia nigra pars compacta, with symptoms of tremors and bradykinesia.173 The pathophysiology of PD correlates with the neuroinflammation theory and involves pyroptosis.174 A recent study reported that salsolinol induces the expression of pyroptosis-related proteins, such as NLRP3, ASC, and caspase-1, in SH-SY5Y cell lines and mouse models.175 In addition, elevated levels of cleaved caspase-1 and ASC have been identified in substantia nigra samples from patients with PD compared to healthy controls.176 Therefore, growing evidence from cellular, animal, and clinical studies supports a correlation between pyroptosis and PD progression.

Ischemic stroke

Known as a crippling central nervous system disease caused by arterial blockage with high mortality, ischemic stroke imposes a high burden on the economy and society. Increasing evidence suggests that inflammation promoted by inflammasomes and pyroptosis is essential for the pathophysiological process of ischemic stroke and is strongly linked to prognosis. METTL14 (methyltransferase-like 14) was found to activate the NLRP3 inflammasome/pyroptosis axis via KAT3B-STING signaling after oxygen-glucose deprivation/reperfusion (OGD/R), which simulates ischemic stroke in vitro.177 Wei et al. demonstrated that TRIM27 downregulated NLRP3 inflammasome-mediated pyroptosis through Akt/Nrf2/HO-1 signaling, ameliorating ischemic stroke.178 Likewise, TRIM29 (Tripartite Motif Containing 29) was reported to exert a negative regulatory effect on pyroptosis in ischemic stroke.179

Other neurological disorders

Associations have also been found between pyroptosis and some other neurological disorders, including MS, amyotrophic lateral sclerosis, and neuropsychiatric diseases. As a chronic inflammatory demyelination disorder, the development of MS is closely related to pyroptosis. Caspase-1-mediated GSDMD pyroptosis and inflammasome activation have been observed in oligodendrocytes (ODCs) and microglial cells in vitro and patients with MS.180 Activated caspase-3 with GSDMD immunopositivity has also been identified in macrophages/microglia within demyelinating lesions of patients with progressive MS and in experimental autoimmune encephalomyelitis (EAE) models.181 Motor neuron loss in the motor cortex is associated with increased inflammasome-triggered pyroptosis in microglia.182 NLRP3 inflammasome activation has also been observed in TDP43A315T and SOD1 transgenic animals.183,184

Neuropsychiatric diseases, such as anxiety and depression, are characterized by cognitive and mental abnormalities. It has been demonstrated that in addition to hereditary variables, elevated inflammation plays a substantial role in many neuropsychiatric illnesses. Simon et al. reported that the monocytes of patients with major depressive disorder (MDD) exhibited signs of premature aging and inflammation, as well as a tendency toward pyroptotic cell death.185 A recent study illustrated that the Kir6.1/K-ATP channel in astrocytes negatively modulated astrocytic pyroptosis by preventing the assembly and activation of the NLRP3 inflammasome, which plays a vital role in the pathogenesis of depression.186 Furthermore, inorganic arsenic exposure may result in the development of generalized anxiety disorder (GAD) by downregulating the expression of miR-425–3p in the prefrontal cortex, which targets the NF-κB/NLRP3/caspase-1/GSDMD signaling axis and causes the release of IL-1β and IL-18.187

Respiratory diseases

Research indicates that pyroptosis is critical for inflammatory diseases, with increasing evidence linking respiratory diseases to inflammation, bringing the role of pyroptosis in respiratory diseases to the forefront of research. Pyroptosis participates in the genesis of chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), asthma, silicosis, pulmonary hypertension, cystic fibrosis, and pulmonary tuberculosis.188–194 In this section, we sum up the roles and corresponding mechanisms of pyroptosis in inflammatory respiratory diseases.

Chronic obstructive pulmonary disease (COPD)

COPD is a severe health issue and the third leading cause of inflammatory respiratory-related mortality globally.195 The most significant risk factor for COPD is cigarette smoke, which can draw inflammatory cells to the lung tissues and trigger the induction of a range of cytokines. Pyroptosis is irreversible when cigarette smoke induces tissue inflammation. For example, cigarette smoking can enhance the expression of sphingosine-1-phosphate receptor 2 (S1PR2) in human bronchial epithelial cells, thus triggering the NLRP3/ASC/caspase-1 pathway, leading to airway inflammation and injury.189 Likewise, cigarette smoke extract contributed to the pyroptosis of human bronchial epithelial cells via the ROS/NLRP3/caspase-1 axis.196 Meanwhile, hydrogen sulfide was reported to alleviate pyroptosis and lung injury in a model of smoking-induced COPD by downregulating the TLR4/NF-κB signaling pathway.197 Furthermore, Wang et al. proved that TREM-1 could activate NLRP3-mediated pyroptosis, thereby aggravating the injury and inflammation that COPD caused to lung tissues.198 Additional studies have revealed that factors, including lncRNA GAS5, TRPV4, and WSPM2.5, aggravated COPD by activating pyroptotic cell death.199–201 Inhibition of pyroptosis by exosomes from adipose-derived stem cells and the Nrf2/HO-1 signaling axis might alleviate COPD.202,203

Acute lung injury (ALI)

ALI is a lethal disease characterized by cytokine storms, leukocyte infiltration, and diffuse alveolar injury.204 Polymorphonuclear neutrophils (PMNs) are essential to inducing sepsis-related ALI. Specifically, exosomal miR-30d-5p from PMNs facilitated sepsis-related ALI by inducing M1 macrophage polarization and activating NF-κB to prime macrophage pyroptosis.205 A recent study revealed that pyroptosis contributed to ALI caused by cecal ligation and puncture (CLP), and aldehyde dehydrogenase 2 (ALDH2) acted as a buffer by limiting pyroptosis.206 A lipid peroxidation product, 4-hydroxynonenal (HNE), was found to attenuate NLRP3 inflammasome-mediated pyroptosis and downstream IL-1β release, independent of the Nrf2 and NF-κB signaling pathways, contributing to sepsis-related ALI.207 Furthermore, many other substances had a regulatory effect on pyroptosis, thus affecting the development of ALI induced by sepsis and other causes.208–212

Asthma

Asthma is a chronic respiratory inflammatory disease featuring reversible airflow limitation and airway hyperresponsiveness.213 Increasing evidence has shown the critical role of pyroptosis in asthmatic airway inflammation and injury. In an ovalbumin-induced asthmatic mouse model, GSDMD silencing significantly reduced Th17 and Th2 inflammatory responses as well as M2 macrophage polarization, all of which are involved in airway remodeling and inflammation.214 Dectin-1 activation in asthma provoked caspase-11/4-mediated macrophage pyroptosis, thereby stimulating the secretion of chemokines and aggravating airway neutrophil inflammation.215 MUC1 suppressed NLRP3 inflammasome-mediated pyroptosis via blocking the TLR4/ MyD88/NF-κB pathway, subsequently alleviating neutrophil airway inflammation in asthma.216

Silicosis

Attributed to long-term inhalation of crystalline silica (CS) particles, silicosis is a severe lung disease marked by irreversible pulmonary fibrosis.217 Emerging evidence has indicated that CS-induced lung injury was closely associated with the activation of pyroptosis. Meiyue Song et al found that macrophages in silicosis lung tissue underwent GSDMD-induced pyroptosis, mediated by both canonical and non-canonical signaling pathways.218 Another mechanistic study elucidated that silica exposure triggered the dysfunction of the P2X7 ion channel, causing intracellular K+ efflux and the formation of the NLRP3 inflammasome, which cooperated with LPS-primed activities to provoke macrophage pyroptosis and pulmonary inflammation.219 Furthermore, CS particles induced damaged mitochondria to release DAMPs, which initiated downstream NLRP3 inflammasome-mediated pyroptosis to promote pulmonary fibrosis.191

Pulmonary tuberculosis

Caused by Mycobacterium tuberculosis (Mtb), tuberculosis (TB) is a highly contagious illness that continues to be the most common infectious agent-related cause of mortality.220 Accumulating evidence has supported pyroptosis as a critical factor in the development of TB. Mycobacterial EST12 binds to the receptor for activated C kinase 1 (RACK1) in macrophages to assemble a complex that engages the deubiquitinase UCHL5 to facilitate the K48-linked deubiquitination of NLRP3, consequently promoting the NLRP3-caspase-1/11-IL-1β immune pathway.221 PtpB, an Mtb phospholipid phosphatase, was recently reported to suppress the host inflammasome-pyroptosis pathway. Mechanistically, PtpB dephosphorylates phosphatidylinositol-4-monophosphate (PI4P) and phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] in the host cell membrane, thereby interfering with the membrane localization of cleaved GSDMD and preventing macrophage pyroptosis.222 In addition to Mtb, host molecules regulate pyroptosis, driving TB disease progression. According to a recent study, S100A4 provoked the pyroptosis of THP-1 macrophages induced by BCG infection via activation of the NF-κB/NLRP3/caspase-1/GSDMD signaling pathways.194 Moreover, researchers have recently discovered many other factors regulating pyroptosis during pulmonary tuberculosis.223–228

Kidney disease

Pyroptosis participates in the initiation and progression of kidney diseases, as most share characteristics such as inflammation and parenchymal cell death. Several studies have shown regulation of pyroptosis in the pathogenesis of kidney diseases, such as acute kidney injury (AKI), chronic kidney disease (CKD), diabetic kidney disease (DKD), lupus nephritis, and kidney allograft transplantation.229–233 This section reviews studies implicating pyroptosis in kidney disease models.

Acute kidney injury

Acute kidney injury (AKI) is a prevalent clinical complication with high worldwide morbidity and mortality rates.234 Increasing evidence suggests that pyroptosis significantly contributes to the pathogenesis of AKI. USF2 upregulated THBS1 to activate the TGF-β/NLRP3 signaling pathway, provoking pyroptosis and further aggravating sepsis-induced AKI.235 According to a recent study, dsDNA-induced AIM2 pyroptosis rapidly removes macrophages, which unexpectedly halts aberrant inflammation during AKI triggered by rhabdomyolysis.236 Baatarjav et al. revealed the pivotal role of GSDME-mediated pyroptosis in AKI development. The cleavage of GSDME by caspase-3 is responsible for forming membrane pores and cell lysis, exacerbating inflammation and renal tubular damage.229 Furthermore, recent investigations have identified numerous proteins, RNAs, and other molecules that implicate pyroptosis as a driver of AKI pathogenesis.237–241

Chronic kidney disease

CKD is an irreversible, progressive illness that massively affects health outcomes.242 Recent research has indicated that pyroptosis contributes to CKD progression. Butyrate plays a renoprotective role, alleviating renal fibrosis in CKD. Mechanistically, STING/NF-κB/p65 pathway downregulation attenuated NLRP3-mediated pyroptosis.243 GSDME was found to contribute to renal tubulointerstitial fibrosis and renal dysfunction induced by ureteral obstruction and 5/6 nephrectomy via pyroptotic cell death.244 In addition, a new study illustrated the collaboration of GSDMD and GSDME in the transition of AKI to CKD.242

Diabetic kidney disease

DKD is the main cause of end-stage renal disease, with a dramatically increased prevalence worldwide over the past decades.245 Recent studies have confirmed that pyroptotic death is essential in the development of DKD. During DKD, caspase-11/4 and GSDMD-mediated pyroptosis are activated, contributing to podocyte loss.246 A recent study demonstrated that alpha‐kinase1 (ALPK1) was activated by hyperglycemia and caused phosphorylation of NF-κB in renal tubular epithelial cells in DKD. Subsequently, the canonical caspase-1-GSDMD pyroptosis pathway is induced, contributing to tubular injury and interstitial inflammation.231 NETs have also been reported to induce glomerular endothelial cell (GEC) pyroptosis, mediated by charge, further inducing the development of DKD.247 Over the past few years, other molecules and substances, such as circRNA, LncRNA, and lysophosphatidic acid have also been reported to target the regulation of pyroptosis in DKD.248–252

Cardiovascular diseases

Accumulating evidence has demonstrated that the regulation of pyroptosis influences the pathogenesis of cardiovascular diseases (CVD). Pyroptosis induces the amplification of inflammatory responses and accelerates the occurrence of cardiovascular diseases such as atherosclerosis, myocardial infarction (MI), arrhythmia, and cardiac hypertrophy.253–255

Atherosclerosis

Arteriosclerosis is a chronic inflammatory process featuring lipid deposition, plaque build-up, and endarterium thickening.256 As the primary etiological factor for cardiovascular and cerebrovascular disorders, atherosclerosis has become a significant global cause of death and disability.257 Emerging studies have suggested that pyroptosis is critical for the development of atherosclerosis. The lncRNA NEAT1 positively regulates the expression of NLRP3 at the transcription level, initiating pyroptosis of vascular endothelial cells. In contrast, exercise attenuates the function of NEAT1, impeding atherosclerosis plaque formation.258 Rnd3 was reported to downregulate the TRAF6/NF-κB/NLRP3 signaling pathway via regulation of TRAF ubiquitination, thus impairing endothelial pyroptosis in atherosclerosis.259 During atherosclerosis, STAT3 in macrophages is activated by ox-LDL or inflammatory cytokines and upregulates GSDME transcription, which increases caspase-3 activity and contributes to the transition from apoptosis to pyroptosis.260 Additionally, many other molecules participate in atherosclerosis by regulating the pyroptosis of endothelial cells or macrophages, including uric acid, homocysteine, nicotine, IQGAP1, and hormones.261–266

Myocardial infarction

Ischemic heart disease, particularly MI, remains the leading cause of death worldwide.267 Directly restoring blood flow in the ischemic region immediately is the most effective method for rescuing dying cardiomyocytes. Reperfusion, however, is a double-edged sword; while it can save ischemic myocardia, it also risks inflicting further damage, a condition known as myocardial ischemia/reperfusion (MI/R) injury.268 Emerging studies have attempted to uncover the pathophysiological role of pyroptosis in MI and MI/R injury. Uric acid was reported to exacerbate MI/R injury via upregulation of the ROS/ NLRP3 pyroptosis pathway.269 Oxytocin (OT) can exert protective effects against myocardial I/R injury with hyperglycemia via regulation of the AMPK/NLRP3 signaling pathway and pyroptosis.270 GSDMD-induced pyroptosis plays a critical role during MI/R injury, and the caspase-11/GSDMD pathway mediated by oxidative stress may be essential for the process.271 Furthermore, over the past few years, several additional mechanisms have been found to contribute to the pathogenesis of MI, such as circHMGA2, HIF-1α/TUG1/FUS, and lncRNA H19.254,272–276

Diabetic cardiomyopathy

Diabetic cardiomyopathy (DCM) is one of the most detrimental consequences of type 2 diabetes. DCM involves abnormal structural remodeling and aberrant cardiac function.277 Recent studies have widely reported the essential role of pyroptosis regulation in cardiomyopathy, particularly in DCM. Meng et al. discovered that METTL14 attenuates pyroptosis and DCM progression via m6A methylation of lncRNA TINCR by downregulating NLRP3 expression.278 Critically, CD38 deficiency alleviates type 2 diabetes-induced DCM by reducing pyroptosis and apoptosis in vitro and in vivo via activation of the NAD+/Sirt3/FOXO3a signaling pathways.279 CircRNA DICAR was identified as a novel endogenous regulator for DCM, with the potential to protect against cardiomyocyte pyroptosis via DICAR-VCP-Med12 degradation.280 What’s more, many other molecules in the human body exert regulatory effects on pyroptosis involved in DCM disease progression, such as folic acid, ghrelin, miR-21-3p, microRNA-223-3p, and lncRNA MIAT.281–285

Arrhythmia

Among the arrhythmia types, atrial fibrillation has been most frequently reported to be associated with cell pyroptosis. Atrial fibrillation is a prevalent arrhythmia in clinical practice, occurring in 1-2% of people worldwide, and has been linked to an increased risk of heart failure and hospitalization.286 Luo et al. discovered that Akkermansia muciniphila (A.muciniphila) protected rats against cold-related atrial fibrillation. Mechanically, cold exposure decreased the abundance of A. muciniphila, further causing augmented TMAO in plasma and TMAO-mediated atrial pyroptosis, which resulted in atrial structural remodeling and atrial fibrillation.287 According to a new study, the extracellular vesicles from adipose tissue-derived mesenchymal stem cells (AMSCs) carrying LncRNA XIST attenuated myocardial cell pyroptosis in atrial fibrillation via blocking miR-214-3p-mediated Arl2 inhibition.288

Cardiac hypertrophy

Pathological hypertrophy of the myocardium is one of the largest contributors to heart failure and has been associated with pyroptosis in recent studies.289 In a model of doxorubicin (Dox)-induced non-ischemic dilated cardiomyopathy, Dox increased the expression of NOX1 and NOX4 and triggered mitochondrial fission via dynamin-related protein 1 (Drp1) activation, resulting in caspase-1-dependent pyroptosis in cardiomyocytes.290 Moreover, TRPA1 deficiency aggravated dilated cardiomyopathy through augmenting S100A8 expression to induce pyroptosis in M1 macrophages.291 Yue et al also reported that NLRP3/caspase-1-dependent pyroptosis has a pathological role in myocardial hypertrophy.292 In a model of pressure-overload cardiac hypertrophy, NLRP3 deficiency exerted cardioprotective effects via activation of TAK1.293 Another study found that Sema4D contributed to pathological myocardial hypertrophy via the MAPK/NF-κB/NLRP3 pathway.294

Drug-induced cardiac injuries

Antineoplastics, antipsychotics, and other drugs can cause toxicity that adversely influences the heart and may result in cardiomyopathies, known as drug-induced cardiac injuries.295 Increasingly, studies have found an association between drug-induced cardiac injury and pyroptosis. Dox enhanced the expression of Bnip3, which activated caspase-3 to induce GSDME-mediated pyroptosis in cardiomyocytes.296 Additionally, mir-34a-5p selectively attenuated the expression of Sirt3 and then augmented autophagy and mitoROS generation, ultimately exacerbating Dox-induced myocardial cell pyroptosis.297 Antipsychotics competitively bonded to CB1R, which was then internalized and directly interacted with NLRP3 inflammasome through amino acid residues 177–209, mediating stabilization of the inflammasome and activation of cardiomyocyte pyroptosis.298

Digestive diseases

The pyroptotic pathway has emerged as an indispensable component of digestive disorders, including gastric ulcer, ulcerative colitis (UC), acute pancreatitis (AP), and hepatic fibrosis.299–302 In this section, we summarize the role of pyroptosis in the pathological processes of digestive diseases.

Ulcerative colitis

UC is an aggressive, chronic inflammatory bowel disease accompanied by a high risk of bowel cancer.303 Accumulating evidence supports pyroptosis as a critical factor in the development of UC. Inhibition of the C3a/C3aR axis in the early stages of UC induces poor prognosis of UC by promoting cell pyroptosis. However, stimulation with a C3aR inhibitor in the later stages of UC alleviated the symptoms of UC by suppressing pyroptosis.304 Overexpression of Txnrd3 induced intracellular calcium outflow, endoplasmic reticulum stress, and ROS accumulation, ultimately leading to pyroptosis and necrosis of colon cancer cells.305 APOL1 overexpression induces the NLRP3/caspase1/GSDMD pyroptosis pathway and promotes the release of the chemokine CXCL1, further aggravating UC.306 Besides, lncRNA MEG3, miR-141-3p, and SLC6A1 have been found to influence the progression of UC via the regulation of pyroptosis.307–309

Acute pancreatitis

AP is an urgent and severe abdominal disease that can have both local and systemic consequences.310 Growing evidence has suggested a close correlation between the inflammasome and its downstream effectors and AP.311 Cathepsin B (CTSB) was reported to induce NLRP3/caspase-1-mediated cell pyroptosis, aggravating AP.312 A recent study uncovered that IL-37 impaired phosphorylated STAT3 and protected against pyroptosis of injured acinar cells in AP.313 Inhibition of TRAF6 was found to attenuate pancreatic injury in hyperlipidemic AP, along with relief of the inflammatory response via pyroptotic cell death.314 High-density lipoprotein (HDL) was reported to relieve oxidative stress and suppress acinar cell pyroptosis, reducing the severity of AP.315 Furthermore, additional factors upregulate cell pyroptosis and promote the progression of AP, such as circHIPK3, endogenous tRNA-derived small RNA, USP25, endoplasmic reticulum stress, and exosomal miR-155-5p.316–320

Liver fibrosis

Liver fibrosis is a chronic liver injury with the potential to progress to cirrhosis and correlates with an elevated risk of HCC over time.321 Accumulating evidence has illustrated that pyroptosis plays a vital role in the development of liver fibrosis. According to a recent study, NLRP3 overactivation resulted in hepatocyte pyroptosis and the release of inflammasome particles into the extracellular space, engendering hepatic stellate cell activation and liver fibrosis.322 STING was found to mediate hepatocyte pyroptosis through epigenetic activation of the IRF3/WDR5/DOT1L transcription activator complex, contributing to liver fibrosis.323 Hepatic histidine-rich calcium-binding protein (HRC) induced paracrine activation of hepatic stem cells (HSCs) by triggering hepatocyte pyroptosis via the NLRP3/caspase-1/HMGB1 signaling axis in liver fibrosis, promoting fibrogenesis.324 In addition, angiotensin II, S100A8, and the METTL3/MALAT1/PTBP1/USP8/TAK1 axis were proven to aggravate liver fibrosis. Concurrently, growth arrest-specific 5 (GAS5) and exosomes produced from bone marrow mesenchymal stem cells exerted an inhibitory effect on liver fibrosis.325–329

Therapeutic strategy regulating pyroptosis

Cancer

It is widely accepted that pyroptotic cell death is implicated in tumor suppression. Generally, activation of the pyroptosis signaling pathway augments anti-tumor immunity, whereas inhibition of the pyroptosis signaling pathway facilitates tumor growth and metastasis. In this section, we review the current literature on molecules that induce or enhance pyroptosis. Notably, some of these molecules have been used in cancer treatment for years, and their mechanisms have previously been solely attributed to the induction of apoptosis.

Therapeutic strategies targeting inflammasome

Inflammasomes are involved in various stages of tumor development and provide tumorigenic and tumor-suppressive functions.5,330,331 Owing to the role of pyroptosis in tumor initiation, targeting inflammasome activation is an encouraging therapeutic policy for cancer treatment.

Molecules that target the NLRP3 inflammasome have received extensive attention. Studies have shown that in tumor cells undergoing Snail-mediated epithelial-mesenchymal transition (EMT), the activity of NLRP3 inflammasomes in tumor-associated macrophages (TAMs) is diminished in response to chemotherapeutic agents. This suppression occurs via the transfer of exosomal miR-21, downregulating PTEN and BRCC3, leading to phosphorylation and lysine-63 ubiquitination of NLRP3. This process effectively prevents the assembly of the NLRP3 inflammasome, resulting in reduced chemotherapy efficacy.332 Therefore, triggering NLRP3-mediated pyroptosis of cells in the tumor microenvironment possesses treatment potential.

Yuan et al. identified cucurbitacin B, derived from muskmelon pedicel, as a natural bioactive compound demonstrating potent anti-tumor effects in lung carcinoma. Cucurbitacin B directly combined with TLR4, triggering the activation of the NLRP3 inflammasome. Subsequently, this activation led to the cleavage of gasdermin D into its N- and C-terminal domains, facilitating the induction of pyroptosis.333 The therapeutic potential of alpine pine flavones (AIF) against HCC has been investigated and demonstrated suppression of proliferation, migration, and invasion in Huh7 and SMMC7721 cell lines, possibly through the excitement of NLRP3 inflammasome assembly, which has also been verified by in vivo findings.334 Metformin, recognized for its glucose-lowering effects, also exhibits antineoplastic effects in HCC by triggering apoptosis and pyroptosis. This activity is mediated by the enhancement of FOXO3 expression by metformin, which subsequently increases NLRP3 transcription and facilitates pyroptosis.335 Another camptothecin anticancer drug, FL118, can also inhibit the progression and metastasis of colorectal cancer by inducing NLRP3-ASC-Caspase-1 mediated pyroptosis.336 A significant correlation was noted between the expression of GSDMD and the presence of NEK7. Silencing NEK7 led to the upregulation of markers associated with pyroptosis, including NLRP3, caspase-1, and GSDMD, thereby diminishing the activation of stellate cells in HCC, suggesting that NEK7 modulates tumor progression and the interaction between cancer and stromal cells in HCC.149 Besides, the administration of IL-17A triggers pyroptosis via the ROS/NLRP3/caspase-4/GSDMD axis, enhancing the release of proinflammatory cytokines and resulting in increased infiltration of CD8+ T cells within tumor tissues.131 Zhao et al. discovered that enhanced expression of circAR-3 escalates cell proliferation and inflammation in prostate cancer (PCa), whereas its suppression exerted contrary effects. This process is facilitated by the acetylation of NLRP3 by KAT2B, furthering the subcellular localization and assembly of the NLRP3 inflammasome complex. This finding suggests that inhibiting NLRP3 acetylation or inflammasome assembly could be a viable strategy for halting the advancement of PCa.337 Yan et al. demonstrated that cisplatin induces the NLRP3/caspase-1/GSDMD pyroptosis pathway through the elevation of long non-coding RNA (lncRNA) maternally expressed gene 3 (MEG3) in TNBC, contributing to its anti-tumor activity. This finding offers a potential new approach for therapeutic intervention in TNBC.338 However, because of the pyroptosis activation effect of cisplatin, there can be severe side effects including acute kidney injury and hearing loss.339,340 To alleviate the side effects induced by cisplatin, animal and cell tests of two potential therapeutic oral anticancer drugs, AZD5438 and dabrafenib, a phase-2 clinical trial protein kinase CDK2 inhibitor and a US Food and Drug Administration-approved drug BRAF inhibitor, respectively, were conducted with the promising result of reduced cell death.341 Therefore, it exemplifies that the side effect of pyroptosis-targeted drugs can be improved when they are combined with other targeted drugs. Conversely, coenzyme Q0, a derivative quinone from Antrodia camphorate, exerted anticancer activity by counteracting NLRP3-mediated inflammation. Coenzyme Q0 suppresses HIF-1α expression and inhibits the NLRP3 inflammasome, as well as ASC/caspase-1 expression, resulting in the downregulation of IL-1β and IL-18 expression in MDA-MB-231 and 468 cells and inhibition of EMT/metastasis of human TNBC and HNSCC cells.342,343 This opposite result implies that in different cancers and different periods of tumor progression, pyroptosis may play different roles, and the treatment strategy should vary accordingly.

Extracts from natural crops have been shown to regulate pyroptosis as well. Radix Sophorae tonkinensis oxymatrine extract possesses anticancer properties. Oxymatrine has anticancer effects against CRC by suppressing LRPPRC, promoting mitophagy, and inhibiting the NLRP3 inflammasome in CRC cell xenografts and liver metastasis models.344 A clinical trial of oxymatrine for the treatment of severe plaque psoriasis found only minor adverse effects, and a clinical trial for CRC is expected.345 Peimine (PM), derived from Fritillaria, was found to mitigate inflammasome activity by reducing endoplasmic reticulum (ER) stress and decreasing the levels of various proteins within the NF-κB and mitogen-activated protein kinase (MAPKs) pathways, limiting the proliferation of breast cancer cells.346

Moreover, applying nanoparticles to regulate NLRP3-mediated pyroptosis is another promising therapeutic strategy. Guo et al. developed novel VB12-tethered nano micelles by enhancing sericin with poly(benzyl-l-glutamate) (PBLG) and encapsulating the near-infrared dye IR780. Under near-infrared light exposure, these specialized nano micelles disrupt ATP synthase function, leading to mitochondrial impairment and subsequent ROS generation. This sequence of events triggered the NLRP3/caspase-1/GSDMD pathway, ultimately resulting in the maturation of dendritic cells.347

Targeting the AIM2 inflammasome also affects cancer development. Curcumin, the principal active compound in turmeric, triggers caspase-1/GSDMD-dependent pyroptosis in leukemia cells by boosting the expression of the IFI16, AIM2, and NLRC4 inflammasomes through the stimulation of ISG3 transcription factor activity.348 Li et al. showed that dihydroartemisinin (DHA) activates the AIM2/caspase-3/GSDME axis, initiating pyroptosis in breast cancer cells.349 Moreover, elevated CCL19 expression markedly suppresses the proliferation of gastric cancer cells and tumor progression, both in vitro and in vivo, by enhancing the CCR7/AIM2 pathway. These findings present an encouraging therapeutic tactic for the treatment of gastric cancer in cases of combination with chemical materials.350 Xu et al. introduced a virus-mimicking particle self-assembled from elongated DNA structures produced via rolling circle amplification (RCA) enveloped in cationic liposomes. This construction initiates the activation of the AIM2 inflammasome, leading to gasdermin D-mediated pyroptosis and enhanced anti-tumor immune responses.351 Furthermore, the development of biodegradable Ca2+ nanomodulators (CaNMs) for pyroptosis-mediated cancer immunotherapy has shown promise, as they cause mitochondrial Ca2+ overload and promote ROS generation, cytochrome C release, and ultimately, the caspase-3/GSDME-dependent pyroptotic pathway.352 Furthermore, in an anaplastic thyroid cancer clinical trial, apatinib upregulates caspase‐1 and melittin activates AIM2 inducing caspase‐3–GSDMD and caspase‐1–GSDME pyroptosis.353

Therapeutic strategies targeting caspases

Caspases are critical effectors of pyroptotic cell death and, therefore, have received much attention as a potentially novel strategy for tumor therapy.104,105,354 Compounds targeting caspase-3 have been favored. For instance, triptolide treatment inhibits the expression of mitochondrial hexokinase and c-Myc II in cancer cells, activating the BAD/BAX caspase-3 cascade and ultimately leading to GSDME-dependent pyroptosis.355 Another small compound, gambogic acid, can also induce caspase-3/GSDME pyroptosis, simultaneously enhancing cancer immunotherapy.356 Miltirone, a natural substance with anticancer activity, simultaneously prompts the proteolytic cleavage of GSDME and caspase-3, thereby inhibiting the viability of HepG2 or Hepa1-6 cells. Mechanistically, miltirone elicits intracellular ROS accumulation, inhibiting the phosphorylation of mitogen-activated and extracellular signal-regulated kinase (MEK) and extracellular regulated protein kinase 1/2 (ERK1/2) and inducing GSDME-dependent pyroptosis. ROS/ERK1/2-BAX-caspase-9-caspase-3-GSDME has been confirmed as the central signaling axis in the regulation of pyroptosis.357 Similarly, tetraarsenic hexoxide can also induce the generation of mitochondrial ROS leading to the caspase-3/GSDME-mediated pyroptosis in cancer cells.358 Nitidine chloride (NC), a benzophenanthridine alkaloid extracted from the Chinese medicinal herb Zanthoxylum nitidum, inhibits the phosphorylation of PI3K and Akt, thus increasing caspase-3/GSDME-mediated pyroptosis in lung cancer cells, indicating that NC is a prospective therapeutic agent for the treatment of lung cancer.359 Curaxin CBL0137, designed to modulate p53 and nuclear factor-κB, has demonstrated the capacity to deactivate the chromatin remodeling complex. This deactivation facilitates chromatin transcription, thereby reducing the transcription of antioxidant genes and promoting oxidative stress, leading to elevated ROS levels. Subsequently, mitochondrial ROS recruit BAX to the mitochondrial membrane, releasing cytochrome c and subsequently activating caspase-3. This cascade prompts caspase-3/GSDME-mediated pyroptosis in ovarian cancer cells.360 Germacrone, a sesquiterpene component obtained from the essential oil of Ezhu, demonstrated anticancer properties by inducing pyroptosis in liver cancer. This effect is mediated through the proteolytic cleavage of caspase 3, accompanied by the cleavage of GSDME, and is notably associated with elevated ROS production.361 Besides, cordyceps militaris extract can also induce caspase-3/PARP/GSDME pyroptosis.362 Although these molecules have not been evaluated in clinical trials, their pyroptosis-targeting effects can harbor great potential for disease treatment.

Xie et al. developed inhaled poly(lactic-co-glycolic acid) (PLGA) porous microspheres loaded with doxorubicin (DOX) and decitabine (DAC), which resulted in elevated expression of cleaved caspase-3 and promotion of cell pyroptosis.363 Additionally, two self-assembling protein nanotoxins, T22-DITOX-H6 and T22-PE24-H6, were designed to target chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma (HNSCC) cells and to promote caspase-3/GSDME-mediated pyroptosis.364 Hu et al. reported a delivery strategy using arsenic trioxide nanoparticles (As2O3-NPs) for HCC treatment. In this approach, caspase-3 is activated to cleave GSDME and release its free N-terminal domain, triggering pyroptosis. Compared with free As2O3 and the control, As2O3-NPs showed better inhibition and induced more pronounced pyroptosis, increasing GSDME-N expression in Huh7 cells.365 These studies show that treatment in the form of nanoparticles may provide an ideal effect; however, more evidence and clinical trials are needed before they can be clinically applied because of potential side effects induced by the components and concerns of biocompatibility.

Targeting caspase-1/GSDMD-induced pyroptosis requires further extensive research. Simvastatin, traditionally used to manage hyperlipidemia, has garnered attention for its novel anticancer properties. Recent studies have revealed its ability to generate intracellular ROS in colon cancer cells, subsequently activating caspase-1 and initiating caspase-1-dependent pyroptosis.366 However, the ROS-generating effect of simvastatin was evaluated in 2016, with the results showing nonsignificant differences with the placebo group.367 Therefore, further evidence is required for the treatment outcome of colon cancer in vivo. Likewise, Chen et al. reported a similar phenomenon for secoisolariciresinol diglucoside in colorectal cancer cells and saikosaponin D in lung cancer cells.368,369 Additionally, a combination of drugs may enhance the ability to target caspase-1. For example, combined with ruthenium (II) polypyridyl complex Δ-Ru1, taxol improved caspase-1/GSDMD induced pyroptosis in Taxol-resistant cancer cells.370

Furthermore, other caspases, such as caspase-8 and caspase-9, have been explored for their interactions with pyroptosis in tumor cells, illustrating a diverse range of potential therapeutic approaches.349,371–373 Moreover, a mechanism of sorafenib therapy against HCC tumors through inducing macrophage (MΦ) pyroptosis and triggering an NK-cell response was explored. Pyroptosis in MΦ via upregulating caspase-1 activity caused the release of proinflammatory cytokines, enhancing the proliferation and activation of NK cells. Subsequently, tumor cells undergo apoptosis due to NK cell cytotoxicity, degranulation, and release of perforin.374 Notably, a phase III clinical trial of sorafenib in the treatment for HCC produced outcomes of unsatisfactory response and survival benefit, which was less significant than that of tislelizumab. However, the potential of combinations with other components is receiving extensive attention.375–377

These developments highlight the potential of targeting caspases and other related pathways as effective strategies for promoting pyroptosis in tumor therapy.

Therapeutic strategies targeting GSDM

Gasdermin is a potential target for anti-tumor therapeutic strategies because it is a critical effector of the pyroptosis axis. Endosomal sorting complexes necessary for transport (ESCRT) III-dependent cell membrane repair have been shown to effectively reduce pyroptosis in tumor cells by repairing and removing GSDM pores. Zhao et al. used a biodegradable, sustained-release calcium chelator based on nanoparticles to design a hydrogel-based delivery system aimed at blocking ESCRT III-dependent membrane repair, with the potential for improved immunotherapy efficacy.378 Another approach involves constructing a recombinant adeno-associated virus (rAAV) system to produce and deliver GSDMNT into tumor cells. Utilizing the Sf9/rBac system, a mammal-specific promoter for packaging rAAV-GSDMDNT, and employing the Cre/lox system to recover and express double-floxed inverted GSDMNT, the system stimulated immune responses by triggering pyroptosis and temporarily opening the blood-brain barrier (BBB).379 These works showed that innovative delivery approaches may improve targeting efficacy and safety.

In addition, the PD-L1/PD-1 immune checkpoint has been found to engage the pyroptosis pathway. Under specific circumstances, PD-L1 translocates to the nucleus, where it enhances GSDMC transcription. Subsequent treatment with TNF-α results in caspase-8-mediated cleavage of GSDMC, leading to pyroptosis and tumor necrosis in breast cancer.36 Furthermore, tumor cell ablation of mixed-lineage leukemia 4 (MLL4) was found to activate the transcriptional reactivation of GSDMD-dependent pyroptosis through enhancer decommissioning and oncolytic parapoxvirus ovis (ORFV) and was shown to pre-stabilize GSDME by mitigating its ubiquitination and subsequently inducing tumor cell pyroptosis.330,380 Additionally, USP48 stabilizes GSDME by removing K48-linked ubiquitination at K120 and K189, thereby promoting pyroptotic death in cancer cells.150

These innovative and diverse approaches demonstrate the potential of targeting GSDM and the pyroptotic pathway in anti-tumor therapeutic strategies, offering promising avenues for further exploration and development, as summarized in Fig. 5 and Table 2.Fig. 5 Potential cancer treatment strategies that target pyroptosis. Tumor cells undergoing pyroptosis release immunogenic substances and pro-inflammatory cytokines that promote immune cell activation and recruitment. This may engage in a positive feedback loop that augments tumor-specific immunity and further increases tumor-specific immunity. Thus, recent research has examined the therapeutic viability and potential of manipulating pyroptosis as an anticancer treatment. Key components in the process, such as NLRP3, AIM2, caspase-1, caspase-3, and gasdermins, have been developed into several specific therapeutic agents for malignancies. The figure was created by Figdraw

Table 2 Summary of agents targeting molecules of pyroptosis in anti-cancer therapeutics

Classification	Drug	Mechanisms	Cancer type	References	
Small compound	FL118	NLRP3/Caspase-1/GSDMD	Colorectal cancer	336	
NPs	VB12-sericin-PBLG-IR780	ROS/NLRP3/Caspase-1/GSDMD	Gastric cancer	347	
Small compound	AIF	NLRP3/Caspase-1/GSDMD	HCC	334	
antidiabetes drug	Metformin	FOXO3/NLRP3/Caspase-1/GSDMD	HCC	335	
FDA-approved drug	Cisplatin	MEG3/NLRP3/Caspase-1/GSDMD	TNBC	338	
Small compound	A438079	NLRP3/Caspase-1/GSDMD pathway by inhibiting P2X7R	Colorectal cancer	153	
Small compound	Curcumin	ISG3/AIM2/Caspase-1/GSDMD, ISG3/IFI16/Caspase-1/GSDMD, ISG3/NLRC4/Caspase-1/GSDMD	Acute myeloid leukemia	348	
NPs	DNF@LIPO	AIM2/Caspase-1/GSDMD	Breast cancer	351	
Antimalarial drug	DHA	AIM2/Caspase-3/GSDME	Breast cancer	349	
NPs	PLGA porous microspheres	Caspase-3/GSDME	Lung cancer	363	
NPs	T22-PE24-H6 and T22-DITOX-H6	Caspase-3/GSDME	HNSCC	364	
NPs	CaNMs	ROS/Caspase-3/GSDME	Breast cancer	352	
NPs	As2O3-NPs	Caspase-3/GSDME	HCC	365	
Small compound	Triptolide	Caspase-3/GSDME	Head and neck cancer	355	
Small compound	Gambogic acid	Caspase-3/GSDME	Colorectal cancer	356	
Small compound	Miltirone	ROS/Bax/Caspase-3/GSDME	HCC	357	
Small compound	Tetraarsenic hexoxide	ROS/Caspase-3/GSDME	TNBC	358	
FDA-approved drug	Cisplatin and paclitaxel	Caspase-3/GSDME	Lung cancer	105	
Chinese medicine	Cordyceps militaris extract	Caspase-3/GSDME	Lung cancer	362	
Small compound	Nitidine chloride	Caspase-3/GSDME pathway by suppressing PI3K/Akt pathway	Lung cancer	359	
FDA-approved drug	Sorafenib	Caspase-1/GSDMD	HCC	374	
NPs	A hydrogel-based delivery system carrying calcium chelator	GSDMD	Breast cancer, melanoma, and ovarian cancer	378	
NPs	Sf9/rBac system and Cre/lox system	GSDMD	Glioblastoma, breast cancer and TNBC	379	
Oncolytic virus	ORFV	GSDME	Melanoma	380	

Neurological disease

Alzheimer’s disease

AD is distinguished by its neuropathological features, such as amyloid-β plaques outside cells, neurofibrillary tangles inside cells, neuroinflammation, and loss of neurons.165 Targeted suppression of inflammasome-dependent pyroptosis alleviates AD-related symptoms. Sodium houttuyfonate (SH) suppressed the expression of NLRP3 and cleavage of GSDMD, ameliorated pyroptosis in hippocampal neurons, and mitigated deficits in spatial learning and memory in mice with AD induced by Aβ1-42.381 L7 (derivative of N-salicyloyl tryptamine) counteracts pyroptosis in BV2 cells triggered by Aβ through the inhibition of the NLRP3-caspase-1 signaling cascade, thereby offering neuroprotection through reduced GSDMD expression.382 1,7-diphenyl-4-hepten-3-one (C1), a natural diarylheptanoid, was found to alleviate AD-like pathology by suppressing pyroptosis via activation of the Nrf2 pathway, thus downregulating the expression of NLRP3, GSDMD, and caspase-1.383 Telmisartan, a widely used anti-hypertensive drug approved by the FDA, can further ameliorate inflammatory effects via the inhibition of the microglial PPARγ/NLRP3 pathway.384 Additionally, artificial silencing of the INPP5D gene could promote NLRP3 production in microglia, providing therapeutic potential for AD treatment.385 The selective blockade of NLRP1, caspase-1, and caspase-6 ameliorates neuroinflammation and cognitive deficits in transgenic mice with AD.386 Chinese traditional medicine acupuncture also exhibits similar treatment efficiency. The Bushen Huoxue acupuncture technique diminishes Aβ generation in the hippocampal tissue of SAMP8 mice, suppresses NLRP1 inflammasome activation-medicated pyroptosis, and ultimately enhances cognitive function in mice with AD.387 Specific blockades of caspase-GSDM-mediated pyroptosis have demonstrated noteworthy neuroprotective effects in animal models of AD. In experiments involving APP/PS1 mice, mafenide (MAF) derivatives restrained GSDMD activation-induced pyroptosis and neuroinflammation by impeding cleavage at the GSDMD-Asp275 site.388 Another study showed that inhibition of inflammasome activation by MCC950, an NLRP3 inhibitor, improved cognitive function in APP/PS1 mice.170

Preserving BBB integrity through suppression of pyroptosis diminishes Aβ aggregation. Research has indicated that inflammatory mediators released from pyroptotic neurons during cerebrovascular disease significantly undermine BBB integrity.389 Traumatic brain injury (TBI) triggers pyroptosis in impaired brain microvascular endothelial cells (BMVECs) via NLRP3 inflammasome activation. The caspase-1 inhibitor AcYVAD-CMK can impede NLRP3 inflammasome activation by preventing GSDMD cleavage and ASC oligomerization, thus preserving the integrity of the BBB.330

Parkinson’s disease

PD symptoms, similar to those of AD, can be alleviated by targeting the suppression of inflammasome-dependent pyroptosis. A small molecular NLRP3 inhibitor, MCC950, inhibited α-synuclein-mediated inflammasome activation, attenuating nigrostriatal dopaminergic degeneration and motor deficits.176 Salidroside (Sal) safeguards dopaminergic neurons by attenuating NLRP3-dependent pyroptosis via (1) indirectly diminishing the synthesis of NLRP3, pro-IL-1β, and pro-IL-18 through the inhibition of the TLR4/MyD88/NF-κB signaling cascade, and (2) directly inhibiting pyroptosis by targeting the TXNIP/NLRP3/caspase-1 signaling pathway.390 Additionally, synchronized upregulation of pyroptosis protein expression and Parkinson’s-like symptoms in 6-hydroxydopamine-induced PD rat models can be inhibited by kaemperfol via the p38MAPK/NF-κB signaling pathway.391 Experimental data from both in vitro and in vivo studies have revealed that the Prussian blue nanozyme (PBzyme) mitigates the activation of microglial NLRP3 inflammasomes and caspase-1 by neutralizing ROS. This action results in reduced cleavage of GSDMD and decreased production of inflammatory mediators, culminating in the suppression of microglial pyroptosis.392 In both in vivo and in vitro PD models, β-hydroxybutyrate (BHB) supplementation suppresses pyroptosis by attenuating the activation of the NLRP3 inflammasome via downregulation of STAT3-mediated signaling.393 Traditional Chinese drugs also exhibited the ability to regulate pyroptosis. Qiji Shujiang granule (QJG) mediates the reduction of pyroptosis by inhibiting the NLRP3/caspase-1 axis, thereby conferring a neuroprotective benefit.394

Targeting the upstream molecules of the pyroptosis pathway is another option. TLR4 has been shown to sense LPS and induce pyroptosis through a signaling cascade.395,396 TLR4 cell-surface expression, LPS sensing, dimerization, and signaling depend on TLR4 binding to MD-2.397 Disulfiram (DSF) was found to modify Cys133 of MD-2 and inhibit TLR4 sensing, suppressing neuroinflammation and dopaminergic neuron loss.398

Stroke

Stroke remains the predominant cause of mortality and persistent impairment globally, with ischemic stroke accounting for approximately 85% of total occurrences.399 Targeting the NLRP3 inflammasome to inhibit pyroptosis has been the dominant strategy for alleviating stroke symptoms in the past few years. Pinocembrin, a natural product, was discovered to inhibit the activation of the TLR4/NF-κB pathway, suppressing the downstream assembly of the NLRP3 inflammasome and ameliorating vascular lesions.400 RRx-001 shows promise as a specific inhibitor of NLRP3, primarily exerting its effects by binding to cysteine 409 of NLRP3 to disrupt the NLRP3-NEK7 interaction, which is crucial for NLRP3 activation. RRx-001, currently undergoing phase III clinical trials, has a reasonably good safety profile and is a promising therapeutic candidate for stroke.401 Meanwhile, inhibition of Janus kinase can ameliorate ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition.402 More drugs, such as lonidamine, edaravone dexborneol, thiolutin, and β-1, 3-galactosyltransferase-2, may inhibit NLRP3 assembly. However, few of these drug candidates could be translated into clinical research.403–406

Multiple sclerosis

The NLRP3 inhibitors JC-171, OLT1177, and MCC950 can efficiently ameliorate EAE pathogenesis, improve deficient symptoms, and prevent cognitive deficits in patients with MS.407–409 Pyroptosis was inhibited by the caspase-1 inhibitor, VX-765, in an EAE model. VX-765 treatment improved neurobehavioral performance and reduced pyroptosis-related protein expression and axonal injury.180,409

Respiratory diseases

Asthma

Yanghe Pingchuan has been used to treat asthma for many years in China. While the detailed mechanism remains unknown, Yanghe Pingchuan was discovered to inhibit airway smooth muscle cell pyroptosis in asthma by suppressing the TLR4/NF-κB/NLRP3 signaling pathway.410 JT002 treats asthma by inhibiting NLRP3 assembly, thus alleviating airway hyperresponsiveness and neutrophilia.411 Likewise, heme oxygenase-1 (HO-1), an enzyme inducible for degrading heme, was shown to inhibit GSDMD-mediated pyroptosis and release of cytokine TSLP in airway epithelial cells by interacting with the RHD domain of NF-κB p65 and modulating NF-κB-dependent pyroptosis.412 Furthermore, additional NF-κB/NRLP3-mediated asthma treatment candidates include Schisandrin B and Protopine.413,414

Chronic obstructive pulmonary disease

COPD, a prevalent condition that can be prevented and managed, is characterized by persistent respiratory symptoms and restricted airflow resulting from airway and alveolar anomalies. Several pyroptosis inhibitors have been explored to treat COPD, with most targeting the NLRP3 inflammasome. Schisandrin A, a lignan of the diphenyl cyclooctadiene class extracted from Schisandra chinensis fruits, possesses a range of pharmacological activities; it mitigates ROS generation and NLRP3 inflammasome activation through the upregulation of Nrf-2, thus exerting anti-inflammatory effects and diminishing pulmonary damage in mouse models of COPD.415 Tian et al. discovered that (-)-epicatechin, a flavonoid compound, suppresses NLRP3 inflammasome activation by enhancing Nrf2 activity and alleviating lung inflammation triggered by cigarette smoke, which was validated through the reduced secretion of IL-1β and IL-18 in a rat model of COPD.416 Similarly, propofol, an anesthetic agent, increases Nrf2 expression and inhibits NLRP3 expression.417

In addition, physical or support methods can alleviate pyroptosis in COPD. For instance, halotherapy was found to alleviate oxidative stress in the lung tissues of COPD rats, diminish the accumulation of CD4+ and CD8+ T cells in the lungs, and reduce the production of inflammatory factors in the serum by suppressing the TLR4/NF-κB/GSDMD and NLRP3/ASC/caspase-1 pathways.418 The success of halotherapy in alleviating pyroptosis in patients with COPD provides incentives for the more detailed exploration of physical treatments in respiratory diseases.

Acute lung injury

Several molecules have been found to improve ALI symptoms by regulating pyroptosis, most of which target the upstream molecules of the NLRP3 inflammasome. For example, buformin, a hypoglycemic agent, can drive phosphorylation of AMPK, inhibit downstream NLRP3 inflammasome production, and accelerate autophagy, which, in turn, promotes NLRP3 inflammasome degradation, inducing a therapeutic effect after ALI.190 Emodin, an anthraquinone compound derived from rhubarb, and Polygonum cuspidatum treat AP-associated ALI by regulating macrophages and neutrophils via the targeting of NLRP3 production. Emodin mitigates the pyroptotic process of alveolar macrophages by decreasing the level of inflammatory cytokines and lactate dehydrogenase via NLRP3 inhibition and cold-inducible RNA-binding protein-activated NLRP3/IL-1β/CXCL1 signaling to dampen neutrophil infiltration.419,420 Furthermore, dehydroandrographolide, sourced from the traditional Chinese herb Andrographis paniculata, mitigates NLRP3-mediated pyroptosis in acute lung injury models by causing ROS-induced mitochondrial damage, which is achieved through the suppression of the Akt/Nrf2 signaling pathway, mediated by PDPK1 ubiquitination.421 Similarly, chicoric acid effectively inhibited pyroptosis by inducing mitochondrial damage via ROS generation. This effect is mediated by the activation of the Akt/Nrf2 pathway via PDPK1 ubiquitination.422 Other potential drugs regulate pyroptosis by targeting distinct pathways. Tangeretin mitigates ALI induced by sepsis by suppressing ROS-mediated activation of the NLRP3 inflammasome by modulating the PLK1/AMPK/DRP1 signaling axis.423 EuHD1 hinders the formation and activation of the NLRP3 inflammasome by suppressing ROS production and ASC oligomerization.424 Ren et al. revealed that the anti-pyroptotic effect of ergolide is conferred through direct targeting of the NACHT domain of NLRP3.425 Finally, britannin is an effective and natural NLRP3 inhibitor.426 The diversity of upstream molecules of NLRP3 offers various choices, but the interactions between these molecules and which one possesses the dominant role remain to be determined.

Other targets of pyroptosis have the potential to treat ALI. Zhang et al. found that Xuebijing, a traditional Chinese medicine recognized for its potent anti-inflammatory properties, inhibited gasdermin-E-mediated pyroptosis of lung cells by suppressing TNF-α production.427 Moreover, targeting pyroptosis has therapeutic implications for other respiratory diseases. For example, targeting caspase-1 by tetracycline blocks pyroptotic cell death in macrophages exposed to silica particles during silicosis.428 Colchicine inhibits NLRP3 inflammasome and inflammation to ameliorate COVID-19 pneumonia which are verified in clinical trials.429

In summary, targeting the NLRP3 inflammasome is a viable strategy for inhibiting pyroptosis and treating respiratory diseases, whereas other targets, such as caspase-1, also exhibit therapeutic potential.

Kidney diseases

Acute kidney injury

Similarly, the NLRP3 inflammasome serves as a potential target for AKI treatment. The carboxy-terminus of Hsc70-interacting protein (CHIP), a U-box E3 ligase, is known to modulate oxidative stress by degrading its target proteins and has been found to engage with NLRP3, ubiquitinating it to facilitate its degradation via the proteasome, thereby suppressing pyroptosis mediated by the NLRP3/ASC inflammasome.430 The Klotho protein, which is beneficial in AKI, including for anti-senescence, anti-oxidation, anti-inflammation, and anti-fibrosis, inhibited the NLRP3 inflammasome by promoting cell autophagy, improving AKI.431 miR-30c-5p can suppress the expression of NLRP3, ASC, and caspase-1 by directly interacting and inhibiting TXNIP.432 Additionally, circ DENND4C, secreted by urine-derived stem cells in the form of exosomes, interacts with the miR 138-5p/FOXO3a axis, inhibiting the NLRP3 inflammasome.433 In addition to the NLRP3 inflammasome, caspase-1 is another candidate target for pyroptosis inhibition. Carnosine, a dipeptide known for its antioxidant and anti-inflammatory effects, reduces damage in kidney tubular epithelial cells by targeting caspase-1 and suppressing caspase-1/GSDMD-driven pyroptosis.434 Although these targets are embedded upstream of the pyroptosis pathway, GSDMD, an executor of pyroptosis, exhibits therapeutic potential. Recent studies have highlighted that dual-specificity phosphatase 2 (DUSP2) is a pivotal modulator of cell death and inflammation in several diseases. Functioning as a nuclear phosphatase, DUSP2 deactivates STAT1, a transcriptional suppressor of GSDMD, thereby limiting GSDMD-mediated pyroptosis in renal tubular epithelial cells.435

Diabetic kidney disease

Three PubMed-indexed studies have targeted pyroptosis for DKD treatment, and all targeted NLRP3-mediated inflammation. Loganin mitigates pyroptosis in HK-2 cells triggered by high glucose levels by suppressing ROS generation and NLRP3 inflammasome activation, resolving renal pathologies in DKD mice, similar to ManNAc in podocytes.436,437 Likewise, the anti-pyroptotic effect of the Tangshen formula acts via the TXNIP-NLRP3-GSDMD axis.438

Lupus nephritis

Honokiol, derived from the bark of Magnolia officinalis, is a versatile lignan with diverse pharmacological effects, including anti-inflammatory, antioxidant, and anti-tumor properties, with minimal side effects.439 Ma et al. unveiled that honokiol can suppress the renal activation of the NLRP3 inflammasome in macrophages, inhibiting the release of IL-33 and IL-1β and avoiding renal tubular epithelial cell death during lupus nephritis.440 Additionally, quercetin, a bioactive compound naturally occurring in various plants, has been identified for its role in improving pyroptosis mediated by inflammasomes and GSDMD. This effect is primarily attributed to the regulation of the IL-33/ST2 pathway and potentially involves the IL-33/TLR4 pathway in renal tubular epithelial cells.441

Cardiovascular diseases

Atherosclerosis

Pyroptosis has been a treatment target for atherosclerosis, as exemplified by the candidate molecule salvianolic acid A in diabetic atherosclerosis.442 Typically, apigenin, lncRNA H19, organogermanium compound 3-(trihydroxygermyl) propanoic acid (THGP), and Z-LLSD-FMK or Z-YVAD-FMK improve atherosclerosis by targeting NF-κB, caspase-1, caspase-1, and GSDMD, respectively.443–446 However, some molecules regulate pyroptosis through distinct targets. Melatonin, a neuroendocrine hormone produced in the pineal gland and other organs, has been shown to suppress macrophage pyroptosis in atherosclerosis by downregulating the SIRT3/FOXO3α/ROS pathway, consequently diminishing caspase-1 dependent pyroptosis.262 Estrogen was reported to recognize estrogen receptor α and promote autophagy of endothelial cells, thereby downregulating the expression of NLRP3, cleaved caspase 1, and GSDMD.265 Likewise, Liu et al. revealed that blocking the p62/Nrf2/ARE signaling pathway using chloroquine through autophagy impairment can promote pyroptosis in macrophages, providing a novel therapeutic target for atherosclerosis treatment.447 Thus, the MALAT1/miR-30c-5p/Cx43 axis is a potential target for atherosclerosis therapy. Yang et al. revealed that the expression of MALAT1 and Cx43 was upregulated, while miR-30c-5p was downregulated in rat aortic endothelial cells during pyroptosis following atherosclerosis. Furthermore, MALAT1/miR-30c-5p/Cx43 comprises a signal cascade that regulates pyroptosis.448

Myocardial infarction

In recent years, numerous drugs and molecules have been explored to treat myocardial injury. Downstream regulation of NLRP3 expression has been the prominent target, by focusing on various upstream molecules. For example, geniposide promotes AMPK phosphorylation, Tanshinone IIA and Qighen granule suppress the TLR4/NF-κB p65 signaling pathway, hydrogen gas inhalation reduces the production of ROS, and chlorogenic acid depresses lncRNA Neat1 expression, ultimately impacting cardiomyocyte pyroptosis.449–453 In clinical trials, coenzyme Q10 is verified to suppress the recruitment of pro-inflammatory CCR2+ macrophages by attenuating the activation of the NLRP3/ IL-1β pathway, ameliorating MI.454 The AIM2 inflammasome also exhibits therapeutic potential in MI. Epigallocatechin-3-gallate, a bioactive polyphenol isolated from green tea, protects cardiomyocytes from pyroptosis via the MEG3/TAF15/AIM2 axis, thereby inhibiting AIM2 expression.455 Moreover, other targets in the canonical pathway, such as GSDMD, have gained attention in MI. Danhong, a traditional Chinese medicine, injection directly blocks GSDMD-N oligomerization and pore formation.101 MicroRNA-182-5p, carried by MSC-derived exosomes, also directly targets GSDMD and suppresses pyroptosis.456 In addition to the direct effects of upstream molecules on the NLRP3 inflammasome, additional targets have been of interest. Magnetic stimulation therapy also contributes to the treatment of MI. Lu et al. found that magnetic vagus nerve stimulation inhibited cardiomyocyte pyroptosis by activating M2AChR to suppress oxoglutarate dehydrogenase-like expression.457 In summary, various targets are involved in the regulation of pyroptosis in MI treatment.

Diabetic cardiomyopathy

Pyroptosis-inhibitory compounds targeting upstream molecules of NLRP3 have been discovered in the context of DCM. For example, the bone morphogenetic protein-7 cascade represses the expression of Nek7, GBP5, and TLR4, eventually inhibiting NLRP3.458 Metformin can activate the AMPK/mTOR pathway, thereby improving cell autophagy and disrupting NLRP3-mediated pyroptosis.459 Similarly, berberine suppresses NLRP3 by disturbing mTOR/mtROS.460 Fufang Zhenzhu Tiaozhi, a Chinese herbal medicine, and pomegranate peel extract exhibit cardioprotective potential through NLRP3 inhibition.461,462 GSDMD is also a target for DCM treatment. Lu et al. discovered that the protective role of irisin and mitochondrial ubiquitin ligase (MITOL/MARCH 5) in DCM was partially offset by the activation of cGAS/STING signaling, inhibiting GSDMD-mediated pyroptosis.463 Targeting Nrf2 has a pivotal role in inhibiting pyroptosis. For instance, curcumin can reduce the accumulation of superoxide in the myocardium through AKT/Nrf2/ARE pathway activation and inhibit pyroptosis, promoting nuclear translocation of Nrf2, increasing expression of antioxidant factors in cells and inhibiting the progression of cell pyroptosis.464,465 Similarly, puerarin and quercetin can inhibit pyroptosis by regulating P2X7 receptor expression. However, these two compounds exhibit opposite effects on the expression of the P2X7 receptor, leaving the mechanism of pyroptosis inhibition to be elucidated.465,466

Digestive diseases

Inflammatory bowel disease

Xu et al. proposed a novel approach using self-adaptive pyroptosis-responsive liposomes to treat autoimmune inflammatory diseases, including inflammatory bowel disease. Following pyroptosis, the activated GSDME-N bound to the cardiolipin on the liposome surface, forming pores releasing encapsulated dimethyl fumarate and inhibiting the caspase 3/GSDME pathway.467 A PLGA-microsphere-carried circGMCL1 was designed to protects against Crohn’s colitis through suppressing NLRP3 inflammasome-dependent pyroptosis via regulation of miR-124-3p/ANXA7-induced autophagy.468 Human umbilical cord mesenchymal stem cell-derived exosomes were found to protect against colitis via the regulation of macrophage pyroptosis in a miR-378a-5p-denpendent manner.469 Furthermore, β-sitosterol, Tou Nong powder, necrosulfonamide, Munronoid I, and ginsenoside Rg3 have been associated with inflammatory bowel disease treatment.470–474

Acute pancreatitis

The natural compound wedelolactone has been reported to impede AP progression and associated lung injury through the canonical caspase-1-mediated pyroptotic pathway and caspase-11-mediated non-canonical pyroptotic pathway.475 Li et al. demonstrated that hair follicle-derived mesenchymal stem cell-derived small extracellular vesicles alleviated AP by suppressing inflammation and pyroptosis in pancreatic acinar cells. Furthermore, compared to the effect of small extracellular vesicles administered intraperitoneally, the therapeutic effect of small extracellular vesicles following intravenous injection seems to be enhanced.476 Qingjie Huagong decoction, a formula consisting of seven traditional medicines, has been reported to exert its anti-AP effects by regulating the circHipk3/miR-193a-5p/ NLRP3 pathway.477 Other therapeutic strategies have also emerged to target pyroptosis in the pathology of AP, including baicalein, disulfiram, sinapic acid, and salidrosidet.478–481

Liver fibrosis

Forsythiaside A (FA), a natural bioactive ingredient derived from traditional Chinese medicine, was loaded into a CD44-targeting exosome nanocarrier and mitigated liver fibrosis. The anti-liver fibrosis mechanism could be attributed to the suppression of NLRP3-mediated pyroptosis.482 Stem cells from human exfoliated deciduous teeth attenuated liver cirrhosis by suppressing the GSDMD-mediated pyroptosis pathway via decreasing ROS in hepatocytes.483 Nicotinic acid (NA), a vitamin used to treat dyslipidemia, was found to inhibit the NF/κB/NLRP3 signaling axis, thereby preventing pyroptosis and liver fibrosis during non-alcoholic steatohepatitis progression.484 Furthermore, researchers have identified various pioneering compounds that target pyroptosis for treating liver fibrosis, such as JT001, trilobatin, ursolic acid, and auranofin.485–488 Additionally, the clinical efficacy of some drugs was tested. A phase I clinical trial verified that emricasan inhibits excessive caspase activation and lowers ALT in patients with non‐alcoholic fatty liver disease, which may ameliorate the progression from fatty liver to liver fibrosis.489 These molecules and targets’ potential for non-cancer disease treatment are summarized and visualized in Fig. 6.Fig. 6 Potential targeted therapeutic strategies for pyroptosis in non-cancer diseases. Investigations into pyroptosis enhance our understanding of the pathological mechanisms underlying various diseases. Key elements involved in pyroptosis, including NLRP3, caspase-1, gasdermin D, and upstream molecules such as TLR4/NF-κB axis, are crucial for human health and have led to the development of numerous targeted therapies for several inflammatory conditions. The figure was created by Figdraw

Conclusion and perspective

Pyroptosis is a distinct form of cell death characterized by inflammasome formation, caspase-mediated gasdermin cleavage, and inflammatory cytokine release. As an RCD form, the ubiquity of pyroptosis in cells indicates its great promise and remarkable drug market potential of pyroptosis-targeted drugs. For example, in cancer cells, pyroptosis can induce regional inflammation and convert “cold tumors” to “hot tumors,” triggering enhanced antitumor immunity and sensitizing checkpoint blockade immunotherapy.490 Pyroptosis-targeted therapy can assist in antitumor immunotherapy by inducing tumor cell pyroptosis, similar to chemotherapy but with fewer side effects. Pyroptosis-targeted drugs are promising therapeutic methods for tumors in addition to classical chemo-, radio, and immunotherapies. In addition, the intraepithelial mast cell-driven gasdermin C-mediated type 2 immunity has also been identified recently, which can be exploited as a potential drug target for allergic diseases.491 Besides, studies focusing on pyroptosis have made significant progress in recent decades at multiple levels, including elucidation of signaling mechanisms, disease regulation, and molecular structures. NLRP3/caspase-1/GSDMD and caspase-3/GSDME are two main druggable pathways for pyroptosis-related diseases. Previous research widely reported that the therapeutic effect of some classical drugs and traditional Chinese medicines is partly mediated through pyroptosis pathways. For instance, the IL-1R inhibitor, Anakinra, can relieve liver inflammation by targeting NLRP3 inflammasome.492 Atorvastatin inhibits the expression of NLRP3 to prohibit the progression of atherosclerosis. As for targeting caspase, numerous natural substances such as dendrobine can inhibit the expression or maturation of caspase-1 to achieve therapeutic outcome.493 Most chemotherapy drugs such as doxorubicin (Dox) and cisplatin induce cancer pyroptosis by activating caspase-3. Furthermore, disulfiram, a drug for alcoholism treatment, can modify the Cys191 amino acid of GSDMD to inhibit its oligomerization, which is promising for inflammatory disease therapy.396 Therefore, large amounts of approved drugs possess the potential to regulate pyroptosis for therapy. Although drug innovation targeting pyroptosis pathways is hard because of the interlaced signal pathway and complicated molecular structures such as NLRP3 inflammasome, increasing small molecule drugs have been reported recently. For example, while UK5099 can selectively inhibit NLRP3 inflammasome, necrosulfonamide, a chemical inhibitor, can selectively bind to GSDMD inhibiting its oligomerization to serve as a potential drug for inflammatory diseases.494,495 Molecular structures identified by cryo-electron microscopy or artificial intelligence such as Alphafold 3 provide increasing structures for scientists to identify novel drug targets by molecular docking, experiment verification, and further clinical trials.496 However, several challenges remain regarding the research and development of pyroptosis drugs with potential therapeutic strategies.

Disease heterogeneity presents a formidable challenge for pyroptosis drugs. For example, tumor heterogeneity exists not only between but also within different malignancies. Variations in the expression and function of pyroptosis-related molecules among different tumors may affect the responsiveness of tumors to pyroptosis-inducing therapies. Crosstalk between pyroptosis and other signaling pathways also complicates the cytoplasmic microenvironment. Given the heterogeneous intracellular and tumor microenvironments, pyroptosis-based therapies are challenging. Identifying a suitable patient population for pyroptosis therapy is crucial for future clinical trials. Inspired by targeted therapy in patients with cancer based on molecular classification, data-driven patient selection is promising for improving the therapeutic efficacy of pyroptosis-based therapies. Integrating omics and clinical information may also help predict the therapeutic outcomes of pyroptosis drugs in patients. For example, the expression level of GSDME in cancer cells may predict the therapeutic response of GSDME-targeted therapy. Molecular classification for selecting suitable patients to receive pyroptosis-targeted therapy is the guarantee of a favorable outcome.

Second, effective and selective drugs that can safely induce or inhibit pyroptosis remain far from satisfactory. Research on pyroptosis-based drugs remains at the laboratory stage, with limited candidates entering the preclinical and clinical trial phases. These clinical trials are summarized in Table 3 among which butyrate and inulin, zinc supplementation, and dapansutrile ameliorate type 2 diabetes, Bechet’s disease, and gout by regulating pyroptosis, respectively.497–499 However, the safety concerns associated with the induction or inhibition of pyroptosis are paramount. Extensive inhibition of pyroptosis inevitably increases the probability of pathogen invasion which may bring unforeseen risks for patients. Off-target effects also deserve wide attention. For example, previous research demonstrated that GSDME activation is reliant on caspase-3 and that the expression level of GSDME is closely linked to the type of cell death induced by chemotherapeutic agents. Cells with high GSDME expression underwent pyroptosis in response to chemotherapy, whereas cells with low or absent GSDME expression experienced apoptosis. However, researchers also noted that GSDME expression is typically low in most tumor cell lines because of methylation of the GSDME gene promoter, while GSDME is broadly overexpressed in normal cell lines.23,103 Therefore, chemotherapy might also trigger caspase-3-mediated pyroptosis in normal cells with high GSDME expression, potentially contributing to the toxicity and side effects observed during chemotherapy. For instance, Zheng et al. demonstrated that the activation of the Bnip3-caspase-3-GSDME pathway following Dox treatment initiated GSDME-mediated pyroptosis, contributing to Dox-induced cardiotoxicity in vivo.296 Dox treatment results in the hyperactivation of the NLRP3 inflammasome and pyroptotic cell death in cardiomyocytes, which is a key mechanism underlying dilated cardiomyopathy in Dox-treated heart tissues. The absence of either NLRP3 or caspase-1 protects mice from Dox-induced dilated cardiomyopathy.290 The specificity of pyroptosis-targeted agents has emerged as a critical issue, emphasizing the need to minimize unintended consequences in healthy cells. Selecting the appropriate drug target, integrating nano-delivery and protein-degradation technologies, and combining other existing therapy strategies are viable pathways to improving therapeutic efficiency while mitigating the risk of toxicity. The identity of molecules’ structure helps to design and deliver drugs. The structure and related mechanism of NLRP1, NLRP3, GSDMB, and GSDMD have been analyzed by cryo-electron microscopy.29,500–502 Specific cell-targeted adeno-associated virus systems also possess the potential to precisely regulate pyroptosis. Furthermore, as immune cells can distinguish cancer cells from normal cells, pyroptosis-mediated immune mobilization by engineered immune cells such as CAR-T can selectively alter the tumor microenvironment, which can greatly reduce side effects.Table 3 Selected clinical trials related to pyroptosis and the corresponding target

Drug	Signal pathway	Mechanism	Disease	References	
Colchicine	NLRP3	Inhibit NLRP3 inflammasome activation and ‘cytokine storm’	COVID-19	429	
Zinc supplementation	NLRP3/caspase-1	Inhibit NLRP3 and caspase-1 expression	Behçet’s disease	498	
Butyrate and Inulin	TLR2/NLRP3/caspase-1

NF-κB1/NLRP3/caspase-1

	Upregulate miR-146a and miR-9 hence inhibiting TLR2 and NF-κB1	Type 2 diabetes	497	
Coenzyme Q10	NLRP3/ IL-1β	Suppress the recruitment of macrophages by inhibiting NLRP3/ IL-1β pathway	Myocardial infarction	454	
Apatinib and Melittin	caspase-1/GSDMD

AIM2/caspase-3/GSDME

	Apatinib and melittin improve caspase‐1–GSDMD and AIM2-caspase‐3–GSDME pyroptosis, respectively	Anaplastic thyroid cancer	353	
CAR-T cell	Caspase-3/GSDME	Release perforin and GzmB to induce tumor cell caspase-3-GSDME pyroptosis	CD19+ relapsed or refractory B cell leukemia	37	
Dapansutrile	NLRP3/IL-6, IL-1β	Inhibit NLRP3 inflammasome thus hindering the cleavage of IL-6 and IL-1β	Gout	499	

Finally, robust preclinical and clinical trials are warranted to determine the clinical applications of pyroptosis-based drugs. In addition to classical cell lines and primary cells from patients, organoids are novel approaches to evaluate drug effectiveness and safety before entering clinical trials. Organoids derived from adult and pluripotent stem cells serve as crucial preclinical models for cancer research and therapy development.503 For instance, Zhou et al. found that NLRP3 inflammasome facilitates silica-induced injury to lung epithelial cells and abnormal regeneration in lung stem/progenitor cell-derived organotypic models.504 In addition to in vitro studies, multi-species in vivo animal model verification is the cornerstone of further clinical trials. For example, MCC950, an NLRP3 inhibitor, is discovered to function in neurodegenerative diseases and myocardial infarction (MI) in mice models.505 Meanwhile, NLRP3-inflammasome inhibition reduces infarct size and preserves cardiac function in a pig MI model.506 Finally, unintended consequences, long-term effects, and a balance between therapeutic benefits and potential risks are issues that need to be addressed in further clinical trials. Therefore, a complete verification chain of in vitro-in vivo-clinical trials is the basis for the clinical translation of pyroptosis-targeted drugs.

In conclusion, scientific progress has pushed us into an exciting era in the field of pyroptosis research. Addressing the previously mentioned challenges is imperative to realizing the full potential of pyroptosis in clinical practice. We expect that the successful translation of pyroptosis-targeted therapy into clinical treatment will soon be a reality.

Author contributions

P.C, H.W., and B.X. designed the review; Y.L., R.P., and Y.O. searched for the literature and wrote the manuscript; Y.L, R.P., and Y.O. drew the figures; W.G., T.X., L.T., and H.Y. assisted in editing and revising the manuscript; P.C., H.W., and B.X. acquired the funding; All authors have read and approved the article.

Funding

This work was supported by grants from the National Natural Science Foundation of China (Grant No. 82173201,82272758 and U23A20456), the Key Research and Development Program of Hunan Province (Grant No.2022SK2026, 2023DK2001, and 2024DK2007, China), the Scientific Research Program of FuRong Laboratory (No.2023SK2094, China), the Natural Science Foundation of Hunan Province (Grant No.2022JJ70020, 2023JJ60120 and 2024JJ3036, China) and Hunan Cancer Hospital Climb Plan (Grant No. 2023NSFC-B005 and ZX2021003, China).

Competing interests

The authors declare no competing interests.

These authors contributed equally: Yifan Liu, Renjie Pan, Yuzhen Ouyang
==== Refs
References

1. Hotchkiss RS Strasser A McDunn JE Swanson PE Cell death N. Engl. J. Med 2009 361 1570 1583 10.1056/NEJMra0901217 19828534
Hotchkiss, R. S., Strasser, A., McDunn, J. E. & Swanson, P. E. Cell death. N. Engl. J. Med. 361, 1570–1583 (2009).19828534
2. Galluzzi L Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 Cell Death Differ. 2018 25 486 541 10.1038/s41418-017-0012-4 29362479
Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486–541 (2018).29362479
3. Querfurth HW LaFerla FM Alzheimer’s disease N. Engl. J. Med 2010 362 329 344 10.1056/NEJMra0909142 20107219
Querfurth, H. W. & LaFerla, F. M. Alzheimer’s disease. N. Engl. J. Med. 362, 329–344 (2010).20107219
4. Green DR The Coming Decade of Cell Death Research: Five Riddles Cell 2019 177 1094 1107 10.1016/j.cell.2019.04.024 31100266
Green, D. R. The Coming Decade of Cell Death Research: Five Riddles. Cell 177, 1094–1107 (2019).31100266
5. Wei X Role of pyroptosis in inflammation and cancer Cell Mol. Immunol. 2022 19 971 992 10.1038/s41423-022-00905-x 35970871
Wei, X. et al. Role of pyroptosis in inflammation and cancer. Cell Mol. Immunol. 19, 971–992 (2022).35970871
6. Black RA Kronheim SR Sleath PR Activation of interleukin-1 beta by a co-induced protease FEBS Lett. 1989 247 386 390 10.1016/0014-5793(89)81376-6 2653864
Black, R. A., Kronheim, S. R. & Sleath, P. R. Activation of interleukin-1 beta by a co-induced protease. FEBS Lett. 247, 386–390 (1989).2653864
7. Kostura MJ Identification of a monocyte specific pre-interleukin 1 beta convertase activity Proc. Natl Acad. Sci. USA 1989 86 5227 5231 10.1073/pnas.86.14.5227 2787508
Kostura, M. J. et al. Identification of a monocyte specific pre-interleukin 1 beta convertase activity. Proc. Natl Acad. Sci. USA 86, 5227–5231 (1989).2787508
8. Yuan J The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme Cell 1993 75 641 652 10.1016/0092-8674(93)90485-9 8242740
Yuan, J. et al. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 75, 641–652 (1993).8242740
9. Alnemri ES Human ICE/CED-3 protease nomenclature Cell 1996 87 171 10.1016/S0092-8674(00)81334-3 8861900
Alnemri, E. S. et al. Human ICE/CED-3 protease nomenclature. Cell 87, 171 (1996).8861900
10. Zychlinsky A Prevost MC Sansonetti PJ Shigella flexneri induces apoptosis in infected macrophages Nature 1992 358 167 169 10.1038/358167a0 1614548
Zychlinsky, A., Prevost, M. C. & Sansonetti, P. J. Shigella flexneri induces apoptosis in infected macrophages. Nature 358, 167–169 (1992).1614548
11. Hersh D The Salmonella invasin SipB induces macrophage apoptosis by binding to caspase-1 Proc. Natl Acad. Sci. USA 1999 96 2396 2401 10.1073/pnas.96.5.2396 10051653
Hersh, D. et al. The Salmonella invasin SipB induces macrophage apoptosis by binding to caspase-1. Proc. Natl Acad. Sci. USA 96, 2396–2401 (1999).10051653
12. Brennan MA Cookson BT Salmonella induces macrophage death by caspase-1-dependent necrosis Mol. Microbiol 2000 38 31 40 10.1046/j.1365-2958.2000.02103.x 11029688
Brennan, M. A. & Cookson, B. T. Salmonella induces macrophage death by caspase-1-dependent necrosis. Mol. Microbiol. 38, 31–40 (2000).11029688
13. Boise LH Collins CM Salmonella-induced cell death: apoptosis, necrosis or programmed cell death? Trends Microbiol 2001 9 64 67 10.1016/S0966-842X(00)01937-5 11173244
Boise, L. H. & Collins, C. M. Salmonella-induced cell death: apoptosis, necrosis or programmed cell death? Trends Microbiol. 9, 64–67 (2001).11173244
14. Man SM Kanneganti TD Converging roles of caspases in inflammasome activation, cell death and innate immunity Nat. Rev. Immunol. 2016 16 7 21 10.1038/nri.2015.7 26655628
Man, S. M. & Kanneganti, T. D. Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nat. Rev. Immunol. 16, 7–21 (2016).26655628
15. Martinon F Burns K Tschopp J The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta Mol. Cell 2002 10 417 426 10.1016/S1097-2765(02)00599-3 12191486
Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10, 417–426 (2002).12191486
16. Agostini L NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder Immunity 2004 20 319 325 10.1016/S1074-7613(04)00046-9 15030775
Agostini, L. et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319–325 (2004).15030775
17. Kayagaki N Non-canonical inflammasome activation targets caspase-11 Nature 2011 479 117 121 10.1038/nature10558 22002608
Kayagaki, N. et al. Non-canonical inflammasome activation targets caspase-11. Nature 479, 117–121 (2011).22002608
18. Kayagaki N Noncanonical inflammasome activation by intracellular LPS independent of TLR4 Science 2013 341 1246 1249 10.1126/science.1240248 23887873
Kayagaki, N. et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 341, 1246–1249 (2013).23887873
19. Shi J Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death Nature 2015 526 660 665 10.1038/nature15514 26375003
Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660–665 (2015).26375003
20. He WT Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion Cell Res 2015 25 1285 1298 10.1038/cr.2015.139 26611636
He, W. T. et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion. Cell Res 25, 1285–1298 (2015).26611636
21. Kayagaki N Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling Nature 2015 526 666 671 10.1038/nature15541 26375259
Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666–671 (2015).26375259
22. Ding J Pore-forming activity and structural autoinhibition of the gasdermin family Nature 2016 535 111 116 10.1038/nature18590 27281216
Ding, J. et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535, 111–116 (2016).27281216
23. Wang Y Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin Nature 2017 547 99 103 10.1038/nature22393 28459430
Wang, Y. et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 547, 99–103 (2017).28459430
24. Orning P Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death Science 2018 362 1064 1069 10.1126/science.aau2818 30361383
Orning, P. et al. Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death. Science 362, 1064–1069 (2018).30361383
25. Sarhan J Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection Proc. Natl Acad. Sci. USA 2018 115 E10888 e10897 10.1073/pnas.1809548115 30381458
Sarhan, J. et al. Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection. Proc. Natl Acad. Sci. USA 115, E10888–e10897 (2018).30381458
26. Zhang Z Gasdermin E suppresses tumour growth by activating anti-tumour immunity Nature 2020 579 415 420 10.1038/s41586-020-2071-9 32188940
Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579, 415–420 (2020).32188940
27. Zhou Z Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells Science 2020 368 eaaz7548 10.1126/science.aaz7548 32299851
Zhou, Z. et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science 368, eaaz7548 (2020).32299851
28. Deng W Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis Nature 2022 602 496 502 10.1038/s41586-021-04384-4 35110732
Deng, W. et al. Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis. Nature 602, 496–502 (2022).35110732
29. Zhong X Structural mechanisms for regulation of GSDMB pore-forming activity Nature 2023 616 598 605 10.1038/s41586-023-05872-5 36991125
Zhong, X. et al. Structural mechanisms for regulation of GSDMB pore-forming activity. Nature 616, 598–605 (2023).36991125
30. Strowig T Henao-Mejia J Elinav E Flavell R Inflammasomes in health and disease Nature 2012 481 278 286 10.1038/nature10759 22258606
Strowig, T., Henao-Mejia, J., Elinav, E. & Flavell, R. Inflammasomes in health and disease. Nature 481, 278–286 (2012).22258606
31. Zhu C The gasdermin family: emerging therapeutic targets in diseases Signal Transduct. Target Ther. 2024 9 87 10.1038/s41392-024-01801-8 38584157
Zhu, C. et al. The gasdermin family: emerging therapeutic targets in diseases. Signal Transduct. Target Ther. 9, 87 (2024).38584157
32. Li J Gsdma3 is required for hair follicle differentiation in mice Biochem Biophys. Res Commun. 2010 403 18 23 10.1016/j.bbrc.2010.10.094 20977888
Li, J. et al. Gsdma3 is required for hair follicle differentiation in mice. Biochem Biophys. Res Commun. 403, 18–23 (2010).20977888
33. Saeki N GASDERMIN, suppressed frequently in gastric cancer, is a target of LMO1 in TGF-beta-dependent apoptotic signalling Oncogene 2007 26 6488 6498 10.1038/sj.onc.1210475 17471240
Saeki, N. et al. GASDERMIN, suppressed frequently in gastric cancer, is a target of LMO1 in TGF-beta-dependent apoptotic signalling. Oncogene 26, 6488–6498 (2007).17471240
34. Saeki N Distinctive expression and function of four GSDM family genes (GSDMA-D) in normal and malignant upper gastrointestinal epithelium Genes Chromosomes Cancer 2009 48 261 271 10.1002/gcc.20636 19051310
Saeki, N. et al. Distinctive expression and function of four GSDM family genes (GSDMA-D) in normal and malignant upper gastrointestinal epithelium. Genes Chromosomes Cancer 48, 261–271 (2009).19051310
35. Chen Q GSDMB promotes non-canonical pyroptosis by enhancing caspase-4 activity J. Mol. Cell Biol. 2019 11 496 508 10.1093/jmcb/mjy056 30321352
Chen, Q. et al. GSDMB promotes non-canonical pyroptosis by enhancing caspase-4 activity. J. Mol. Cell Biol. 11, 496–508 (2019).30321352
36. Hou J PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis Nat. Cell Biol. 2020 22 1264 1275 10.1038/s41556-020-0575-z 32929201
Hou, J. et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat. Cell Biol. 22, 1264–1275 (2020).32929201
37. Liu Y Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome Sci. Immunol. 2020 5 eaax7969 10.1126/sciimmunol.aax7969 31953257
Liu, Y. et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci. Immunol. 5, eaax7969 (2020).31953257
38. Hergueta-Redondo M Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer Oncotarget 2016 7 56295 56308 10.18632/oncotarget.10787 27462779
Hergueta-Redondo, M. et al. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget 7, 56295–56308 (2016).27462779
39. Orning P Lien E Fitzgerald KA Gasdermins and their role in immunity and inflammation J. Exp. Med 2019 216 2453 2465 10.1084/jem.20190545 31548300
Orning, P., Lien, E. & Fitzgerald, K. A. Gasdermins and their role in immunity and inflammation. J. Exp. Med. 216, 2453–2465 (2019).31548300
40. Yu P Pyroptosis: mechanisms and diseases Signal Transduct. Target Ther. 2021 6 128 10.1038/s41392-021-00507-5 33776057
Yu, P. et al. Pyroptosis: mechanisms and diseases. Signal Transduct. Target Ther. 6, 128 (2021).33776057
41. Vande Walle L Lamkanfi M Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets Nat. Rev. Drug Discov. 2024 23 43 66 10.1038/s41573-023-00822-2 38030687
Vande Walle, L. & Lamkanfi, M. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat. Rev. Drug Discov. 23, 43–66 (2024).38030687
42. Liu J Engineering materials for pyroptosis induction in cancer treatment Bioact. Mater. 2024 33 30 45 38024228
Liu, J. et al. Engineering materials for pyroptosis induction in cancer treatment. Bioact. Mater. 33, 30–45 (2024).38024228
43. Wang M Fu Q Nanomaterials for Disease Treatment by Modulating the Pyroptosis Pathway Adv. Health. Mater. 2024 13 e2301266 10.1002/adhm.202301266
Wang, M. & Fu, Q. Nanomaterials for Disease Treatment by Modulating the Pyroptosis Pathway. Adv. Health. Mater. 13, e2301266 (2024).
44. Liu X Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c Cell 1996 86 147 157 10.1016/S0092-8674(00)80085-9 8689682
Liu, X. et al. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86, 147–157 (1996).8689682
45. Fraser A Evan G A license to kill Cell 1996 85 781 784 10.1016/S0092-8674(00)81005-3 8681372
Fraser, A. & Evan, G. A license to kill. Cell 85, 781–784 (1996).8681372
46. Bertheloot D Latz E Franklin BS Necroptosis, pyroptosis and apoptosis: an intricate game of cell death Cell Mol. Immunol. 2021 18 1106 1121 10.1038/s41423-020-00630-3 33785842
Bertheloot, D., Latz, E. & Franklin, B. S. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol. Immunol. 18, 1106–1121 (2021).33785842
47. Chen X Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis Cell Res 2016 26 1007 1020 10.1038/cr.2016.100 27573174
Chen, X. et al. Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res. 26, 1007–1020 (2016).27573174
48. Xu X Lai Y Hua ZC Apoptosis and apoptotic body: disease message and therapeutic target potentials Biosci. Rep. 2019 39 BSR20180992 10.1042/BSR20180992 30530866
Xu, X., Lai, Y. & Hua, Z. C. Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci. Rep. 39, BSR20180992 (2019).30530866
49. Li J Yuan J Caspases in apoptosis and beyond Oncogene 2008 27 6194 6206 10.1038/onc.2008.297 18931687
Li, J. & Yuan, J. Caspases in apoptosis and beyond. Oncogene 27, 6194–6206 (2008).18931687
50. Mompeán M The Structure of the Necrosome RIPK1-RIPK3 Core, a Human Hetero-Amyloid Signaling Complex Cell 2018 173 1244 1253.e1210 10.1016/j.cell.2018.03.032 29681455
Mompeán, M. et al. The Structure of the Necrosome RIPK1-RIPK3 Core, a Human Hetero-Amyloid Signaling Complex. Cell 173, 1244–1253.e1210 (2018).29681455
51. Sun L Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase Cell 2012 148 213 227 10.1016/j.cell.2011.11.031 22265413
Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213–227 (2012).22265413
52. Stockwell BR Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism Redox Biol., Dis. Cell. 2017 171 273 285
Stockwell, B. R. et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism. Redox Biol., Dis. Cell. 171, 273–285 (2017).
53. Dixon SJ Ferroptosis: an iron-dependent form of nonapoptotic cell death Cell 2012 149 1060 1072 10.1016/j.cell.2012.03.042 22632970
Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012).22632970
54. Degterev A Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury Nat. Chem. Biol. 2005 1 112 119 10.1038/nchembio711 16408008
Degterev, A. et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1, 112–119 (2005).16408008
55. Temkin V Inhibition of ADP/ATP exchange in receptor-interacting protein-mediated necrosis Mol. Cell Biol. 2006 26 2215 2225 10.1128/MCB.26.6.2215-2225.2006 16507998
Temkin, V. et al. Inhibition of ADP/ATP exchange in receptor-interacting protein-mediated necrosis. Mol. Cell Biol. 26, 2215–2225 (2006).16507998
56. Kaiser WJ Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL J. Biol. Chem. 2013 288 31268 31279 10.1074/jbc.M113.462341 24019532
Kaiser, W. J. et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J. Biol. Chem. 288, 31268–31279 (2013).24019532
57. Frank D Vince JE Pyroptosis versus necroptosis: similarities, differences, and crosstalk Cell Death Differ. 2019 26 99 114 10.1038/s41418-018-0212-6 30341423
Frank, D. & Vince, J. E. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death Differ. 26, 99–114 (2019).30341423
58. Sun Y The emerging role of ferroptosis in inflammation Biomed. Pharmacother. 2020 127 110108 10.1016/j.biopha.2020.110108 32234642
Sun, Y. et al. The emerging role of ferroptosis in inflammation. Biomed. Pharmacother. 127, 110108 (2020).32234642
59. Friedmann Angeli JP Krysko DV Conrad M Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion Nat. Rev. Cancer 2019 19 405 414 10.1038/s41568-019-0149-1 31101865
Friedmann Angeli, J. P., Krysko, D. V. & Conrad, M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Cancer 19, 405–414 (2019).31101865
60. Chen X Ferroptosis: machinery and regulation Autophagy 2021 17 2054 2081 10.1080/15548627.2020.1810918 32804006
Chen, X. et al. Ferroptosis: machinery and regulation. Autophagy 17, 2054–2081 (2021).32804006
61. Tang D The molecular machinery of regulated cell death Cell Res 2019 29 347 364 10.1038/s41422-019-0164-5 30948788
Tang, D. et al. The molecular machinery of regulated cell death. Cell Res. 29, 347–364 (2019).30948788
62. Kuang S Structure insight of GSDMD reveals the basis of GSDMD autoinhibition in cell pyroptosis Proc. Natl Acad. Sci. USA 2017 114 10642 10647 10.1073/pnas.1708194114 28928145
Kuang, S. et al. Structure insight of GSDMD reveals the basis of GSDMD autoinhibition in cell pyroptosis. Proc. Natl Acad. Sci. USA 114, 10642–10647 (2017).28928145
63. Liu Z Crystal Structures of the Full-Length Murine and Human Gasdermin D Reveal Mechanisms of Autoinhibition, Lipid Binding, and Oligomerization Immunity 2019 51 43 49.e44 10.1016/j.immuni.2019.04.017 31097341
Liu, Z. et al. Crystal Structures of the Full-Length Murine and Human Gasdermin D Reveal Mechanisms of Autoinhibition, Lipid Binding, and Oligomerization. Immunity 51, 43–49.e44 (2019).31097341
64. Rogers C Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation Nat. Commun. 2019 10 1689 10.1038/s41467-019-09397-2 30976076
Rogers, C. et al. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat. Commun. 10, 1689 (2019).30976076
65. Liu X Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores Nature 2016 535 153 158 10.1038/nature18629 27383986
Liu, X. et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535, 153–158 (2016).27383986
66. Cookson BT Brennan MA Pro-inflammatory programmed cell death Trends Microbiol 2001 9 113 114 10.1016/S0966-842X(00)01936-3 11303500
Cookson, B. T. & Brennan, M. A. Pro-inflammatory programmed cell death. Trends Microbiol. 9, 113–114 (2001).11303500
67. He Y Amer AO Microbial modulation of host apoptosis and pyroptosis Front Cell Infect. Microbiol 2014 4 83 10.3389/fcimb.2014.00083 24995165
He, Y. & Amer, A. O. Microbial modulation of host apoptosis and pyroptosis. Front Cell Infect. Microbiol. 4, 83 (2014).24995165
68. Jackson DN Theiss AL Gut bacteria signaling to mitochondria in intestinal inflammation and cancer Gut Microbes 2020 11 285 304 10.1080/19490976.2019.1592421 30913966
Jackson, D. N. & Theiss, A. L. Gut bacteria signaling to mitochondria in intestinal inflammation and cancer. Gut Microbes 11, 285–304 (2020).30913966
69. Li P Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock Cell 1995 80 401 411 10.1016/0092-8674(95)90490-5 7859282
Li, P. et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80, 401–411 (1995).7859282
70. Nunes T de Souza HS Inflammasome in intestinal inflammation and cancer Mediators Inflamm. 2013 2013 654963 10.1155/2013/654963 23606794
Nunes, T. & de Souza, H. S. Inflammasome in intestinal inflammation and cancer. Mediators Inflamm. 2013, 654963 (2013).23606794
71. He Y Hara H Núñez G Mechanism and Regulation of NLRP3 Inflammasome Activation Trends Biochem Sci. 2016 41 1012 1021 10.1016/j.tibs.2016.09.002 27669650
He, Y., Hara, H. & Núñez, G. Mechanism and Regulation of NLRP3 Inflammasome Activation. Trends Biochem Sci. 41, 1012–1021 (2016).27669650
72. Sha W Human NLRP3 inflammasome senses multiple types of bacterial RNAs Proc. Natl Acad. Sci. USA 2014 111 16059 16064 10.1073/pnas.1412487111 25355909
Sha, W. et al. Human NLRP3 inflammasome senses multiple types of bacterial RNAs. Proc. Natl Acad. Sci. USA 111, 16059–16064 (2014).25355909
73. Dowling JK O’Neill LAJ Biochemical regulation of the inflammasome Crit. Rev. Biochem. Mol. Biol. 2012 47 424 443 10.3109/10409238.2012.694844 22681257
Dowling, J. K. & O’Neill, L. A. J. Biochemical regulation of the inflammasome. Crit. Rev. Biochem. Mol. Biol. 47, 424–443 (2012).22681257
74. Liston A Masters SL Homeostasis-altering molecular processes as mechanisms of inflammasome activation Nat. Rev. Immunol. 2017 17 208 214 10.1038/nri.2016.151 28163301
Liston, A. & Masters, S. L. Homeostasis-altering molecular processes as mechanisms of inflammasome activation. Nat. Rev. Immunol. 17, 208–214 (2017).28163301
75. Wang YY Liu XL Zhao R Induction of Pyroptosis and Its Implications in Cancer Management Front Oncol. 2019 9 971 10.3389/fonc.2019.00971 31616642
Wang, Y. Y., Liu, X. L. & Zhao, R. Induction of Pyroptosis and Its Implications in Cancer Management. Front Oncol. 9, 971 (2019).31616642
76. Broz P Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1 Nature 2012 490 288 291 10.1038/nature11419 22895188
Broz, P. et al. Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature 490, 288–291 (2012).22895188
77. Chen GY Nuñez G Sterile inflammation: sensing and reacting to damage Nat. Rev. Immunol. 2010 10 826 837 10.1038/nri2873 21088683
Chen, G. Y. & Nuñez, G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10, 826–837 (2010).21088683
78. Lamkanfi M Dixit VM Mechanisms and functions of inflammasomes Cell 2014 157 1013 1022 10.1016/j.cell.2014.04.007 24855941
Lamkanfi, M. & Dixit, V. M. Mechanisms and functions of inflammasomes. Cell 157, 1013–1022 (2014).24855941
79. Fernandes-Alnemri T AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA Nature 2009 458 509 513 10.1038/nature07710 19158676
Fernandes-Alnemri, T. et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458, 509–513 (2009).19158676
80. Jorgensen I Zhang Y Krantz BA Miao EA Pyroptosis triggers pore-induced intracellular traps (PITs) that capture bacteria and lead to their clearance by efferocytosis J. Exp. Med 2016 213 2113 2128 10.1084/jem.20151613 27573815
Jorgensen, I., Zhang, Y., Krantz, B. A. & Miao, E. A. Pyroptosis triggers pore-induced intracellular traps (PITs) that capture bacteria and lead to their clearance by efferocytosis. J. Exp. Med. 213, 2113–2128 (2016).27573815
81. Martinon F Gout-associated uric acid crystals activate the NALP3 inflammasome Nature 2006 440 237 241 10.1038/nature04516 16407889
Martinon, F. et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).16407889
82. Barton GM Medzhitov R Toll-like receptor signaling pathways Science 2003 300 1524 1525 10.1126/science.1085536 12791976
Barton, G. M. & Medzhitov, R. Toll-like receptor signaling pathways. Science 300, 1524–1525 (2003).12791976
83. Lamkanfi M Emerging inflammasome effector mechanisms Nat. Rev. Immunol. 2011 11 213 220 10.1038/nri2936 21350580
Lamkanfi, M. Emerging inflammasome effector mechanisms. Nat. Rev. Immunol. 11, 213–220 (2011).21350580
84. Zitvogel L Kepp O Galluzzi L Kroemer G Inflammasomes in carcinogenesis and anticancer immune responses Nat. Immunol. 2012 13 343 351 10.1038/ni.2224 22430787
Zitvogel, L., Kepp, O., Galluzzi, L. & Kroemer, G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 13, 343–351 (2012).22430787
85. Broz P Dixit VM Inflammasomes: mechanism of assembly, regulation and signalling Nat. Rev. Immunol. 2016 16 407 420 10.1038/nri.2016.58 27291964
Broz, P. & Dixit, V. M. Inflammasomes: mechanism of assembly, regulation and signalling. Nat. Rev. Immunol. 16, 407–420 (2016).27291964
86. Lamkanfi M Dixit VM Inflammasomes and their roles in health and disease Annu Rev. Cell Dev. Biol. 2012 28 137 161 10.1146/annurev-cellbio-101011-155745 22974247
Lamkanfi, M. & Dixit, V. M. Inflammasomes and their roles in health and disease. Annu Rev. Cell Dev. Biol. 28, 137–161 (2012).22974247
87. Duncan JA Canna SW The NLRC4 Inflammasome Immunol. Rev. 2018 281 115 123 10.1111/imr.12607 29247997
Duncan, J. A. & Canna, S. W. The NLRC4 Inflammasome. Immunol. Rev. 281, 115–123 (2018).29247997
88. Zhao Y The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus Nature 2011 477 596 600 10.1038/nature10510 21918512
Zhao, Y. et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477, 596–600 (2011).21918512
89. Sollberger G Caspase-1: the inflammasome and beyond Innate Immun. 2014 20 115 125 10.1177/1753425913484374 23676582
Sollberger, G. et al. Caspase-1: the inflammasome and beyond. Innate Immun. 20, 115–125 (2014).23676582
90. Liu S MLKL forms disulfide bond-dependent amyloid-like polymers to induce necroptosis Proc. Natl Acad. Sci. USA 2017 114 E7450 e7459 10.1073/pnas.1707531114 28827318
Liu, S. et al. MLKL forms disulfide bond-dependent amyloid-like polymers to induce necroptosis. Proc. Natl Acad. Sci. USA 114, E7450–e7459 (2017).28827318
91. Sborgi L GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death Embo j. 2016 35 1766 1778 10.15252/embj.201694696 27418190
Sborgi, L. et al. GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death. Embo j. 35, 1766–1778 (2016).27418190
92. Thornberry NA A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes Nature 1992 356 768 774 10.1038/356768a0 1574116
Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356, 768–774 (1992).1574116
93. Carty M Cell Survival and Cytokine Release after Inflammasome Activation Is Regulated by the Toll-IL-1R Protein SARM Immunity 2019 50 1412 1424.e1416 10.1016/j.immuni.2019.04.005 31076360
Carty, M. et al. Cell Survival and Cytokine Release after Inflammasome Activation Is Regulated by the Toll-IL-1R Protein SARM. Immunity 50, 1412–1424.e1416 (2019).31076360
94. Shi J Inflammatory caspases are innate immune receptors for intracellular LPS Nature 2014 514 187 192 10.1038/nature13683 25119034
Shi, J. et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514, 187–192 (2014).25119034
95. Chu LH The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages Nat. Commun. 2018 9 996 10.1038/s41467-018-03409-3 29520027
Chu, L. H. et al. The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages. Nat. Commun. 9, 996 (2018).29520027
96. Shi J Gao W Shao F Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death Trends Biochem Sci. 2017 42 245 254 10.1016/j.tibs.2016.10.004 27932073
Shi, J., Gao, W. & Shao, F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends Biochem Sci. 42, 245–254 (2017).27932073
97. Baker PJ NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5 Eur. J. Immunol. 2015 45 2918 2926 10.1002/eji.201545655 26173988
Baker, P. J. et al. NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5. Eur. J. Immunol. 45, 2918–2926 (2015).26173988
98. Rühl S Broz P Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux Eur. J. Immunol. 2015 45 2927 2936 10.1002/eji.201545772 26173909
Rühl, S. & Broz, P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux. Eur. J. Immunol. 45, 2927–2936 (2015).26173909
99. Schmid-Burgk JL Caspase-4 mediates non-canonical activation of the NLRP3 inflammasome in human myeloid cells Eur. J. Immunol. 2015 45 2911 2917 10.1002/eji.201545523 26174085
Schmid-Burgk, J. L. et al. Caspase-4 mediates non-canonical activation of the NLRP3 inflammasome in human myeloid cells. Eur. J. Immunol. 45, 2911–2917 (2015).26174085
100. Yang D Caspase-11 Requires the Pannexin-1 Channel and the Purinergic P2X7 Pore to Mediate Pyroptosis and Endotoxic Shock Immunity 2015 43 923 932 10.1016/j.immuni.2015.10.009 26572062
Yang, D. et al. Caspase-11 Requires the Pannexin-1 Channel and the Purinergic P2X7 Pore to Mediate Pyroptosis and Endotoxic Shock. Immunity 43, 923–932 (2015).26572062
101. Chao YY Human T(H)17 cells engage gasdermin E pores to release IL-1α on NLRP3 inflammasome activation Nat. Immunol. 2023 24 295 308 10.1038/s41590-022-01386-w 36604548
Chao, Y. Y. et al. Human T(H)17 cells engage gasdermin E pores to release IL-1α on NLRP3 inflammasome activation. Nat. Immunol. 24, 295–308 (2023).36604548
102. Hu L Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate Cell Death Dis. 2020 11 281 10.1038/s41419-020-2476-2 32332857
Hu, L. et al. Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate. Cell Death Dis. 11, 281 (2020).32332857
103. Rogers C Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death Nat. Commun. 2017 8 14128 10.1038/ncomms14128 28045099
Rogers, C. et al. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. Nat. Commun. 8, 14128 (2017).28045099
104. Yu J Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells Cell Death Dis. 2019 10 193 10.1038/s41419-019-1441-4 30804337
Yu, J. et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells. Cell Death Dis. 10, 193 (2019).30804337
105. Zhang CC Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation Apoptosis 2019 24 312 325 10.1007/s10495-019-01515-1 30710195
Zhang, C. C. et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation. Apoptosis 24, 312–325 (2019).30710195
106. Fritsch M Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis Nature 2019 575 683 687 10.1038/s41586-019-1770-6 31748744
Fritsch, M. et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature 575, 683–687 (2019).31748744
107. Kong Q Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis Sci. Immunol. 2023 8 eadg3196 10.1126/sciimmunol.adg3196 37115914
Kong, Q. et al. Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis. Sci. Immunol. 8, eadg3196 (2023).37115914
108. Zou J The Versatile Gasdermin Family: Their Function and Roles in Diseases Front Immunol. 2021 12 751533 10.3389/fimmu.2021.751533 34858408
Zou, J. et al. The Versatile Gasdermin Family: Their Function and Roles in Diseases. Front Immunol. 12, 751533 (2021).34858408
109. Volchuk A Indirect regulation of HMGB1 release by gasdermin D Nat. Commun. 2020 11 4561 10.1038/s41467-020-18443-3 32917873
Volchuk, A. et al. Indirect regulation of HMGB1 release by gasdermin D. Nat. Commun. 11, 4561 (2020).32917873
110. Mantovani A Dinarello CA Molgora M Garlanda C Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity Immunity 2019 50 778 795 10.1016/j.immuni.2019.03.012 30995499
Mantovani, A., Dinarello, C. A., Molgora, M. & Garlanda, C. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity 50, 778–795 (2019).30995499
111. Dinarello CA Overview of the IL-1 family in innate inflammation and acquired immunity Immunol. Rev. 2018 281 8 27 10.1111/imr.12621 29247995
Dinarello, C. A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev. 281, 8–27 (2018).29247995
112. Robinson N Programmed necrotic cell death of macrophages: Focus on pyroptosis, necroptosis, and parthanatos Redox Biol. 2019 26 101239 10.1016/j.redox.2019.101239 31212216
Robinson, N. et al. Programmed necrotic cell death of macrophages: Focus on pyroptosis, necroptosis, and parthanatos. Redox Biol. 26, 101239 (2019).31212216
113. Zheng D ROS-triggered endothelial cell death mechanisms: Focus on pyroptosis, parthanatos, and ferroptosis Front Immunol. 2022 13 1039241 10.3389/fimmu.2022.1039241 36389728
Zheng, D. et al. ROS-triggered endothelial cell death mechanisms: Focus on pyroptosis, parthanatos, and ferroptosis. Front Immunol. 13, 1039241 (2022).36389728
114. Zhang J Epithelial Gasdermin D shapes the host-microbial interface by driving mucus layer formation Sci. Immunol. 2022 7 eabk2092 10.1126/sciimmunol.abk2092 35119941
Zhang, J. et al. Epithelial Gasdermin D shapes the host-microbial interface by driving mucus layer formation. Sci. Immunol. 7, eabk2092 (2022).35119941
115. Lin PH Lin HY Kuo CC Yang LT N-terminal functional domain of Gasdermin A3 regulates mitochondrial homeostasis via mitochondrial targeting J. Biomed. Sci. 2015 22 44 10.1186/s12929-015-0152-0 26100518
Lin, P. H., Lin, H. Y., Kuo, C. C. & Yang, L. T. N-terminal functional domain of Gasdermin A3 regulates mitochondrial homeostasis via mitochondrial targeting. J. Biomed. Sci. 22, 44 (2015).26100518
116. Sollberger G Gasdermin D plays a vital role in the generation of neutrophil extracellular traps Sci. Immunol. 2018 3 eaar6689 10.1126/sciimmunol.aar6689 30143555
Sollberger, G. et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. Sci. Immunol. 3, eaar6689 (2018).30143555
117. Tanaka S A new Gsdma3 mutation affecting anagen phase of first hair cycle Biochem. Biophys. Res. Commun 2007 359 902 907 10.1016/j.bbrc.2007.05.209 17572385
Tanaka, S. et al. A new Gsdma3 mutation affecting anagen phase of first hair cycle. Biochem. Biophys. Res. Commun. 359, 902–907 (2007).17572385
118. Li M Gasdermin D maintains bone mass by rewiring the endo-lysosomal pathway of osteoclastic bone resorption Dev. Cell 2022 57 2365 2380.e2368 10.1016/j.devcel.2022.09.013 36243012
Li, M. et al. Gasdermin D maintains bone mass by rewiring the endo-lysosomal pathway of osteoclastic bone resorption. Dev. Cell 57, 2365–2380.e2368 (2022).36243012
119. He K Gasdermin D licenses MHCII induction to maintain food tolerance in small intestine Cell 2023 186 3033 3048.e3020 10.1016/j.cell.2023.05.027 37327784
He, K. et al. Gasdermin D licenses MHCII induction to maintain food tolerance in small intestine. Cell 186, 3033–3048.e3020 (2023).37327784
120. Ahechu P NLRP3 Inflammasome: A Possible Link Between Obesity-Associated Low-Grade Chronic Inflammation and Colorectal Cancer Development Front Immunol. 2018 9 2918 10.3389/fimmu.2018.02918 30619282
Ahechu, P. et al. NLRP3 Inflammasome: A Possible Link Between Obesity-Associated Low-Grade Chronic Inflammation and Colorectal Cancer Development. Front Immunol. 9, 2918 (2018).30619282
121. Galluzzi L Immunogenic cell death in cancer and infectious disease Nat. Rev. Immunol. 2017 17 97 111 10.1038/nri.2016.107 27748397
Galluzzi, L. et al. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111 (2017).27748397
122. Parker KH Horn LA Ostrand-Rosenberg S High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy J. Leukoc. Biol. 2016 100 463 470 10.1189/jlb.3HI0715-305R 26864266
Parker, K. H., Horn, L. A. & Ostrand-Rosenberg, S. High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy. J. Leukoc. Biol. 100, 463–470 (2016).26864266
123. Ben-Sasson SZ IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells J. Exp. Med 2013 210 491 502 10.1084/jem.20122006 23460726
Ben-Sasson, S. Z. et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J. Exp. Med. 210, 491–502 (2013).23460726
124. Jin S Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment Biomark. Res 2020 8 21 10.1186/s40364-020-00201-8 32551121
Jin, S. et al. Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment. Biomark. Res. 8, 21 (2020).32551121
125. Ostrand-Rosenberg S Beury DW Parker KH Horn LA Survival of the fittest: how myeloid-derived suppressor cells survive in the inhospitable tumor microenvironment Cancer Immunol. Immunother. 2020 69 215 221 10.1007/s00262-019-02388-8 31501954
Ostrand-Rosenberg, S., Beury, D. W., Parker, K. H. & Horn, L. A. Survival of the fittest: how myeloid-derived suppressor cells survive in the inhospitable tumor microenvironment. Cancer Immunol. Immunother. 69, 215–221 (2020).31501954
126. Jain A Song R Wakeland EK Pasare C T cell-intrinsic IL-1R signaling licenses effector cytokine production by memory CD4 T cells Nat. Commun. 2018 9 3185 10.1038/s41467-018-05489-7 30093707
Jain, A., Song, R., Wakeland, E. K. & Pasare, C. T cell-intrinsic IL-1R signaling licenses effector cytokine production by memory CD4 T cells. Nat. Commun. 9, 3185 (2018).30093707
127. Dai J LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer Cell Death Dis. 2023 14 312 10.1038/s41419-023-05840-x 37156816
Dai, J. et al. LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer. Cell Death Dis. 14, 312 (2023).37156816
128. Fu L Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer Gastric Cancer 2022 25 542 557 10.1007/s10120-022-01283-z 35166958
Fu, L. et al. Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer. Gastric Cancer 25, 542–557 (2022).35166958
129. Xia J Mitochondrial Protein UCP1 Inhibits the Malignant Behaviors of Triple-negative Breast Cancer through Activation of Mitophagy and Pyroptosis Int J. Biol. Sci. 2022 18 2949 2961 10.7150/ijbs.68438 35541900
Xia, J. et al. Mitochondrial Protein UCP1 Inhibits the Malignant Behaviors of Triple-negative Breast Cancer through Activation of Mitophagy and Pyroptosis. Int J. Biol. Sci. 18, 2949–2961 (2022).35541900
130. Li Z Sorcin regulate pyroptosis by interacting with NLRP3 inflammasomes to facilitate the progression of hepatocellular carcinoma Cell Death Dis. 2023 14 678 10.1038/s41419-023-06096-1 37833249
Li, Z. et al. Sorcin regulate pyroptosis by interacting with NLRP3 inflammasomes to facilitate the progression of hepatocellular carcinoma. Cell Death Dis. 14, 678 (2023).37833249
131. Feng W-Q IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8 + T-cell tumour infiltration J. Transl. Med 2023 21 335 10.1186/s12967-023-04187-3 37211606
Feng, W.-Q. et al. IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8 + T-cell tumour infiltration. J. Transl. Med. 21, 335 (2023).37211606
132. Thai AA Lung cancer Lancet 2021 398 535 554 10.1016/S0140-6736(21)00312-3 34273294
Thai, A. A. et al. Lung cancer. Lancet 398, 535–554 (2021).34273294
133. Wang W Effects of TRAF3 on the proliferation and migration of lung adenocarcinoma depend partly on pyroptosis BMC Cancer 2023 23 942 10.1186/s12885-023-11468-z 37798663
Wang, W. et al. Effects of TRAF3 on the proliferation and migration of lung adenocarcinoma depend partly on pyroptosis. BMC Cancer 23, 942 (2023).37798663
134. Su L Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models Sci. Transl. Med 2023 15 eabl7895 10.1126/scitranslmed.abl7895 36630483
Su, L. et al. Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models. Sci. Transl. Med. 15, eabl7895 (2023).36630483
135. Fang, Y. et al. ANGPTL4 Regulates Lung Adenocarcinoma Pyroptosis and Apoptosis via NLRP3\ASC\Caspase 8 Signaling Pathway to Promote Resistance to Gefitinib. J. Oncol. 2022, 3623570 (2022).
136. Liu J Downregulation of LncRNA-XIST inhibited development of non-small cell lung cancer by activating miR-335/SOD2/ROS signal pathway mediated pyroptotic cell death Aging (Albany NY) 2019 11 7830 7846 10.18632/aging.102291 31553952
Liu, J. et al. Downregulation of LncRNA-XIST inhibited development of non-small cell lung cancer by activating miR-335/SOD2/ROS signal pathway mediated pyroptotic cell death. Aging (Albany NY) 11, 7830–7846 (2019).31553952
137. Shi F Zhang L Liu X Wang Y Knock-down of microRNA miR-556-5p increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via activating NLR family pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death Bioengineered 2021 12 6332 6342 10.1080/21655979.2021.1971502 34488537
Shi, F., Zhang, L., Liu, X. & Wang, Y. Knock-down of microRNA miR-556-5p increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via activating NLR family pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death. Bioengineered 12, 6332–6342 (2021).34488537
138. Chen LK AMIGO2 attenuates innate cisplatin sensitivity by suppression of GSDME-conferred pyroptosis in non-small cell lung cancer J. Cell Mol. Med 2023 27 2412 2423 10.1111/jcmm.17827 37438979
Chen, L. K. et al. AMIGO2 attenuates innate cisplatin sensitivity by suppression of GSDME-conferred pyroptosis in non-small cell lung cancer. J. Cell Mol. Med. 27, 2412–2423 (2023).37438979
139. Smyth EC Gastric cancer Lancet 2020 396 635 648 10.1016/S0140-6736(20)31288-5 32861308
Smyth, E. C. et al. Gastric cancer. Lancet 396, 635–648 (2020).32861308
140. Ren N LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis Aging (Albany NY) 2020 12 11025 11041 10.18632/aging.103314 32516127
Ren, N. et al. LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis. Aging (Albany NY) 12, 11025–11041 (2020).32516127
141. Zhao C USP50 regulates NLRP3 inflammasome activation in duodenogastric reflux-induced gastric tumorigenesis Front Immunol. 2024 15 1326137 10.3389/fimmu.2024.1326137 38469295
Zhao, C. et al. USP50 regulates NLRP3 inflammasome activation in duodenogastric reflux-induced gastric tumorigenesis. Front Immunol. 15, 1326137 (2024).38469295
142. Pachathundikandi SK Blaser N Bruns H Backert S Helicobacter pylori Avoids the Critical Activation of NLRP3 Inflammasome-Mediated Production of Oncogenic Mature IL-1β in Human Immune Cells Cancers (Basel) 2020 12 803 10.3390/cancers12040803 32230726
Pachathundikandi, S. K., Blaser, N., Bruns, H. & Backert, S. Helicobacter pylori Avoids the Critical Activation of NLRP3 Inflammasome-Mediated Production of Oncogenic Mature IL-1β in Human Immune Cells. Cancers (Basel) 12, 803 (2020).32230726
143. Wang XJ RNA-binding protein CPSF6 regulates IBSP to affect pyroptosis in gastric cancer World J. Gastrointest. Oncol. 2023 15 1531 1543 10.4251/wjgo.v15.i9.1531 37746647
Wang, X. J. et al. RNA-binding protein CPSF6 regulates IBSP to affect pyroptosis in gastric cancer. World J. Gastrointest. Oncol. 15, 1531–1543 (2023).37746647
144. Loibl S Breast cancer Lancet 2021 397 1750 1769 10.1016/S0140-6736(20)32381-3 33812473
Loibl, S. et al. Breast cancer. Lancet 397, 1750–1769 (2021).33812473
145. Tan Y Tumor suppressor DRD2 facilitates M1 macrophages and restricts NF-κB signaling to trigger pyroptosis in breast cancer Theranostics 2021 11 5214 5231 10.7150/thno.58322 33859743
Tan, Y. et al. Tumor suppressor DRD2 facilitates M1 macrophages and restricts NF-κB signaling to trigger pyroptosis in breast cancer. Theranostics 11, 5214–5231 (2021).33859743
146. Lei S Azurocidin 1 inhibits the aberrant proliferation of triple‑negative breast cancer through the regulation of pyroptosis Oncol. Rep. 2023 50 188 10.3892/or.2023.8625 37681500
Lei, S. et al. Azurocidin 1 inhibits the aberrant proliferation of triple‑negative breast cancer through the regulation of pyroptosis. Oncol. Rep. 50, 188 (2023).37681500
147. Wang Y Targeting the ZNF-148/miR-335/SOD2 signaling cascade triggers oxidative stress-mediated pyroptosis and suppresses breast cancer progression Cancer Med 2023 12 21308 21320 10.1002/cam4.6673 37909239
Wang, Y. et al. Targeting the ZNF-148/miR-335/SOD2 signaling cascade triggers oxidative stress-mediated pyroptosis and suppresses breast cancer progression. Cancer Med. 12, 21308–21320 (2023).37909239
148. Vogel A Hepatocellular carcinoma Lancet 2022 400 1345 1362 10.1016/S0140-6736(22)01200-4 36084663
Vogel, A. et al. Hepatocellular carcinoma. Lancet 400, 1345–1362 (2022).36084663
149. Yan Z Inhibition of NEK7 Suppressed Hepatocellular Carcinoma Progression by Mediating Cancer Cell Pyroptosis Front Oncol. 2022 12 812655 10.3389/fonc.2022.812655 35223495
Yan, Z. et al. Inhibition of NEK7 Suppressed Hepatocellular Carcinoma Progression by Mediating Cancer Cell Pyroptosis. Front Oncol. 12, 812655 (2022).35223495
150. Ren Y USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer Cancer Res 2023 83 1074 1093 10.1158/0008-5472.CAN-22-1812 36607699
Ren, Y. et al. USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer. Cancer Res. 83, 1074–1093 (2023).36607699
151. Zheng Y CHMP3 promotes the progression of hepatocellular carcinoma by inhibiting caspase‑1‑dependent pyroptosis Int J. Oncol. 2024 64 8 10.3892/ijo.2023.5596 38038147
Zheng, Y. et al. CHMP3 promotes the progression of hepatocellular carcinoma by inhibiting caspase‑1‑dependent pyroptosis. Int J. Oncol. 64, 8 (2024).38038147
152. Dekker E Colorectal cancer Lancet 2019 394 1467 1480 10.1016/S0140-6736(19)32319-0 31631858
Dekker, E. et al. Colorectal cancer. Lancet 394, 1467–1480 (2019).31631858
153. Zhang Y Li F Wang L Lou Y A438079 affects colorectal cancer cell proliferation, migration, apoptosis, and pyroptosis by inhibiting the P2X7 receptor Biochem Biophys. Res. Commun. 2021 558 147 153 10.1016/j.bbrc.2021.04.076 33915328
Zhang, Y., Li, F., Wang, L. & Lou, Y. A438079 affects colorectal cancer cell proliferation, migration, apoptosis, and pyroptosis by inhibiting the P2X7 receptor. Biochem Biophys. Res. Commun. 558, 147–153 (2021).33915328
154. Huang Y Nrf2 inhibition increases sensitivity to chemotherapy of colorectal cancer by promoting ferroptosis and pyroptosis Sci. Rep. 2023 13 14359 10.1038/s41598-023-41490-x 37658132
Huang, Y. et al. Nrf2 inhibition increases sensitivity to chemotherapy of colorectal cancer by promoting ferroptosis and pyroptosis. Sci. Rep. 13, 14359 (2023).37658132
155. Hou X USP47-Mediated Deubiquitination and Stabilization of TCEA3 Attenuates Pyroptosis and Apoptosis of Colorectal Cancer Cells Induced by Chemotherapeutic Doxorubicin Front Pharm. 2021 12 713322 10.3389/fphar.2021.713322
Hou, X. et al. USP47-Mediated Deubiquitination and Stabilization of TCEA3 Attenuates Pyroptosis and Apoptosis of Colorectal Cancer Cells Induced by Chemotherapeutic Doxorubicin. Front Pharm. 12, 713322 (2021).
156. Stancu I-C Aggregated Tau activates NLRP3–ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo Acta Neuropathol. 2019 137 599 617 10.1007/s00401-018-01957-y 30721409
Stancu, I.-C. et al. Aggregated Tau activates NLRP3–ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathol. 137, 599–617 (2019).30721409
157. Li S Gasdermin D in peripheral myeloid cells drives neuroinflammation in experimental autoimmune encephalomyelitis J. Exp. Med 2019 216 2562 2581 10.1084/jem.20190377 31467036
Li, S. et al. Gasdermin D in peripheral myeloid cells drives neuroinflammation in experimental autoimmune encephalomyelitis. J. Exp. Med. 216, 2562–2581 (2019).31467036
158. Zhou Y Gu Y Liu J BRD4 suppression alleviates cerebral ischemia-induced brain injury by blocking glial activation via the inhibition of inflammatory response and pyroptosis Biochem Biophys. Res. Commun 2019 519 481 488 10.1016/j.bbrc.2019.07.097 31530390
Zhou, Y., Gu, Y. & Liu, J. BRD4 suppression alleviates cerebral ischemia-induced brain injury by blocking glial activation via the inhibition of inflammatory response and pyroptosis. Biochem Biophys. Res. Commun. 519, 481–488 (2019).31530390
159. Xu S CD73 alleviates GSDMD-mediated microglia pyroptosis in spinal cord injury through PI3K/AKT/Foxo1 signaling Clin. Transl. Med 2021 11 e269 10.1002/ctm2.269 33463071
Xu, S. et al. CD73 alleviates GSDMD-mediated microglia pyroptosis in spinal cord injury through PI3K/AKT/Foxo1 signaling. Clin. Transl. Med. 11, e269 (2021).33463071
160. Xu X-X Neuronal nitric oxide synthase/reactive oxygen species pathway is involved in apoptosis and pyroptosis in epilepsy Neural Regen. Res 2023 18 1277 1285 10.4103/1673-5374.357906 36453412
Xu, X.-X. et al. Neuronal nitric oxide synthase/reactive oxygen species pathway is involved in apoptosis and pyroptosis in epilepsy. Neural Regen. Res. 18, 1277–1285 (2023).36453412
161. Zhan T Implication of lncRNA MSTRG.81401 in Hippocampal Pyroptosis Induced by P2X7 Receptor in Type 2 Diabetic Rats with Neuropathic Pain Combined with Depression Int J. Mol. Sci. 2024 25 1186 10.3390/ijms25021186 38256257
Zhan, T. et al. Implication of lncRNA MSTRG.81401 in Hippocampal Pyroptosis Induced by P2X7 Receptor in Type 2 Diabetic Rats with Neuropathic Pain Combined with Depression. Int J. Mol. Sci. 25, 1186 (2024).38256257
162. Lammert CR AIM2 inflammasome surveillance of DNA damage shapes neurodevelopment Nature 2020 580 647 652 10.1038/s41586-020-2174-3 32350463
Lammert, C. R. et al. AIM2 inflammasome surveillance of DNA damage shapes neurodevelopment. Nature 580, 647–652 (2020).32350463
163. Trejo-Lopez JA Yachnis AT Prokop S Neuropathology of Alzheimer’s Disease Neurotherapeutics 2022 19 173 185 10.1007/s13311-021-01146-y 34729690
Trejo-Lopez, J. A., Yachnis, A. T. & Prokop, S. Neuropathology of Alzheimer’s Disease. Neurotherapeutics 19, 173–185 (2022).34729690
164. Oladapo A Jackson T Menolascino J Periyasamy P Role of pyroptosis in the pathogenesis of various neurological diseases Brain Behav. Immun. 2024 117 428 446 10.1016/j.bbi.2024.02.001 38336022
Oladapo, A., Jackson, T., Menolascino, J. & Periyasamy, P. Role of pyroptosis in the pathogenesis of various neurological diseases. Brain Behav. Immun. 117, 428–446 (2024).38336022
165. Moonen S Pyroptosis in Alzheimer’s disease: cell type-specific activation in microglia, astrocytes and neurons Acta Neuropathol. 2023 145 175 195 10.1007/s00401-022-02528-y 36481964
Moonen, S. et al. Pyroptosis in Alzheimer’s disease: cell type-specific activation in microglia, astrocytes and neurons. Acta Neuropathol. 145, 175–195 (2023).36481964
166. Han C New mechanism of nerve injury in Alzheimer’s disease: β-amyloid-induced neuronal pyroptosis J. Cell Mol. Med 2020 24 8078 8090 10.1111/jcmm.15439 32521573
Han, C. et al. New mechanism of nerve injury in Alzheimer’s disease: β-amyloid-induced neuronal pyroptosis. J. Cell Mol. Med. 24, 8078–8090 (2020).32521573
167. Liu Y Beta-amyloid activates NLRP3 inflammasome via TLR4 in mouse microglia Neurosci. Lett. 2020 736 135279 10.1016/j.neulet.2020.135279 32726591
Liu, Y. et al. Beta-amyloid activates NLRP3 inflammasome via TLR4 in mouse microglia. Neurosci. Lett. 736, 135279 (2020).32726591
168. Friker LL β-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia Cell Rep. 2020 30 3743 3754.e3746 10.1016/j.celrep.2020.02.025 32187546
Friker, L. L. et al. β-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia. Cell Rep. 30, 3743–3754.e3746 (2020).32187546
169. Stancu IC Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo Acta Neuropathol. 2019 137 599 617 10.1007/s00401-018-01957-y 30721409
Stancu, I. C. et al. Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathol. 137, 599–617 (2019).30721409
170. Venegas C Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease Nature 2017 552 355 361 10.1038/nature25158 29293211
Venegas, C. et al. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease. Nature 552, 355–361 (2017).29293211
171. de Dios C Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis Transl. Neurodegener. 2023 12 10 10.1186/s40035-023-00343-3 36895045
de Dios, C. et al. Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis. Transl. Neurodegener. 12, 10 (2023).36895045
172. Nussbaum RL Ellis CE Alzheimer’s disease and Parkinson’s disease N. Engl. J. Med 2003 348 1356 1364 10.1056/NEJM2003ra020003 12672864
Nussbaum, R. L. & Ellis, C. E. Alzheimer’s disease and Parkinson’s disease. N. Engl. J. Med 348, 1356–1364 (2003).12672864
173. Nutt JG Wooten GF Clinical practice. Diagnosis and initial management of Parkinson’s disease N. Engl. J. Med 2005 353 1021 1027 10.1056/NEJMcp043908 16148287
Nutt, J. G. & Wooten, G. F. Clinical practice. Diagnosis and initial management of Parkinson’s disease. N. Engl. J. Med. 353, 1021–1027 (2005).16148287
174. De Virgilio A Parkinson’s disease: Autoimmunity and neuroinflammation Autoimmun. Rev. 2016 15 1005 1011 10.1016/j.autrev.2016.07.022 27497913
De Virgilio, A. et al. Parkinson’s disease: Autoimmunity and neuroinflammation. Autoimmun. Rev. 15, 1005–1011 (2016).27497913
175. Tong X Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research J. Hematol. Oncol. 2022 15 174 10.1186/s13045-022-01392-3 36482419
Tong, X. et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J. Hematol. Oncol. 15, 174 (2022).36482419
176. Gordon R Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice Sci. Transl. Med 2018 10 eaah4066 10.1126/scitranslmed.aah4066 30381407
Gordon, R. et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci. Transl. Med. 10, eaah4066 (2018).30381407
177. Li Y METTL14 regulates microglia/macrophage polarization and NLRP3 inflammasome activation after ischemic stroke by the KAT3B-STING axis Neurobiol. Dis. 2023 185 106253 10.1016/j.nbd.2023.106253 37541353
Li, Y. et al. METTL14 regulates microglia/macrophage polarization and NLRP3 inflammasome activation after ischemic stroke by the KAT3B-STING axis. Neurobiol. Dis. 185, 106253 (2023).37541353
178. Wei X TRIM27 ameliorates ischemic stroke by regulating NLRP3 inflammasome-mediated pyroptosis via the Akt/Nrf2/HO-1 signaling Exp. Neurol. 2024 371 114599 10.1016/j.expneurol.2023.114599 37914066
Wei, X. et al. TRIM27 ameliorates ischemic stroke by regulating NLRP3 inflammasome-mediated pyroptosis via the Akt/Nrf2/HO-1 signaling. Exp. Neurol. 371, 114599 (2024).37914066
179. Deng Y TRIM29 (Tripartite Motif Containing 29) Alleviates NLRC4 (NLR Family CARD Domain Containing Protein 4) Inflammasome Related Cerebral Injury via Promoting Proteasomal Degradation of NLRC4 in Ischemic Stroke Stroke 2023 54 1377 1389 10.1161/STROKEAHA.122.038757 37021569
Deng, Y. et al. TRIM29 (Tripartite Motif Containing 29) Alleviates NLRC4 (NLR Family CARD Domain Containing Protein 4) Inflammasome Related Cerebral Injury via Promoting Proteasomal Degradation of NLRC4 in Ischemic Stroke. Stroke 54, 1377–1389 (2023).37021569
180. McKenzie BA Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis Proc. Natl Acad. Sci. USA 2018 115 E6065 e6074 10.1073/pnas.1722041115 29895691
McKenzie, B. A. et al. Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proc. Natl Acad. Sci. USA 115, E6065–e6074 (2018).29895691
181. McKenzie BA Activation of the executioner caspases-3 and -7 promotes microglial pyroptosis in models of multiple sclerosis J. Neuroinflammation 2020 17 253 10.1186/s12974-020-01902-5 32861242
McKenzie, B. A. et al. Activation of the executioner caspases-3 and -7 promotes microglial pyroptosis in models of multiple sclerosis. J. Neuroinflammation 17, 253 (2020).32861242
182. Van Schoor E Increased pyroptosis activation in white matter microglia is associated with neuronal loss in ALS motor cortex Acta Neuropathol. 2022 144 393 411 10.1007/s00401-022-02466-9 35867112
Van Schoor, E. et al. Increased pyroptosis activation in white matter microglia is associated with neuronal loss in ALS motor cortex. Acta Neuropathol. 144, 393–411 (2022).35867112
183. Johann S NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients Glia 2015 63 2260 2273 10.1002/glia.22891 26200799
Johann, S. et al. NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia 63, 2260–2273 (2015).26200799
184. Gugliandolo A Giacoppo S Bramanti P Mazzon E NLRP3 Inflammasome Activation in a Transgenic Amyotrophic Lateral Sclerosis Model Inflammation 2018 41 93 103 10.1007/s10753-017-0667-5 28936769
Gugliandolo, A., Giacoppo, S., Bramanti, P. & Mazzon, E. NLRP3 Inflammasome Activation in a Transgenic Amyotrophic Lateral Sclerosis Model. Inflammation 41, 93–103 (2018).28936769
185. Simon MS Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2021 111 110391 10.1016/j.pnpbp.2021.110391
Simon, M. S. et al. Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 111, 110391 (2021).
186. Li F Kir6.1/K-ATP channel in astrocytes is an essential negative modulator of astrocytic pyroptosis in mouse model of depression Theranostics 2022 12 6611 6625 10.7150/thno.77455 36185602
Li, F. et al. Kir6.1/K-ATP channel in astrocytes is an essential negative modulator of astrocytic pyroptosis in mouse model of depression. Theranostics 12, 6611–6625 (2022).36185602
187. Lei W-X The role and mechanism of miR-425–3p regulating neuronal pyroptosis -mediated inorganic arsenic-induced generalized anxiety disorder Ecotoxicol. Environ. Saf. 2024 269 115781 10.1016/j.ecoenv.2023.115781 38056122
Lei, W.-X. et al. The role and mechanism of miR-425–3p regulating neuronal pyroptosis -mediated inorganic arsenic-induced generalized anxiety disorder. Ecotoxicol. Environ. Saf. 269, 115781 (2024).38056122
188. Wang L-Q Perfluoroalkyl substance pollutants activate the innate immune system through the AIM2 inflammasome Nat. Commun. 2021 12 2915 10.1038/s41467-021-23201-0 34006824
Wang, L.-Q. et al. Perfluoroalkyl substance pollutants activate the innate immune system through the AIM2 inflammasome. Nat. Commun. 12, 2915 (2021).34006824
189. Xu H S1PR2 is Important for Cigarette Smoke-induced Pyroptosis in Human Bronchial Epithelial Cells Arch. Med. Res 2023 54 277 286 10.1016/j.arcmed.2023.03.005 36990889
Xu, H. et al. S1PR2 is Important for Cigarette Smoke-induced Pyroptosis in Human Bronchial Epithelial Cells. Arch. Med. Res. 54, 277–286 (2023).36990889
190. Liu B Buformin alleviates sepsis-induced acute lung injury via inhibiting NLRP3-mediated pyroptosis through an AMPK-dependent pathway Clin. Sci. (Lond.) 2022 136 273 289 10.1042/CS20211156 35132999
Liu, B. et al. Buformin alleviates sepsis-induced acute lung injury via inhibiting NLRP3-mediated pyroptosis through an AMPK-dependent pathway. Clin. Sci. (Lond.) 136, 273–289 (2022).35132999
191. Wei Y Crystalline silica-induced macrophage pyroptosis interacting with mitophagy contributes to pulmonary fibrosis via modulating mitochondria homeostasis J. Hazard Mater. 2023 454 131562 10.1016/j.jhazmat.2023.131562 37148789
Wei, Y. et al. Crystalline silica-induced macrophage pyroptosis interacting with mitophagy contributes to pulmonary fibrosis via modulating mitochondria homeostasis. J. Hazard Mater. 454, 131562 (2023).37148789
192. Jiang Y Hypoxia activates GPR146 which participates in pulmonary vascular remodeling by promoting pyroptosis of pulmonary artery endothelial cells Eur. J. Pharmacol. 2023 941 175502 10.1016/j.ejphar.2023.175502 36638952
Jiang, Y. et al. Hypoxia activates GPR146 which participates in pulmonary vascular remodeling by promoting pyroptosis of pulmonary artery endothelial cells. Eur. J. Pharmacol. 941, 175502 (2023).36638952
193. Gabillard-Lefort C Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis Am. J. Respir. Crit. Care Med 2022 205 783 794 10.1164/rccm.202106-1426OC 35021019
Gabillard-Lefort, C. et al. Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 205, 783–794 (2022).35021019
194. Li M S100A4 Promotes BCG-Induced Pyroptosis of Macrophages by Activating the NF-κB/NLRP3 Inflammasome Signaling Pathway Int J. Mol. Sci. 2023 24 12709 10.3390/ijms241612709 37628889
Li, M. et al. S100A4 Promotes BCG-Induced Pyroptosis of Macrophages by Activating the NF-κB/NLRP3 Inflammasome Signaling Pathway. Int J. Mol. Sci. 24, 12709 (2023).37628889
195. Halpin DMG Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med 2021 203 24 36 10.1164/rccm.202009-3533SO 33146552
Halpin, D. M. G. et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 203, 24–36 (2021).33146552
196. Zhang MY Cigarette smoke extract induces pyroptosis in human bronchial epithelial cells through the ROS/NLRP3/caspase-1 pathway Life Sci. 2021 269 119090 10.1016/j.lfs.2021.119090 33465393
Zhang, M. Y. et al. Cigarette smoke extract induces pyroptosis in human bronchial epithelial cells through the ROS/NLRP3/caspase-1 pathway. Life Sci. 269, 119090 (2021).33465393
197. Wang L Hydrogen sulfide attenuates cigarette smoke‑induced pyroptosis through the TLR4/NF‑κB signaling pathway Int J. Mol. Med 2022 49 56 10.3892/ijmm.2022.5112 35234268
Wang, L. et al. Hydrogen sulfide attenuates cigarette smoke‑induced pyroptosis through the TLR4/NF‑κB signaling pathway. Int J. Mol. Med. 49, 56 (2022).35234268
198. Wang L TREM-1 aggravates chronic obstructive pulmonary disease development via activation NLRP3 inflammasome-mediated pyroptosis Inflamm. Res 2021 70 971 980 10.1007/s00011-021-01490-x 34374795
Wang, L. et al. TREM-1 aggravates chronic obstructive pulmonary disease development via activation NLRP3 inflammasome-mediated pyroptosis. Inflamm. Res. 70, 971–980 (2021).34374795
199. Mo R Li J Chen Y Ding Y lncRNA GAS5 promotes pyroptosis in COPD by functioning as a ceRNA to regulate the miR‑223‑3p/NLRP3 axis Mol. Med. Rep 2022 26 219 10.3892/mmr.2022.12735 35583006
Mo, R., Li, J., Chen, Y. & Ding, Y. lncRNA GAS5 promotes pyroptosis in COPD by functioning as a ceRNA to regulate the miR‑223‑3p/NLRP3 axis. Mol. Med. Rep. 26, 219 (2022).35583006
200. Rao Y Transient Receptor Potential Cation Channel Subfamily V Member 4 Mediates Pyroptosis in Chronic Obstructive Pulmonary Disease Front Physiol. 2021 12 783891 10.3389/fphys.2021.783891 35002766
Rao, Y. et al. Transient Receptor Potential Cation Channel Subfamily V Member 4 Mediates Pyroptosis in Chronic Obstructive Pulmonary Disease. Front Physiol. 12, 783891 (2021).35002766
201. Fu X Wood smoke particulate matter (WSPM2.5) induces pyroptosis through both Caspase-1/IL-1β/IL-18 and ATP/P2Y-dependent mechanisms in human bronchial epithelial cells Chemosphere 2022 307 135726 10.1016/j.chemosphere.2022.135726 35850226
Fu, X. et al. Wood smoke particulate matter (WSPM2.5) induces pyroptosis through both Caspase-1/IL-1β/IL-18 and ATP/P2Y-dependent mechanisms in human bronchial epithelial cells. Chemosphere 307, 135726 (2022).35850226
202. Zhu Z Exosomes derived from adipose-derived stem cells alleviate cigarette smoke-induced lung inflammation and injury by inhibiting alveolar macrophages pyroptosis Respir. Res 2022 23 5 10.1186/s12931-022-01926-w 35016678
Zhu, Z. et al. Exosomes derived from adipose-derived stem cells alleviate cigarette smoke-induced lung inflammation and injury by inhibiting alveolar macrophages pyroptosis. Respir. Res. 23, 5 (2022).35016678
203. Zhang Y Wang J Wang Y Lei K Nrf2/HO-1 signaling activation alleviates cigarette smoke-induced inflammation in chronic obstructive pulmonary disease by suppressing NLRP3-mediated pyroptosis J. Cardiothorac. Surg. 2024 19 58 10.1186/s13019-024-02530-3 38317168
Zhang, Y., Wang, J., Wang, Y. & Lei, K. Nrf2/HO-1 signaling activation alleviates cigarette smoke-induced inflammation in chronic obstructive pulmonary disease by suppressing NLRP3-mediated pyroptosis. J. Cardiothorac. Surg. 19, 58 (2024).38317168
204. Ackermann M Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 N. Engl. J. Med 2020 383 120 128 10.1056/NEJMoa2015432 32437596
Ackermann, M. et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N. Engl. J. Med. 383, 120–128 (2020).32437596
205. Jiao Y Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury Crit. Care 2021 25 356 10.1186/s13054-021-03775-3 34641966
Jiao, Y. et al. Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury. Crit. Care 25, 356 (2021).34641966
206. Cao Z Crosstalk of pyroptosis, ferroptosis, and mitochondrial aldehyde dehydrogenase 2-related mechanisms in sepsis-induced lung injury in a mouse model Bioengineered 2022 13 4810 4820 10.1080/21655979.2022.2033381 35188436
Cao, Z. et al. Crosstalk of pyroptosis, ferroptosis, and mitochondrial aldehyde dehydrogenase 2-related mechanisms in sepsis-induced lung injury in a mouse model. Bioengineered 13, 4810–4820 (2022).35188436
207. Hsu CG The lipid peroxidation product 4-hydroxynonenal inhibits NLRP3 inflammasome activation and macrophage pyroptosis Cell Death Differ. 2022 29 1790 1803 10.1038/s41418-022-00966-5 35264781
Hsu, C. G. et al. The lipid peroxidation product 4-hydroxynonenal inhibits NLRP3 inflammasome activation and macrophage pyroptosis. Cell Death Differ. 29, 1790–1803 (2022).35264781
208. Pu Z Wang W Xie H Wang W Apolipoprotein C3 (ApoC3) facilitates NLRP3 mediated pyroptosis of macrophages through mitochondrial damage by accelerating of the interaction between SCIMP and SYK pathway in acute lung injury Int Immunopharmacol. 2024 128 111537 10.1016/j.intimp.2024.111537 38232538
Pu, Z., Wang, W., Xie, H. & Wang, W. Apolipoprotein C3 (ApoC3) facilitates NLRP3 mediated pyroptosis of macrophages through mitochondrial damage by accelerating of the interaction between SCIMP and SYK pathway in acute lung injury. Int Immunopharmacol. 128, 111537 (2024).38232538
209. Zhang T Exosome from BMMSC Attenuates Cardiopulmonary Bypass-Induced Acute Lung Injury Via YAP/β-Catenin Pathway: Downregulation of Pyroptosis Stem Cells 2022 40 1122 1133 10.1093/stmcls/sxac063 36063391
Zhang, T. et al. Exosome from BMMSC Attenuates Cardiopulmonary Bypass-Induced Acute Lung Injury Via YAP/β-Catenin Pathway: Downregulation of Pyroptosis. Stem Cells 40, 1122–1133 (2022).36063391
210. Xie WM FTO Deficiency Alleviates LPS-induced Acute Lung Injury by TXNIP/NLRP3-mediated Alveolar Epithelial Cell Pyroptosis Am. J. Respir. Cell Mol. Biol. 2024 70 351 363 10.1165/rcmb.2023-0251OC 38271683
Xie, W. M. et al. FTO Deficiency Alleviates LPS-induced Acute Lung Injury by TXNIP/NLRP3-mediated Alveolar Epithelial Cell Pyroptosis. Am. J. Respir. Cell Mol. Biol. 70, 351–363 (2024).38271683
211. Huang W GBP2 upregulated in LPS-stimulated macrophages-derived exosomes accelerates septic lung injury by activating epithelial cell NLRP3 signaling Int Immunopharmacol. 2023 124 111017 10.1016/j.intimp.2023.111017 37812968
Huang, W. et al. GBP2 upregulated in LPS-stimulated macrophages-derived exosomes accelerates septic lung injury by activating epithelial cell NLRP3 signaling. Int Immunopharmacol. 124, 111017 (2023).37812968
212. Li N HDAC3 promotes macrophage pyroptosis via regulating histone deacetylation in acute lung injury iScience 2023 26 107158 10.1016/j.isci.2023.107158 37404376
Li, N. et al. HDAC3 promotes macrophage pyroptosis via regulating histone deacetylation in acute lung injury. iScience 26, 107158 (2023).37404376
213. Lommatzsch M A(2)BCD: a concise guide for asthma management Lancet Respir. Med 2023 11 573 576 10.1016/S2213-2600(22)00490-8 36716752
Lommatzsch, M. et al. A(2)BCD: a concise guide for asthma management. Lancet Respir. Med. 11, 573–576 (2023).36716752
214. Wu J Gasdermin D silencing alleviates airway inflammation and remodeling in an ovalbumin-induced asthmatic mouse model Cell Death Dis. 2024 15 400 10.1038/s41419-024-06777-5 38849380
Wu, J. et al. Gasdermin D silencing alleviates airway inflammation and remodeling in an ovalbumin-induced asthmatic mouse model. Cell Death Dis. 15, 400 (2024).38849380
215. Cai R Dectin-1 aggravates neutrophil inflammation through caspase-11/4-mediated macrophage pyroptosis in asthma Respir. Res 2024 25 119 10.1186/s12931-024-02743-z 38459541
Cai, R. et al. Dectin-1 aggravates neutrophil inflammation through caspase-11/4-mediated macrophage pyroptosis in asthma. Respir. Res 25, 119 (2024).38459541
216. Liu L MUC1 attenuates neutrophilic airway inflammation in asthma by reducing NLRP3 inflammasome-mediated pyroptosis through the inhibition of the TLR4/MyD88/NF-κB pathway Respir. Res 2023 24 255 10.1186/s12931-023-02550-y 37880668
Liu, L. et al. MUC1 attenuates neutrophilic airway inflammation in asthma by reducing NLRP3 inflammasome-mediated pyroptosis through the inhibition of the TLR4/MyD88/NF-κB pathway. Respir. Res 24, 255 (2023).37880668
217. Leung CC Yu IT Chen W Silicosis Lancet 2012 379 2008 2018 10.1016/S0140-6736(12)60235-9 22534002
Leung, C. C., Yu, I. T. & Chen, W. Silicosis. Lancet 379, 2008–2018 (2012).22534002
218. Song M Inhibition of gasdermin D-dependent pyroptosis attenuates the progression of silica-induced pulmonary inflammation and fibrosis Acta Pharm. Sin. B 2022 12 1213 1224 10.1016/j.apsb.2021.10.006 35530143
Song, M. et al. Inhibition of gasdermin D-dependent pyroptosis attenuates the progression of silica-induced pulmonary inflammation and fibrosis. Acta Pharm. Sin. B 12, 1213–1224 (2022).35530143
219. Zhang L Tian J Ma L Duan S Mechanistic insights into severe pulmonary inflammation caused by silica stimulation: The role of macrophage pyroptosis Ecotoxicol. Environ. Saf. 2023 258 114975 10.1016/j.ecoenv.2023.114975 37148754
Zhang, L., Tian, J., Ma, L. & Duan, S. Mechanistic insights into severe pulmonary inflammation caused by silica stimulation: The role of macrophage pyroptosis. Ecotoxicol. Environ. Saf. 258, 114975 (2023).37148754
220. Bagcchi S Dismal global tuberculosis situation due to COVID-19 Lancet Infect. Dis. 2021 21 1636 10.1016/S1473-3099(21)00713-1 34838229
Bagcchi, S. Dismal global tuberculosis situation due to COVID-19. Lancet Infect. Dis. 21, 1636 (2021).34838229
221. Zhao P Programming cell pyroptosis with biomimetic nanoparticles for solid tumor immunotherapy Biomaterials 2020 254 120142 10.1016/j.biomaterials.2020.120142 32485591
Zhao, P. et al. Programming cell pyroptosis with biomimetic nanoparticles for solid tumor immunotherapy. Biomaterials 254, 120142 (2020).32485591
222. Chai Q A bacterial phospholipid phosphatase inhibits host pyroptosis by hijacking ubiquitin Science 2022 378 eabq0132 10.1126/science.abq0132 36227980
Chai, Q. et al. A bacterial phospholipid phosphatase inhibits host pyroptosis by hijacking ubiquitin. Science 378, eabq0132 (2022).36227980
223. Ma B GSK2656157, a PERK Inhibitor, Alleviates Pyroptosis of Macrophages Induced by Mycobacterium Bacillus Calmette-Guerin Infection Int J. Mol. Sci. 2023 24 16239 10.3390/ijms242216239 38003429
Ma, B. et al. GSK2656157, a PERK Inhibitor, Alleviates Pyroptosis of Macrophages Induced by Mycobacterium Bacillus Calmette-Guerin Infection. Int J. Mol. Sci. 24, 16239 (2023).38003429
224. Yao Q Lnc-EST12, which is negatively regulated by mycobacterial EST12, suppresses antimycobacterial innate immunity through its interaction with FUBP3 Cell Mol. Immunol. 2022 19 883 897 10.1038/s41423-022-00878-x 35637281
Yao, Q. et al. Lnc-EST12, which is negatively regulated by mycobacterial EST12, suppresses antimycobacterial innate immunity through its interaction with FUBP3. Cell Mol. Immunol. 19, 883–897 (2022).35637281
225. Rastogi S Mycobacterium tuberculosis inhibits the NLRP3 inflammasome activation via its phosphokinase PknF PLoS Pathog. 2021 17 e1009712 10.1371/journal.ppat.1009712 34324582
Rastogi, S. et al. Mycobacterium tuberculosis inhibits the NLRP3 inflammasome activation via its phosphokinase PknF. PLoS Pathog. 17, e1009712 (2021).34324582
226. Qian J Mycobacterium tuberculosis PE_PGRS19 Induces Pyroptosis through a Non-Classical Caspase-11/GSDMD Pathway in Macrophages Microorganisms 2022 10 2473 10.3390/microorganisms10122473 36557726
Qian, J. et al. Mycobacterium tuberculosis PE_PGRS19 Induces Pyroptosis through a Non-Classical Caspase-11/GSDMD Pathway in Macrophages. Microorganisms 10, 2473 (2022).36557726
227. Escobar-Chavarría O Necrotic Cell Death and Inflammasome NLRP3 Activity in Mycobacterium bovis-Infected Bovine Macrophages Cells 2023 12 2079 10.3390/cells12162079 37626889
Escobar-Chavarría, O. et al. Necrotic Cell Death and Inflammasome NLRP3 Activity in Mycobacterium bovis-Infected Bovine Macrophages. Cells 12, 2079 (2023).37626889
228. Nie X Endoplasmic Reticulum Stress Mediated NLRP3 Inflammasome Activation and Pyroptosis in THP-1 Macrophages Infected with Bacillus Calmette-Guérin Int J. Mol. Sci. 2023 24 11692 10.3390/ijms241411692 37511451
Nie, X. et al. Endoplasmic Reticulum Stress Mediated NLRP3 Inflammasome Activation and Pyroptosis in THP-1 Macrophages Infected with Bacillus Calmette-Guérin. Int J. Mol. Sci. 24, 11692 (2023).37511451
229. Xia W Gasdermin E deficiency attenuates acute kidney injury by inhibiting pyroptosis and inflammation Cell Death Dis. 2021 12 139 10.1038/s41419-021-03431-2 33542198
Xia, W. et al. Gasdermin E deficiency attenuates acute kidney injury by inhibiting pyroptosis and inflammation. Cell Death Dis. 12, 139 (2021).33542198
230. Li Y GSDME-mediated pyroptosis promotes inflammation and fibrosis in obstructive nephropathy Cell Death Differ. 2021 28 2333 2350 10.1038/s41418-021-00755-6 33664482
Li, Y. et al. GSDME-mediated pyroptosis promotes inflammation and fibrosis in obstructive nephropathy. Cell Death Differ. 28, 2333–2350 (2021).33664482
231. Cui X Alpha-kinase1 promotes tubular injury and interstitial inflammation in diabetic nephropathy by canonical pyroptosis pathway Biol. Res 2023 56 5 10.1186/s40659-023-00416-7 36732854
Cui, X. et al. Alpha-kinase1 promotes tubular injury and interstitial inflammation in diabetic nephropathy by canonical pyroptosis pathway. Biol. Res. 56, 5 (2023).36732854
232. Zou H C/EBPβ isoform-specific regulation of podocyte pyroptosis in lupus nephritis-induced renal injury J. Pathol. 2023 261 269 285 10.1002/path.6174 37602503
Zou, H. et al. C/EBPβ isoform-specific regulation of podocyte pyroptosis in lupus nephritis-induced renal injury. J. Pathol. 261, 269–285 (2023).37602503
233. Su X NLRP3 inflammasome: A potential therapeutic target to minimize renal ischemia/reperfusion injury during transplantation Transpl. Immunol. 2022 75 101718 10.1016/j.trim.2022.101718 36126906
Su, X. et al. NLRP3 inflammasome: A potential therapeutic target to minimize renal ischemia/reperfusion injury during transplantation. Transpl. Immunol. 75, 101718 (2022).36126906
234. Lameire NH Acute kidney injury: an increasing global concern Lancet 2013 382 170 179 10.1016/S0140-6736(13)60647-9 23727171
Lameire, N. H. et al. Acute kidney injury: an increasing global concern. Lancet 382, 170–179 (2013).23727171
235. Sun J USF2 knockdown downregulates THBS1 to inhibit the TGF-β signaling pathway and reduce pyroptosis in sepsis-induced acute kidney injury Pharm. Res 2022 176 105962 10.1016/j.phrs.2021.105962
Sun, J. et al. USF2 knockdown downregulates THBS1 to inhibit the TGF-β signaling pathway and reduce pyroptosis in sepsis-induced acute kidney injury. Pharm. Res. 176, 105962 (2022).
236. Baatarjav C dsDNA-induced AIM2 pyroptosis halts aberrant inflammation during rhabdomyolysis-induced acute kidney injury Cell Death Differ. 2022 29 2487 2502 10.1038/s41418-022-01033-9 35739254
Baatarjav, C. et al. dsDNA-induced AIM2 pyroptosis halts aberrant inflammation during rhabdomyolysis-induced acute kidney injury. Cell Death Differ. 29, 2487–2502 (2022).35739254
237. Ling H LncRNA GAS5 inhibits miR-579-3p to activate SIRT1/PGC-1α/Nrf2 signaling pathway to reduce cell pyroptosis in sepsis-associated renal injury Am. J. Physiol. Cell Physiol. 2021 321 C117 c133 10.1152/ajpcell.00394.2020 34010066
Ling, H. et al. LncRNA GAS5 inhibits miR-579-3p to activate SIRT1/PGC-1α/Nrf2 signaling pathway to reduce cell pyroptosis in sepsis-associated renal injury. Am. J. Physiol. Cell Physiol. 321, C117–c133 (2021).34010066
238. Ni J Hydrogen sulfide reduces pyroptosis and alleviates ischemia-reperfusion-induced acute kidney injury by inhibiting NLRP3 inflammasome Life Sci. 2021 284 119466 10.1016/j.lfs.2021.119466 33811893
Ni, J. et al. Hydrogen sulfide reduces pyroptosis and alleviates ischemia-reperfusion-induced acute kidney injury by inhibiting NLRP3 inflammasome. Life Sci. 284, 119466 (2021).33811893
239. Zhang Y Zhang Y Yang A Xia F Downregulation of IRF2 Alleviates Sepsis-Related Acute Kidney Injury in vitro and in vivo Drug Des. Devel Ther. 2021 15 5123 5132 10.2147/DDDT.S334518 34992348
Zhang, Y., Zhang, Y., Yang, A. & Xia, F. Downregulation of IRF2 Alleviates Sepsis-Related Acute Kidney Injury in vitro and in vivo. Drug Des. Devel Ther. 15, 5123–5132 (2021).34992348
240. Li N Myoglobin promotes macrophage polarization to M1 type and pyroptosis via the RIG-I/Caspase1/GSDMD signaling pathway in CS-AKI Cell Death Discov. 2022 8 90 10.1038/s41420-022-00894-w 35228524
Li, N. et al. Myoglobin promotes macrophage polarization to M1 type and pyroptosis via the RIG-I/Caspase1/GSDMD signaling pathway in CS-AKI. Cell Death Discov. 8, 90 (2022).35228524
241. Cao Y STING contributes to lipopolysaccharide-induced tubular cell inflammation and pyroptosis by activating endoplasmic reticulum stress in acute kidney injury Cell Death Dis. 2024 15 217 10.1038/s41419-024-06600-1 38485717
Cao, Y. et al. STING contributes to lipopolysaccharide-induced tubular cell inflammation and pyroptosis by activating endoplasmic reticulum stress in acute kidney injury. Cell Death Dis. 15, 217 (2024).38485717
242. Chen Z GSDMD and GSDME synergy in the transition of acute kidney injury to chronic kidney disease Nephrol. Dialysis Transplant. 2024 39 1344 1359 10.1093/ndt/gfae014
Chen, Z. et al. GSDMD and GSDME synergy in the transition of acute kidney injury to chronic kidney disease. Nephrol. Dialysis Transplant. 39, 1344–1359 (2024).
243. Tian X Butyrate alleviates renal fibrosis in CKD by regulating NLRP3-mediated pyroptosis via the STING/NF-κB/p65 pathway Int Immunopharmacol. 2023 124 111010 10.1016/j.intimp.2023.111010 37852118
Tian, X. et al. Butyrate alleviates renal fibrosis in CKD by regulating NLRP3-mediated pyroptosis via the STING/NF-κB/p65 pathway. Int Immunopharmacol. 124, 111010 (2023).37852118
244. Wu M Gasdermin E Deletion Attenuates Ureteral Obstruction- and 5/6 Nephrectomy-Induced Renal Fibrosis and Kidney Dysfunction Front Cell Dev. Biol. 2021 9 754134 10.3389/fcell.2021.754134 34746148
Wu, M. et al. Gasdermin E Deletion Attenuates Ureteral Obstruction- and 5/6 Nephrectomy-Induced Renal Fibrosis and Kidney Dysfunction. Front Cell Dev. Biol. 9, 754134 (2021).34746148
245. Thomas MC Cooper ME Zimmet P Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease Nat. Rev. Nephrol. 2016 12 73 81 10.1038/nrneph.2015.173 26553517
Thomas, M. C., Cooper, M. E. & Zimmet, P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat. Rev. Nephrol. 12, 73–81 (2016).26553517
246. Cheng Q Caspase-11/4 and gasdermin D-mediated pyroptosis contributes to podocyte injury in mouse diabetic nephropathy Acta Pharm. Sin. 2021 42 954 963 10.1038/s41401-020-00525-z
Cheng, Q. et al. Caspase-11/4 and gasdermin D-mediated pyroptosis contributes to podocyte injury in mouse diabetic nephropathy. Acta Pharm. Sin. 42, 954–963 (2021).
247. Zheng F Neutrophil Extracellular Traps Induce Glomerular Endothelial Cell Dysfunction and Pyroptosis in Diabetic Kidney Disease Diabetes 2022 71 2739 2750 10.2337/db22-0153 36095260
Zheng, F. et al. Neutrophil Extracellular Traps Induce Glomerular Endothelial Cell Dysfunction and Pyroptosis in Diabetic Kidney Disease. Diabetes 71, 2739–2750 (2022).36095260
248. Li Y Yu W Xiong H Yuan F Circ_0000181 regulates miR-667-5p/NLRC4 axis to promote pyroptosis progression in diabetic nephropathy Sci. Rep. 2022 12 11994 10.1038/s41598-022-15607-7 35835791
Li, Y., Yu, W., Xiong, H. & Yuan, F. Circ_0000181 regulates miR-667-5p/NLRC4 axis to promote pyroptosis progression in diabetic nephropathy. Sci. Rep. 12, 11994 (2022).35835791
249. Shoeib HM Interplay between long non-coding RNA MALAT1 and pyroptosis in diabetic nephropathy patients Gene 2023 851 146978 10.1016/j.gene.2022.146978 36270460
Shoeib, H. M. et al. Interplay between long non-coding RNA MALAT1 and pyroptosis in diabetic nephropathy patients. Gene 851, 146978 (2023).36270460
250. Qin Y N6-methyladenosine methylation regulator RBM15 promotes the progression of diabetic nephropathy by regulating cell proliferation, inflammation, oxidative stress, and pyroptosis through activating the AGE-RAGE pathway Environ. Toxicol. 2023 38 2772 2782 10.1002/tox.23917 37551785
Qin, Y. et al. N6-methyladenosine methylation regulator RBM15 promotes the progression of diabetic nephropathy by regulating cell proliferation, inflammation, oxidative stress, and pyroptosis through activating the AGE-RAGE pathway. Environ. Toxicol. 38, 2772–2782 (2023).37551785
251. Lan J WTAP-mediated N(6)-methyladenosine modification of NLRP3 mRNA in kidney injury of diabetic nephropathy Cell Mol. Biol. Lett. 2022 27 51 10.1186/s11658-022-00350-8 35761192
Lan, J. et al. WTAP-mediated N(6)-methyladenosine modification of NLRP3 mRNA in kidney injury of diabetic nephropathy. Cell Mol. Biol. Lett. 27, 51 (2022).35761192
252. Kim D Ban KY Lee GH Jun HS Lysophosphatidic Acid Induces Podocyte Pyroptosis in Diabetic Nephropathy by an Increase of Egr1 Expression via Downregulation of EzH2 Int J. Mol. Sci. 2023 24 9968 10.3390/ijms24129968 37373116
Kim, D., Ban, K. Y., Lee, G. H. & Jun, H. S. Lysophosphatidic Acid Induces Podocyte Pyroptosis in Diabetic Nephropathy by an Increase of Egr1 Expression via Downregulation of EzH2. Int J. Mol. Sci. 24, 9968 (2023).37373116
253. Liang Y Linc00657 promoted pyroptosis in THP-1-derived macrophages and exacerbated atherosclerosis via the miR-106b-5p/TXNIP/NLRP3 axis Int. J. Biol. Macromol. 2023 253 126953 10.1016/j.ijbiomac.2023.126953 37734516
Liang, Y. et al. Linc00657 promoted pyroptosis in THP-1-derived macrophages and exacerbated atherosclerosis via the miR-106b-5p/TXNIP/NLRP3 axis. Int. J. Biol. Macromol. 253, 126953 (2023).37734516
254. Wang YW HIF-1α-regulated lncRNA-TUG1 promotes mitochondrial dysfunction and pyroptosis by directly binding to FUS in myocardial infarction Cell Death Discov. 2022 8 178 10.1038/s41420-022-00969-8 35396503
Wang, Y. W. et al. HIF-1α-regulated lncRNA-TUG1 promotes mitochondrial dysfunction and pyroptosis by directly binding to FUS in myocardial infarction. Cell Death Discov. 8, 178 (2022).35396503
255. You J GSDMD-mediated pyroptosis promotes cardiac remodeling in pressure overload Clin. Exp. Hypertens. 2023 45 2189138 10.1080/10641963.2023.2189138 36906959
You, J. et al. GSDMD-mediated pyroptosis promotes cardiac remodeling in pressure overload. Clin. Exp. Hypertens. 45, 2189138 (2023).36906959
256. Blaschke F Liver X Receptor Agonists Suppress Vascular Smooth Muscle Cell Proliferation and Inhibit Neointima Formation in Balloon-Injured Rat Carotid Arteries Circ. Res. 2004 95 e110 e123 10.1161/01.RES.0000150368.56660.4f 15539633
Blaschke, F. et al. Liver X Receptor Agonists Suppress Vascular Smooth Muscle Cell Proliferation and Inhibit Neointima Formation in Balloon-Injured Rat Carotid Arteries. Circ. Res. 95, e110–e123 (2004).15539633
257. Herrington W Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease Circ. Res. 2016 118 535 546 10.1161/CIRCRESAHA.115.307611 26892956
Herrington, W. et al. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ. Res. 118, 535–546 (2016).26892956
258. Yang Q Exercise Mitigates Endothelial Pyroptosis and Atherosclerosis by Downregulating NEAT1 Through N6-Methyladenosine Modifications Arterioscler Thromb. Vasc. Biol. 2023 43 910 926 10.1161/ATVBAHA.123.319251 37078289
Yang, Q. et al. Exercise Mitigates Endothelial Pyroptosis and Atherosclerosis by Downregulating NEAT1 Through N6-Methyladenosine Modifications. Arterioscler Thromb. Vasc. Biol. 43, 910–926 (2023).37078289
259. Zhang Y Rnd3 suppresses endothelial cell pyroptosis in atherosclerosis through regulation of ubiquitination of TRAF6 Clin. Transl. Med 2023 13 e1406 10.1002/ctm2.1406 37743632
Zhang, Y. et al. Rnd3 suppresses endothelial cell pyroptosis in atherosclerosis through regulation of ubiquitination of TRAF6. Clin. Transl. Med. 13, e1406 (2023).37743632
260. Wei Y GSDME-mediated pyroptosis promotes the progression and associated inflammation of atherosclerosis Nat. Commun. 2023 14 929 10.1038/s41467-023-36614-w 36807553
Wei, Y. et al. GSDME-mediated pyroptosis promotes the progression and associated inflammation of atherosclerosis. Nat. Commun. 14, 929 (2023).36807553
261. An C IQGAP1 promotes mitochondrial damage and activation of the mtDNA sensor cGAS-STING pathway to induce endothelial cell pyroptosis leading to atherosclerosis Int Immunopharmacol. 2023 123 110795 10.1016/j.intimp.2023.110795 37597406
An, C. et al. IQGAP1 promotes mitochondrial damage and activation of the mtDNA sensor cGAS-STING pathway to induce endothelial cell pyroptosis leading to atherosclerosis. Int Immunopharmacol. 123, 110795 (2023).37597406
262. Cong L Melatonin alleviates pyroptosis by regulating the SIRT3/FOXO3α/ROS axis and interacting with apoptosis in Atherosclerosis progression Biol. Res 2023 56 62 10.1186/s40659-023-00479-6 38041171
Cong, L. et al. Melatonin alleviates pyroptosis by regulating the SIRT3/FOXO3α/ROS axis and interacting with apoptosis in Atherosclerosis progression. Biol. Res 56, 62 (2023).38041171
263. He B Hyperuricemia promotes the progression of atherosclerosis by activating endothelial cell pyroptosis via the ROS/NLRP3 pathway J. Cell Physiol. 2023 238 1808 1822 10.1002/jcp.31038 37475193
He, B. et al. Hyperuricemia promotes the progression of atherosclerosis by activating endothelial cell pyroptosis via the ROS/NLRP3 pathway. J. Cell Physiol. 238, 1808–1822 (2023).37475193
264. Hou L Nicotine induces macrophage pyroptosis via LINC01272/miR-515/KLF6 axis Ecotoxicol. Environ. Saf. 2023 263 115265 10.1016/j.ecoenv.2023.115265 37478567
Hou, L. et al. Nicotine induces macrophage pyroptosis via LINC01272/miR-515/KLF6 axis. Ecotoxicol. Environ. Saf. 263, 115265 (2023).37478567
265. Meng Q Estrogen prevent atherosclerosis by attenuating endothelial cell pyroptosis via activation of estrogen receptor α-mediated autophagy J. Adv. Res 2021 28 149 164 10.1016/j.jare.2020.08.010 33364052
Meng, Q. et al. Estrogen prevent atherosclerosis by attenuating endothelial cell pyroptosis via activation of estrogen receptor α-mediated autophagy. J. Adv. Res. 28, 149–164 (2021).33364052
266. Zhang S Homocysteine promotes atherosclerosis through macrophage pyroptosis via endoplasmic reticulum stress and calcium disorder Mol. Med 2023 29 73 10.1186/s10020-023-00656-z 37308812
Zhang, S. et al. Homocysteine promotes atherosclerosis through macrophage pyroptosis via endoplasmic reticulum stress and calcium disorder. Mol. Med. 29, 73 (2023).37308812
267. O’Gara PT 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 2013 127 e362 e425 10.1161/CIR.0b013e3182742c84 23247304
O’Gara, P. T. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127, e362–e425 (2013).23247304
268. Vander Heide RS Steenbergen C Cardioprotection and myocardial reperfusion: pitfalls to clinical application Circ. Res 2013 113 464 477 10.1161/CIRCRESAHA.113.300765 23908333
Vander Heide, R. S. & Steenbergen, C. Cardioprotection and myocardial reperfusion: pitfalls to clinical application. Circ. Res. 113, 464–477 (2013).23908333
269. Shen S Uric acid aggravates myocardial ischemia-reperfusion injury via ROS/NLRP3 pyroptosis pathway Biomed. Pharmacother. 2021 133 110990 10.1016/j.biopha.2020.110990 33232925
Shen, S. et al. Uric acid aggravates myocardial ischemia-reperfusion injury via ROS/NLRP3 pyroptosis pathway. Biomed. Pharmacother. 133, 110990 (2021).33232925
270. Yao M Oxytocin ameliorates high glucose- and ischemia/reperfusion-induced myocardial injury by suppressing pyroptosis via AMPK signaling pathway Biomed. Pharmacother. 2022 153 113498 10.1016/j.biopha.2022.113498 36076588
Yao, M. et al. Oxytocin ameliorates high glucose- and ischemia/reperfusion-induced myocardial injury by suppressing pyroptosis via AMPK signaling pathway. Biomed. Pharmacother. 153, 113498 (2022).36076588
271. Shi H GSDMD-Mediated Cardiomyocyte Pyroptosis Promotes Myocardial I/R Injury Circ. Res 2021 129 383 396 10.1161/CIRCRESAHA.120.318629 34015941
Shi, H. et al. GSDMD-Mediated Cardiomyocyte Pyroptosis Promotes Myocardial I/R Injury. Circ. Res. 129, 383–396 (2021).34015941
272. Feng P Effect and mechanism of circHMGA2 on ferroptosis and pyroptosis in myocardial ischemia-reperfusion model CircHMGA2 exacerbates MI/R injury Heliyon 2023 9 e17849 10.1016/j.heliyon.2023.e17849 37501954
Feng, P. et al. Effect and mechanism of circHMGA2 on ferroptosis and pyroptosis in myocardial ischemia-reperfusion model CircHMGA2 exacerbates MI/R injury. Heliyon 9, e17849 (2023).37501954
273. Piamsiri C GSDMD-mediated pyroptosis dominantly promotes left ventricular remodeling and dysfunction in post-myocardial infarction: a comparison across modes of programmed cell death and mitochondrial involvement J. Transl. Med 2023 21 16 10.1186/s12967-023-03873-6 36627703
Piamsiri, C. et al. GSDMD-mediated pyroptosis dominantly promotes left ventricular remodeling and dysfunction in post-myocardial infarction: a comparison across modes of programmed cell death and mitochondrial involvement. J. Transl. Med. 21, 16 (2023).36627703
274. Han Y Dong B Chen M Yao C LncRNA H19 suppresses pyroptosis of cardiomyocytes to attenuate myocardial infarction in a PBX3/CYP1B1-dependent manner Mol. Cell Biochem 2021 476 1387 1400 10.1007/s11010-020-03998-y 33389498
Han, Y., Dong, B., Chen, M. & Yao, C. LncRNA H19 suppresses pyroptosis of cardiomyocytes to attenuate myocardial infarction in a PBX3/CYP1B1-dependent manner. Mol. Cell Biochem. 476, 1387–1400 (2021).33389498
275. Ma M Mitofilin Mitigates Myocardial Damage in Acute Myocardial Infarction by Regulating Pyroptosis of Cardiomyocytes Front Cardiovasc Med 2022 9 823591 10.3389/fcvm.2022.823591 35586659
Ma, M. et al. Mitofilin Mitigates Myocardial Damage in Acute Myocardial Infarction by Regulating Pyroptosis of Cardiomyocytes. Front Cardiovasc Med 9, 823591 (2022).35586659
276. Shi M TRIM16 exerts protective function on myocardial ischemia/reperfusion injury through reducing pyroptosis and inflammation via NLRP3 signaling Biochem Biophys. Res. Commun 2022 632 122 128 10.1016/j.bbrc.2022.09.057 36208489
Shi, M. et al. TRIM16 exerts protective function on myocardial ischemia/reperfusion injury through reducing pyroptosis and inflammation via NLRP3 signaling. Biochem Biophys. Res. Commun. 632, 122–128 (2022).36208489
277. Tan Y Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence Nat. Rev. Cardiol. 2020 17 585 607 10.1038/s41569-020-0339-2 32080423
Tan, Y. et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat. Rev. Cardiol. 17, 585–607 (2020).32080423
278. Meng L METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA Cell Death Dis. 2022 13 38 10.1038/s41419-021-04484-z 35013106
Meng, L. et al. METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA. Cell Death Dis. 13, 38 (2022).35013106
279. Wang LF CD38 Deficiency Alleviates Diabetic Cardiomyopathy by Coordinately Inhibiting Pyroptosis and Apoptosis Int J. Mol. Sci. 2023 24 16008 10.3390/ijms242116008 37958991
Wang, L. F. et al. CD38 Deficiency Alleviates Diabetic Cardiomyopathy by Coordinately Inhibiting Pyroptosis and Apoptosis. Int J. Mol. Sci. 24, 16008 (2023).37958991
280. Yuan Q CircRNA DICAR as a novel endogenous regulator for diabetic cardiomyopathy and diabetic pyroptosis of cardiomyocytes Signal Transduct. Target Ther. 2023 8 99 10.1038/s41392-022-01306-2 36882410
Yuan, Q. et al. CircRNA DICAR as a novel endogenous regulator for diabetic cardiomyopathy and diabetic pyroptosis of cardiomyocytes. Signal Transduct. Target Ther. 8, 99 (2023).36882410
281. Hong L Folic Acid Alleviates High Glucose and Fat-Induced Pyroptosis via Inhibition of the Hippo Signal Pathway on H9C2 Cells Front Mol. Biosci. 2021 8 698698 10.3389/fmolb.2021.698698 34692767
Hong, L. et al. Folic Acid Alleviates High Glucose and Fat-Induced Pyroptosis via Inhibition of the Hippo Signal Pathway on H9C2 Cells. Front Mol. Biosci. 8, 698698 (2021).34692767
282. Shi P MiR-21-3p triggers cardiac fibroblasts pyroptosis in diabetic cardiac fibrosis via inhibiting androgen receptor Exp. Cell Res 2021 399 112464 10.1016/j.yexcr.2020.112464 33385416
Shi, P. et al. MiR-21-3p triggers cardiac fibroblasts pyroptosis in diabetic cardiac fibrosis via inhibiting androgen receptor. Exp. Cell Res. 399, 112464 (2021).33385416
283. Xiao W Long non-coding RNA MIAT is involved in the regulation of pyroptosis in diabetic cardiomyopathy via targeting miR-214-3p iScience 2021 24 103518 10.1016/j.isci.2021.103518 34950859
Xiao, W. et al. Long non-coding RNA MIAT is involved in the regulation of pyroptosis in diabetic cardiomyopathy via targeting miR-214-3p. iScience 24, 103518 (2021).34950859
284. Zhao S MicroRNA-223-3p promotes pyroptosis of cardiomyocyte and release of inflammasome factors via downregulating the expression level of SPI1 (PU.1) Toxicology 2022 476 153252 10.1016/j.tox.2022.153252 35792203
Zhao, S. et al. MicroRNA-223-3p promotes pyroptosis of cardiomyocyte and release of inflammasome factors via downregulating the expression level of SPI1 (PU.1). Toxicology 476, 153252 (2022).35792203
285. Wang F Ghrelin inhibits myocardial pyroptosis in diabetic cardiomyopathy by regulating ERS and NLRP3 inflammasome crosstalk through the PI3K/AKT pathway J. Drug Target 2024 32 148 158 10.1080/1061186X.2023.2295268 38088811
Wang, F. et al. Ghrelin inhibits myocardial pyroptosis in diabetic cardiomyopathy by regulating ERS and NLRP3 inflammasome crosstalk through the PI3K/AKT pathway. J. Drug Target 32, 148–158 (2024).38088811
286. Al-Khatib SM Atrial Fibrillation Ann. Intern Med 2023 176 Itc97 itc112 10.7326/AITC202307180 37429028
Al-Khatib, S. M. Atrial Fibrillation. Ann. Intern Med 176, Itc97–itc112 (2023).37429028
287. Luo Y Akkermansia muciniphila prevents cold-related atrial fibrillation in rats by modulation of TMAO induced cardiac pyroptosis EBioMedicine 2022 82 104087 10.1016/j.ebiom.2022.104087 35797768
Luo, Y. et al. Akkermansia muciniphila prevents cold-related atrial fibrillation in rats by modulation of TMAO induced cardiac pyroptosis. EBioMedicine 82, 104087 (2022).35797768
288. Yan B LncRNA XIST shuttled by adipose tissue-derived mesenchymal stem cell-derived extracellular vesicles suppresses myocardial pyroptosis in atrial fibrillation by disrupting miR-214-3p-mediated Arl2 inhibition Lab Invest 2021 101 1427 1438 10.1038/s41374-021-00635-0 34389797
Yan, B. et al. LncRNA XIST shuttled by adipose tissue-derived mesenchymal stem cell-derived extracellular vesicles suppresses myocardial pyroptosis in atrial fibrillation by disrupting miR-214-3p-mediated Arl2 inhibition. Lab Invest 101, 1427–1438 (2021).34389797
289. Nakamura M Sadoshima J Mechanisms of physiological and pathological cardiac hypertrophy Nat. Rev. Cardiol. 2018 15 387 407 10.1038/s41569-018-0007-y 29674714
Nakamura, M. & Sadoshima, J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat. Rev. Cardiol. 15, 387–407 (2018).29674714
290. Zeng C NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy Redox Biol. 2020 34 101523 10.1016/j.redox.2020.101523 32273259
Zeng, C. et al. NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. Redox Biol. 34, 101523 (2020).32273259
291. Wang M TRPA1 deficiency aggravates dilated cardiomyopathy by promoting S100A8 expression to induce M1 macrophage polarization in rats Faseb j. 2023 37 e22982 10.1096/fj.202202079RR 37219522
Wang, M. et al. TRPA1 deficiency aggravates dilated cardiomyopathy by promoting S100A8 expression to induce M1 macrophage polarization in rats. Faseb j. 37, e22982 (2023).37219522
292. Yue R NLRP3-mediated pyroptosis aggravates pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction in mice: cardioprotective role of irisin Cell Death Discov. 2021 7 50 10.1038/s41420-021-00434-y 33723236
Yue, R. et al. NLRP3-mediated pyroptosis aggravates pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction in mice: cardioprotective role of irisin. Cell Death Discov. 7, 50 (2021).33723236
293. Li X TAK1 Activation by NLRP3 Deficiency Confers Cardioprotection Against Pressure Overload-Induced Cardiomyocyte Pyroptosis and Hypertrophy JACC Basic Transl. Sci. 2023 8 1555 1573 10.1016/j.jacbts.2023.05.008 38205342
Li, X. et al. TAK1 Activation by NLRP3 Deficiency Confers Cardioprotection Against Pressure Overload-Induced Cardiomyocyte Pyroptosis and Hypertrophy. JACC Basic Transl. Sci. 8, 1555–1573 (2023).38205342
294. Wu B Inhibition of Sema4D attenuates pressure overload-induced pathological myocardial hypertrophy via the MAPK/NF-κB/NLRP3 pathways Biochim Biophys. Acta Mol. Basis Dis. 2024 1870 166944 10.1016/j.bbadis.2023.166944 37952827
Wu, B. et al. Inhibition of Sema4D attenuates pressure overload-induced pathological myocardial hypertrophy via the MAPK/NF-κB/NLRP3 pathways. Biochim Biophys. Acta Mol. Basis Dis. 1870, 166944 (2024).37952827
295. Ewer MS Ewer SM Cardiotoxicity of anticancer treatments Nat. Rev. Cardiol. 2015 12 547 558 10.1038/nrcardio.2015.65 25962976
Ewer, M. S. & Ewer, S. M. Cardiotoxicity of anticancer treatments. Nat. Rev. Cardiol. 12, 547–558 (2015).25962976
296. Zheng X Bnip3 mediates doxorubicin-induced cardiomyocyte pyroptosis via caspase-3/GSDME Life Sci. 2020 242 117186 10.1016/j.lfs.2019.117186 31862454
Zheng, X. et al. Bnip3 mediates doxorubicin-induced cardiomyocyte pyroptosis via caspase-3/GSDME. Life Sci. 242, 117186 (2020).31862454
297. Zhong Z Inhibiting mir-34a-5p regulates doxorubicin-induced autophagy disorder and alleviates myocardial pyroptosis by targeting Sirt3-AMPK pathway Biomed. Pharmacother. 2023 168 115654 10.1016/j.biopha.2023.115654 37806095
Zhong, Z. et al. Inhibiting mir-34a-5p regulates doxorubicin-induced autophagy disorder and alleviates myocardial pyroptosis by targeting Sirt3-AMPK pathway. Biomed. Pharmacother. 168, 115654 (2023).37806095
298. Li L CB1R-stabilized NLRP3 inflammasome drives antipsychotics cardiotoxicity Signal Transduct. Target Ther. 2022 7 190 10.1038/s41392-022-01018-7 35739093
Li, L. et al. CB1R-stabilized NLRP3 inflammasome drives antipsychotics cardiotoxicity. Signal Transduct. Target Ther. 7, 190 (2022).35739093
299. Selim HM Fucoidan mitigates gastric ulcer injury through managing inflammation, oxidative stress, and NLRP3-mediated pyroptosis Int Immunopharmacol. 2023 120 110335 10.1016/j.intimp.2023.110335 37201406
Selim, H. M. et al. Fucoidan mitigates gastric ulcer injury through managing inflammation, oxidative stress, and NLRP3-mediated pyroptosis. Int Immunopharmacol. 120, 110335 (2023).37201406
300. Sun S Lactic Acid-Producing Probiotic Saccharomyces cerevisiae Attenuates Ulcerative Colitis via Suppressing Macrophage Pyroptosis and Modulating Gut Microbiota Front Immunol. 2021 12 777665 10.3389/fimmu.2021.777665 34899735
Sun, S. et al. Lactic Acid-Producing Probiotic Saccharomyces cerevisiae Attenuates Ulcerative Colitis via Suppressing Macrophage Pyroptosis and Modulating Gut Microbiota. Front Immunol. 12, 777665 (2021).34899735
301. Al Mamun A Pyroptosis in acute pancreatitis and its therapeutic regulation Apoptosis 2022 27 465 481 10.1007/s10495-022-01729-w 35687256
Al Mamun, A. et al. Pyroptosis in acute pancreatitis and its therapeutic regulation. Apoptosis 27, 465–481 (2022).35687256
302. Zhao Q Parabacteroides distasonis ameliorates hepatic fibrosis potentially via modulating intestinal bile acid metabolism and hepatocyte pyroptosis in male mice Nat. Commun. 2023 14 1829 10.1038/s41467-023-37459-z 37005411
Zhao, Q. et al. Parabacteroides distasonis ameliorates hepatic fibrosis potentially via modulating intestinal bile acid metabolism and hepatocyte pyroptosis in male mice. Nat. Commun. 14, 1829 (2023).37005411
303. Ungaro R Ulcerative colitis Lancet 2017 389 1756 1770 10.1016/S0140-6736(16)32126-2 27914657
Ungaro, R. et al. Ulcerative colitis. Lancet 389, 1756–1770 (2017).27914657
304. Zhang X Inhibition of C3a/C3aR Axis in Diverse Stages of Ulcerative Colitis Affected the Prognosis of UC by Modulating the Pyroptosis and Expression of Caspase-11 Inflammation 2020 43 2128 2136 10.1007/s10753-020-01280-3 32617860
Zhang, X. et al. Inhibition of C3a/C3aR Axis in Diverse Stages of Ulcerative Colitis Affected the Prognosis of UC by Modulating the Pyroptosis and Expression of Caspase-11. Inflammation 43, 2128–2136 (2020).32617860
305. Liu Q Thioredoxin reductase 3 suppression promotes colitis and carcinogenesis via activating pyroptosis and necrosis Cell Mol. Life Sci. 2022 79 106 10.1007/s00018-022-04155-y 35094204
Liu, Q. et al. Thioredoxin reductase 3 suppression promotes colitis and carcinogenesis via activating pyroptosis and necrosis. Cell Mol. Life Sci. 79, 106 (2022).35094204
306. Zhu F APOL1 Induces Pyroptosis of Fibroblasts Through NLRP3/Caspase-1/GSDMD Signaling Pathway in Ulcerative Colitis J. Inflamm. Res 2023 16 6385 6396 10.2147/JIR.S437875 38161356
Zhu, F. et al. APOL1 Induces Pyroptosis of Fibroblasts Through NLRP3/Caspase-1/GSDMD Signaling Pathway in Ulcerative Colitis. J. Inflamm. Res. 16, 6385–6396 (2023).38161356
307. Wang Y Long Non-coding RNA MEG3 Alleviated Ulcerative Colitis Through Upregulating miR-98-5p-Sponged IL-10 Inflammation 2021 44 1049 1059 10.1007/s10753-020-01400-z 33394187
Wang, Y. et al. Long Non-coding RNA MEG3 Alleviated Ulcerative Colitis Through Upregulating miR-98-5p-Sponged IL-10. Inflammation 44, 1049–1059 (2021).33394187
308. Yan R Liang X Hu J miR-141-3p alleviates ulcerative colitis by targeting SUGT1 to inhibit colonic epithelial cell pyroptosis Autoimmunity 2023 56 2220988 10.1080/08916934.2023.2220988 37317573
Yan, R., Liang, X. & Hu, J. miR-141-3p alleviates ulcerative colitis by targeting SUGT1 to inhibit colonic epithelial cell pyroptosis. Autoimmunity 56, 2220988 (2023).37317573
309. Gu Q SLC6A14 promotes ulcerative colitis progression by facilitating NLRP3 inflammasome-mediated pyroptosis World J. Gastroenterol. 2024 30 252 267 10.3748/wjg.v30.i3.252 38314135
Gu, Q. et al. SLC6A14 promotes ulcerative colitis progression by facilitating NLRP3 inflammasome-mediated pyroptosis. World J. Gastroenterol. 30, 252–267 (2024).38314135
310. Tenner S Baillie J DeWitt J Vege SS American College of Gastroenterology Guideline: Management of Acute Pancreatitis Am. J. Gastroenterol. 2013 108 1400 1415 10.1038/ajg.2013.218 23896955
Tenner, S., Baillie, J., DeWitt, J. & Vege, S. S. American College of Gastroenterology Guideline: Management of Acute Pancreatitis. Am. J. Gastroenterol. 108, 1400–1415 (2013).23896955
311. Gao L Acinar cell NLRP3 inflammasome and gasdermin D (GSDMD) activation mediates pyroptosis and systemic inflammation in acute pancreatitis Br. J. Pharm. 2021 178 3533 3552 10.1111/bph.15499
Gao, L. et al. Acinar cell NLRP3 inflammasome and gasdermin D (GSDMD) activation mediates pyroptosis and systemic inflammation in acute pancreatitis. Br. J. Pharm. 178, 3533–3552 (2021).
312. Wang J Cathepsin B aggravates acute pancreatitis by activating the NLRP3 inflammasome and promoting the caspase-1-induced pyroptosis Int Immunopharmacol. 2021 94 107496 10.1016/j.intimp.2021.107496 33639565
Wang, J. et al. Cathepsin B aggravates acute pancreatitis by activating the NLRP3 inflammasome and promoting the caspase-1-induced pyroptosis. Int Immunopharmacol. 94, 107496 (2021).33639565
313. Ma N Interleukin-37 protects against acinar cell pyroptosis in acute pancreatitis JCI Insight 2022 7 e161244 10.1172/jci.insight.161244 36166295
Ma, N. et al. Interleukin-37 protects against acinar cell pyroptosis in acute pancreatitis. JCI Insight 7, e161244 (2022).36166295
314. Wei B Inhibition of TRAF6 improves hyperlipidemic acute pancreatitis by alleviating pyroptosis in vitro and in vivo rat models Biol. Direct 2023 18 23 10.1186/s13062-023-00380-y 37165439
Wei, B. et al. Inhibition of TRAF6 improves hyperlipidemic acute pancreatitis by alleviating pyroptosis in vitro and in vivo rat models. Biol. Direct 18, 23 (2023).37165439
315. Lu Y HDL inhibits pancreatic acinar cell NLRP3 inflammasome activation and protect against acinar cell pyroptosis in acute pancreatitis Int Immunopharmacol. 2023 125 110950 10.1016/j.intimp.2023.110950 37890377
Lu, Y. et al. HDL inhibits pancreatic acinar cell NLRP3 inflammasome activation and protect against acinar cell pyroptosis in acute pancreatitis. Int Immunopharmacol. 125, 110950 (2023).37890377
316. Wang J CircHIPK3 Promotes Pyroptosis in Acinar Cells Through Regulation of the miR-193a-5p/GSDMD Axis Front Med. (Lausanne) 2020 7 88 10.3389/fmed.2020.00088 32318575
Wang, J. et al. CircHIPK3 Promotes Pyroptosis in Acinar Cells Through Regulation of the miR-193a-5p/GSDMD Axis. Front Med. (Lausanne) 7, 88 (2020).32318575
317. Sun B Endogenous tRNA-derived small RNA (tRF3-Thr-AGT) inhibits ZBP1/NLRP3 pathway-mediated cell pyroptosis to attenuate acute pancreatitis (AP) J. Cell Mol. Med 2021 25 10441 10453 10.1111/jcmm.16972 34643045
Sun, B. et al. Endogenous tRNA-derived small RNA (tRF3-Thr-AGT) inhibits ZBP1/NLRP3 pathway-mediated cell pyroptosis to attenuate acute pancreatitis (AP). J. Cell Mol. Med. 25, 10441–10453 (2021).34643045
318. Lv H Liu X Zhou H USP25 UPREGULATION BOOSTS GSDMD -MEDIATED PYROPTOSIS OF ACINAR CELLS IN ACUTE PANCREATITIS Shock 2022 58 408 416 10.1097/SHK.0000000000001992 36155610
Lv, H., Liu, X. & Zhou, H. USP25 UPREGULATION BOOSTS GSDMD -MEDIATED PYROPTOSIS OF ACINAR CELLS IN ACUTE PANCREATITIS. Shock 58, 408–416 (2022).36155610
319. Shao Y Circulating exosomal miR-155-5p contributes to severe acute pancreatitis-associated intestinal barrier injury by targeting SOCS1 to activate NLRP3 inflammasome-mediated pyroptosis Faseb j. 2023 37 e23003 10.1096/fj.202300237R 37219532
Shao, Y. et al. Circulating exosomal miR-155-5p contributes to severe acute pancreatitis-associated intestinal barrier injury by targeting SOCS1 to activate NLRP3 inflammasome-mediated pyroptosis. Faseb j. 37, e23003 (2023).37219532
320. Yan C Endoplasmic reticulum stress promotes caspase-1-dependent acinar cell pyroptosis through the PERK pathway to aggravate acute pancreatitis Int Immunopharmacol. 2023 120 110293 10.1016/j.intimp.2023.110293 37182453
Yan, C. et al. Endoplasmic reticulum stress promotes caspase-1-dependent acinar cell pyroptosis through the PERK pathway to aggravate acute pancreatitis. Int Immunopharmacol. 120, 110293 (2023).37182453
321. Hernandez-Gea V Friedman SL Pathogenesis of liver fibrosis Annu Rev. Pathol. 2011 6 425 456 10.1146/annurev-pathol-011110-130246 21073339
Hernandez-Gea, V. & Friedman, S. L. Pathogenesis of liver fibrosis. Annu Rev. Pathol. 6, 425–456 (2011).21073339
322. Gaul S Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis J. Hepatol. 2021 74 156 167 10.1016/j.jhep.2020.07.041 32763266
Gaul, S. et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J. Hepatol. 74, 156–167 (2021).32763266
323. Xiao Y STING mediates hepatocyte pyroptosis in liver fibrosis by Epigenetically activating the NLRP3 inflammasome Redox Biol. 2023 62 102691 10.1016/j.redox.2023.102691 37018971
Xiao, Y. et al. STING mediates hepatocyte pyroptosis in liver fibrosis by Epigenetically activating the NLRP3 inflammasome. Redox Biol. 62, 102691 (2023).37018971
324. Wu J Hepatic HRC induces hepatocyte pyroptosis and HSCs activation via NLRP3/caspase-1 pathway J. Mol. Med. (Berl.) 2022 100 1787 1799 10.1007/s00109-022-02270-8 36371595
Wu, J. et al. Hepatic HRC induces hepatocyte pyroptosis and HSCs activation via NLRP3/caspase-1 pathway. J. Mol. Med. (Berl.) 100, 1787–1799 (2022).36371595
325. Xie ZY Xu YX Yao L Angiotensin II can trigger HSC-LX2 pyroptosis through both classical and non-classical pathways Life Sci. 2022 307 120878 10.1016/j.lfs.2022.120878 35961596
Xie, Z. Y., Xu, Y. X. & Yao, L. Angiotensin II can trigger HSC-LX2 pyroptosis through both classical and non-classical pathways. Life Sci. 307, 120878 (2022).35961596
326. Zhang Y Exosomes Derived from BMMSCs Mitigate the Hepatic Fibrosis via Anti-Pyroptosis Pathway in a Cirrhosis Model Cells 2022 11 4004 10.3390/cells11244004 36552767
Zhang, Y. et al. Exosomes Derived from BMMSCs Mitigate the Hepatic Fibrosis via Anti-Pyroptosis Pathway in a Cirrhosis Model. Cells 11, 4004 (2022).36552767
327. Lang Z GAS5-inhibited hepatocyte pyroptosis contributes to hepatic stellate cell inactivation via microRNA-684 and AHR iScience 2023 26 107326 10.1016/j.isci.2023.107326 37529102
Lang, Z. et al. GAS5-inhibited hepatocyte pyroptosis contributes to hepatic stellate cell inactivation via microRNA-684 and AHR. iScience 26, 107326 (2023).37529102
328. Shu B The METTL3/MALAT1/PTBP1/USP8/TAK1 axis promotes pyroptosis and M1 polarization of macrophages and contributes to liver fibrosis Cell Death Discov. 2021 7 368 10.1038/s41420-021-00756-x 34839365
Shu, B. et al. The METTL3/MALAT1/PTBP1/USP8/TAK1 axis promotes pyroptosis and M1 polarization of macrophages and contributes to liver fibrosis. Cell Death Discov. 7, 368 (2021).34839365
329. Liu Y S100A8-Mediated NLRP3 Inflammasome-Dependent Pyroptosis in Macrophages Facilitates Liver Fibrosis Progression Cells 2022 11 3579 10.3390/cells11223579 36429008
Liu, Y. et al. S100A8-Mediated NLRP3 Inflammasome-Dependent Pyroptosis in Macrophages Facilitates Liver Fibrosis Progression. Cells 11, 3579 (2022).36429008
330. Rao Z Pyroptosis in inflammatory diseases and cancer Theranostics 2022 12 4310 4329 10.7150/thno.71086 35673561
Rao, Z. et al. Pyroptosis in inflammatory diseases and cancer. Theranostics 12, 4310–4329 (2022).35673561
331. Sharma BR Kanneganti TD NLRP3 inflammasome in cancer and metabolic diseases Nat. Immunol. 2021 22 550 559 10.1038/s41590-021-00886-5 33707781
Sharma, B. R. & Kanneganti, T. D. NLRP3 inflammasome in cancer and metabolic diseases. Nat. Immunol. 22, 550–559 (2021).33707781
332. Cheng HY Snail-regulated exosomal microRNA-21 suppresses NLRP3 inflammasome activity to enhance cisplatin resistance J. Immunother. Cancer 2022 10 e004832 10.1136/jitc-2022-004832 36002186
Cheng, H. Y. et al. Snail-regulated exosomal microRNA-21 suppresses NLRP3 inflammasome activity to enhance cisplatin resistance. J. Immunother. Cancer 10, e004832 (2022).36002186
333. Yuan R Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis Pharm. Res 2021 170 105748 10.1016/j.phrs.2021.105748
Yuan, R. et al. Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis. Pharm. Res 170, 105748 (2021).
334. Zhang Y Alpinumisoflavone suppresses hepatocellular carcinoma cell growth and metastasis via NLRP3 inflammasome-mediated pyroptosis Pharm. Rep. 2020 72 1370 1382 10.1007/s43440-020-00064-8
Zhang, Y. et al. Alpinumisoflavone suppresses hepatocellular carcinoma cell growth and metastasis via NLRP3 inflammasome-mediated pyroptosis. Pharm. Rep. 72, 1370–1382 (2020).
335. Shen Z Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3 Aging (Albany NY) 2021 13 22120 22133 10.18632/aging.203464 34546972
Shen, Z. et al. Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3. Aging (Albany NY) 13, 22120–22133 (2021).34546972
336. Tang Z Pyroptosis is involved in the inhibitory effect of FL118 on growth and metastasis in colorectal cancer Life Sci. 2020 257 118065 10.1016/j.lfs.2020.118065 32659366
Tang, Z. et al. Pyroptosis is involved in the inhibitory effect of FL118 on growth and metastasis in colorectal cancer. Life Sci. 257, 118065 (2020).32659366
337. Zhao AN Disturbing NLRP3 acetylation and inflammasome assembly inhibits androgen receptor-promoted inflammatory responses and prostate cancer progression Faseb j. 2022 36 e22602 10.1096/fj.202200673RRR 36250925
Zhao, A. N. et al. Disturbing NLRP3 acetylation and inflammasome assembly inhibits androgen receptor-promoted inflammatory responses and prostate cancer progression. Faseb j. 36, e22602 (2022).36250925
338. Yan H Cisplatin Induces Pyroptosis via Activation of MEG3/NLRP3/caspase-1/GSDMD Pathway in Triple-Negative Breast Cancer Int J. Biol. Sci. 2021 17 2606 2621 10.7150/ijbs.60292 34326697
Yan, H. et al. Cisplatin Induces Pyroptosis via Activation of MEG3/NLRP3/caspase-1/GSDMD Pathway in Triple-Negative Breast Cancer. Int J. Biol. Sci. 17, 2606–2621 (2021).34326697
339. McSweeney KR Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations Cancers 2021 13 1572 10.3390/cancers13071572 33805488
McSweeney, K. R. et al. Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations. Cancers 13, 1572 (2021).33805488
340. Waissbluth S Maass JC Sanchez HA Martínez AD Supporting Cells and Their Potential Roles in Cisplatin-Induced Ototoxicity Front Neurosci. 2022 16 867034 10.3389/fnins.2022.867034 35573297
Waissbluth, S., Maass, J. C., Sanchez, H. A. & Martínez, A. D. Supporting Cells and Their Potential Roles in Cisplatin-Induced Ototoxicity. Front Neurosci. 16, 867034 (2022).35573297
341. Pushpan CK Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced AKI J. Am. Soc. Nephrol. 2024 35 22 40 10.1681/ASN.0000000000000261 37962623
Pushpan, C. K. et al. Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced AKI. J. Am. Soc. Nephrol. 35, 22–40 (2024).37962623
342. Yang HL Coenzyme Q(0) defeats NLRP3-mediated inflammation, EMT/metastasis, and Warburg effects by inhibiting HIF-1α expression in human triple-negative breast cancer cells Arch. Toxicol. 2023 97 1047 1068 10.1007/s00204-023-03456-w 36847822
Yang, H. L. et al. Coenzyme Q(0) defeats NLRP3-mediated inflammation, EMT/metastasis, and Warburg effects by inhibiting HIF-1α expression in human triple-negative breast cancer cells. Arch. Toxicol. 97, 1047–1068 (2023).36847822
343. Yang HL Coenzyme Q(0) inhibited the NLRP3 inflammasome, metastasis/EMT, and Warburg effect by suppressing hypoxia-induced HIF-1α expression in HNSCC cells Int J. Biol. Sci. 2024 20 2790 2813 10.7150/ijbs.93943 38904007
Yang, H. L. et al. Coenzyme Q(0) inhibited the NLRP3 inflammasome, metastasis/EMT, and Warburg effect by suppressing hypoxia-induced HIF-1α expression in HNSCC cells. Int J. Biol. Sci. 20, 2790–2813 (2024).38904007
344. Liang L Oxymatrine suppresses colorectal cancer progression by inhibiting NLRP3 inflammasome activation through mitophagy induction in vitro and in vivo Phytother. Res 2023 37 3342 3362 10.1002/ptr.7808 36974424
Liang, L. et al. Oxymatrine suppresses colorectal cancer progression by inhibiting NLRP3 inflammasome activation through mitophagy induction in vitro and in vivo. Phytother. Res 37, 3342–3362 (2023).36974424
345. Zhou H Efficacy of oxymatrine for treatment and relapse suppression of severe plaque psoriasis: results from a single-blinded randomized controlled clinical trial Br. J. Dermatol 2017 176 1446 1455 10.1111/bjd.15316 28112799
Zhou, H. et al. Efficacy of oxymatrine for treatment and relapse suppression of severe plaque psoriasis: results from a single-blinded randomized controlled clinical trial. Br. J. Dermatol 176, 1446–1455 (2017).28112799
346. Sun J Li J Kong X Guo Q Peimine Inhibits MCF-7 Breast Cancer Cell Growth by Modulating Inflammasome Activation: Critical Roles of MAPK and NF-κB Signaling Anticancer Agents Med Chem. 2023 23 317 327 10.2174/1871520622666220324100510 35331099
Sun, J., Li, J., Kong, X. & Guo, Q. Peimine Inhibits MCF-7 Breast Cancer Cell Growth by Modulating Inflammasome Activation: Critical Roles of MAPK and NF-κB Signaling. Anticancer Agents Med Chem. 23, 317–327 (2023).35331099
347. Guo W VB12-Sericin-PBLG-IR780 Nanomicelles for Programming Cell Pyroptosis via Photothermal (PTT)/Photodynamic (PDT) Effect-Induced Mitochondrial DNA (mitoDNA) Oxidative Damage ACS Appl Mater. Interfaces 2022 14 17008 17021 10.1021/acsami.1c22804 35394753
Guo, W. et al. VB12-Sericin-PBLG-IR780 Nanomicelles for Programming Cell Pyroptosis via Photothermal (PTT)/Photodynamic (PDT) Effect-Induced Mitochondrial DNA (mitoDNA) Oxidative Damage. ACS Appl Mater. Interfaces 14, 17008–17021 (2022).35394753
348. Zhou Y Curcumin activates NLRC4, AIM2, and IFI16 inflammasomes and induces pyroptosis by up-regulated ISG3 transcript factor in acute myeloid leukemia cell lines Cancer Biol. Ther. 2022 23 328 335 10.1080/15384047.2022.2058862 35435150
Zhou, Y. et al. Curcumin activates NLRC4, AIM2, and IFI16 inflammasomes and induces pyroptosis by up-regulated ISG3 transcript factor in acute myeloid leukemia cell lines. Cancer Biol. Ther. 23, 328–335 (2022).35435150
349. Li Y Dihydroartemisinin induces pyroptosis by promoting the AIM2/caspase-3/DFNA5 axis in breast cancer cells Chem. Biol. Interact. 2021 340 109434 10.1016/j.cbi.2021.109434 33689708
Li, Y. et al. Dihydroartemisinin induces pyroptosis by promoting the AIM2/caspase-3/DFNA5 axis in breast cancer cells. Chem. Biol. Interact. 340, 109434 (2021).33689708
350. Zhou R CCL19 suppresses gastric cancer cell proliferation, migration, and invasion through the CCL19/CCR7/AIM2 pathway Hum. Cell 2020 33 1120 1132 10.1007/s13577-020-00375-1 32564199
Zhou, R. et al. CCL19 suppresses gastric cancer cell proliferation, migration, and invasion through the CCL19/CCR7/AIM2 pathway. Hum. Cell 33, 1120–1132 (2020).32564199
351. Xu X Virus-Like Particle-Induced cGAS-STING Activation and AIM2 Inflammasome-Mediated Pyroptosis for Robust Cancer Immunotherapy Angew. Chem. Int Ed. Engl. 2023 62 e202303010 10.1002/anie.202303010 37040149
Xu, X. et al. Virus-Like Particle-Induced cGAS-STING Activation and AIM2 Inflammasome-Mediated Pyroptosis for Robust Cancer Immunotherapy. Angew. Chem. Int Ed. Engl. 62, e202303010 (2023).37040149
352. Zheng P Biodegradable Ca(2+) Nanomodulators Activate Pyroptosis through Mitochondrial Ca(2+) Overload for Cancer Immunotherapy Angew. Chem. Int Ed. Engl. 2022 61 e202204904 10.1002/anie.202204904 35687022
Zheng, P. et al. Biodegradable Ca(2+) Nanomodulators Activate Pyroptosis through Mitochondrial Ca(2+) Overload for Cancer Immunotherapy. Angew. Chem. Int Ed. Engl. 61, e202204904 (2022).35687022
353. Zhao Q The central role of a two-way positive feedback pathway in molecular targeted therapies-mediated pyroptosis in anaplastic thyroid cancer Clin. Transl. Med 2022 12 e727 10.1002/ctm2.727 35184413
Zhao, Q. et al. The central role of a two-way positive feedback pathway in molecular targeted therapies-mediated pyroptosis in anaplastic thyroid cancer. Clin. Transl. Med. 12, e727 (2022).35184413
354. Zheng Z Metformin activates AMPK/SIRT1/NF-κB pathway and induces mitochondrial dysfunction to drive caspase3/GSDME-mediated cancer cell pyroptosis Cell Cycle 2020 19 1089 1104 10.1080/15384101.2020.1743911 32286137
Zheng, Z. et al. Metformin activates AMPK/SIRT1/NF-κB pathway and induces mitochondrial dysfunction to drive caspase3/GSDME-mediated cancer cell pyroptosis. Cell Cycle 19, 1089–1104 (2020).32286137
355. Cai J Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ J. Exp. Clin. Cancer Res 2021 40 190 10.1186/s13046-021-01995-7 34108030
Cai, J. et al. Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ. J. Exp. Clin. Cancer Res. 40, 190 (2021).34108030
356. Xu H Gambogic Acid Induces Pyroptosis of Colorectal Cancer Cells through the GSDME-Dependent Pathway and Elicits an Antitumor Immune Response Cancers 2022 14 5505 10.3390/cancers14225505 36428598
Xu, H. et al. Gambogic Acid Induces Pyroptosis of Colorectal Cancer Cells through the GSDME-Dependent Pathway and Elicits an Antitumor Immune Response. Cancers 14, 5505 (2022).36428598
357. Zhang X Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis Acta Pharm. Sin. B 2020 10 1397 1413 10.1016/j.apsb.2020.06.015 32963939
Zhang, X. et al. Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis. Acta Pharm. Sin. B 10, 1397–1413 (2020).32963939
358. An H Tetraarsenic hexoxide enhances generation of mitochondrial ROS to promote pyroptosis by inducing the activation of caspase-3/GSDME in triple-negative breast cancer cells Cell Death Dis. 2021 12 159 10.1038/s41419-021-03454-9 33558527
An, H. et al. Tetraarsenic hexoxide enhances generation of mitochondrial ROS to promote pyroptosis by inducing the activation of caspase-3/GSDME in triple-negative breast cancer cells. Cell Death Dis. 12, 159 (2021).33558527
359. Yu F Nitidine chloride induces caspase 3/GSDME-dependent pyroptosis by inhibting PI3K/Akt pathway in lung cancer Chin. Med 2022 17 115 10.1186/s13020-022-00671-y 36175965
Yu, F. et al. Nitidine chloride induces caspase 3/GSDME-dependent pyroptosis by inhibting PI3K/Akt pathway in lung cancer. Chin. Med 17, 115 (2022).36175965
360. Yang C CBL0137 activates ROS/BAX signaling to promote caspase-3/GSDME-dependent pyroptosis in ovarian cancer cells Biomed. Pharmacother. 2023 161 114529 10.1016/j.biopha.2023.114529 37002567
Yang, C. et al. CBL0137 activates ROS/BAX signaling to promote caspase-3/GSDME-dependent pyroptosis in ovarian cancer cells. Biomed. Pharmacother. 161, 114529 (2023).37002567
361. Sun X Germacrone induces caspase-3/GSDME activation and enhances ROS production, causing HepG2 pyroptosis Exp. Ther. Med 2022 24 456 10.3892/etm.2022.11383 35747157
Sun, X. et al. Germacrone induces caspase-3/GSDME activation and enhances ROS production, causing HepG2 pyroptosis. Exp. Ther. Med. 24, 456 (2022).35747157
362. Hu Z Cordyceps militaris extract induces apoptosis and pyroptosis via caspase-3/PARP/GSDME pathways in A549 cell line Food Sci. Nutr. 2022 10 21 38 10.1002/fsn3.2636 35035907
Hu, Z. et al. Cordyceps militaris extract induces apoptosis and pyroptosis via caspase-3/PARP/GSDME pathways in A549 cell line. Food Sci. Nutr. 10, 21–38 (2022).35035907
363. Xie B Combination of DNA demethylation and chemotherapy to trigger cell pyroptosis for inhalation treatment of lung cancer Nanoscale 2021 13 18608 18615 10.1039/D1NR05001J 34730599
Xie, B. et al. Combination of DNA demethylation and chemotherapy to trigger cell pyroptosis for inhalation treatment of lung cancer. Nanoscale 13, 18608–18615 (2021).34730599
364. Rioja-Blanco E CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma J. Exp. Clin. Cancer Res 2022 41 49 10.1186/s13046-022-02267-8 35120582
Rioja-Blanco, E. et al. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma. J. Exp. Clin. Cancer Res. 41, 49 (2022).35120582
365. Hu J Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment Signal Transduct. Target Ther. 2019 4 28 10.1038/s41392-019-0062-9 31637008
Hu, J. et al. Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment. Signal Transduct. Target Ther. 4, 28 (2019).31637008
366. Xie W Simvastatin induces pyroptosis via ROS/caspase-1/GSDMD pathway in colon cancer Cell Commun. Signal 2023 21 329 10.1186/s12964-023-01359-y 37974278
Xie, W. et al. Simvastatin induces pyroptosis via ROS/caspase-1/GSDMD pathway in colon cancer. Cell Commun. Signal 21, 329 (2023).37974278
367. Rasmussen ST Simvastatin and oxidative stress in humans: A randomized, double-blinded, placebo-controlled clinical trial Redox Biol. 2016 9 32 38 10.1016/j.redox.2016.05.007 27281490
Rasmussen, S. T. et al. Simvastatin and oxidative stress in humans: A randomized, double-blinded, placebo-controlled clinical trial. Redox Biol. 9, 32–38 (2016).27281490
368. Chen T Secoisolariciresinol diglucoside induces pyroptosis by activating caspase-1 to cleave GSDMD in colorectal cancer cells Drug Dev. Res 2022 83 1152 1166 10.1002/ddr.21939 35472101
Chen, T. et al. Secoisolariciresinol diglucoside induces pyroptosis by activating caspase-1 to cleave GSDMD in colorectal cancer cells. Drug Dev. Res. 83, 1152–1166 (2022).35472101
369. Chen M Saikosaponin-D induces the pyroptosis of lung cancer by increasing ROS and activating the NF-κB/NLRP3/caspase-1/GSDMD pathway J. Biochem Mol. Toxicol. 2023 37 e23444 10.1002/jbt.23444 37393521
Chen, M. et al. Saikosaponin-D induces the pyroptosis of lung cancer by increasing ROS and activating the NF-κB/NLRP3/caspase-1/GSDMD pathway. J. Biochem Mol. Toxicol. 37, e23444 (2023).37393521
370. Chen D Combination of ruthenium (II) polypyridyl complex Δ-Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD-mediated pyroptosis J. Inorg. Biochem 2022 230 111749 10.1016/j.jinorgbio.2022.111749 35144218
Chen, D. et al. Combination of ruthenium (II) polypyridyl complex Δ-Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD-mediated pyroptosis. J. Inorg. Biochem. 230, 111749 (2022).35144218
371. Li L Photodynamic therapy induces human esophageal carcinoma cell pyroptosis by targeting the PKM2/caspase-8/caspase-3/GSDME axis Cancer Lett. 2021 520 143 159 10.1016/j.canlet.2021.07.014 34256094
Li, L. et al. Photodynamic therapy induces human esophageal carcinoma cell pyroptosis by targeting the PKM2/caspase-8/caspase-3/GSDME axis. Cancer Lett. 520, 143–159 (2021).34256094
372. Li RY Cisplatin-induced pyroptosis is mediated via the CAPN1/CAPN2-BAK/BAX-caspase-9-caspase-3-GSDME axis in esophageal cancer Chem. Biol. Interact. 2022 361 109967 10.1016/j.cbi.2022.109967 35525317
Li, R. Y. et al. Cisplatin-induced pyroptosis is mediated via the CAPN1/CAPN2-BAK/BAX-caspase-9-caspase-3-GSDME axis in esophageal cancer. Chem. Biol. Interact. 361, 109967 (2022).35525317
373. Liu Z Apoptin induces pyroptosis of colorectal cancer cells via the GSDME-dependent pathway Int J. Biol. Sci. 2022 18 717 730 10.7150/ijbs.64350 35002520
Liu, Z. et al. Apoptin induces pyroptosis of colorectal cancer cells via the GSDME-dependent pathway. Int J. Biol. Sci. 18, 717–730 (2022).35002520
374. Hage C Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma Hepatology 2019 70 1280 1297 10.1002/hep.30666 31002440
Hage, C. et al. Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma. Hepatology 70, 1280–1297 (2019).31002440
375. Yoon SM Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial JAMA Oncol. 2018 4 661 669 10.1001/jamaoncol.2017.5847 29543938
Yoon, S. M. et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 4, 661–669 (2018).29543938
376. Qin S Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial JAMA Oncol. 2023 9 1651 1659 10.1001/jamaoncol.2023.4003 37796513
Qin, S. et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 9, 1651–1659 (2023).37796513
377. Yau T Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial JAMA Oncol. 2020 6 e204564 10.1001/jamaoncol.2020.4564 33001135
Yau, T. et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 6, e204564 (2020).33001135
378. Li Z Enhancing Gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response Nat. Commun. 2022 13 6321 10.1038/s41467-022-34036-8 36280674
Li, Z. et al. Enhancing Gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response. Nat. Commun. 13, 6321 (2022).36280674
379. Lu Y Strategies to package recombinant Adeno-Associated Virus expressing the N-terminal gasdermin domain for tumor treatment Nat. Commun. 2021 12 7155 10.1038/s41467-021-27407-0 34887423
Lu, Y. et al. Strategies to package recombinant Adeno-Associated Virus expressing the N-terminal gasdermin domain for tumor treatment. Nat. Commun. 12, 7155 (2021).34887423
380. Lin J Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity Nat. Commun. 2023 14 224 10.1038/s41467-023-35917-2 36641456
Lin, J. et al. Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity. Nat. Commun. 14, 224 (2023).36641456
381. Zhao Y Tian Y Feng T Sodium Houttuyfonate Ameliorates β-amyloid(1-42)-Induced Memory Impairment and Neuroinflammation through Inhibiting the NLRP3/GSDMD Pathway in Alzheimer’s Disease Mediators Inflamm. 2021 2021 8817698 10.1155/2021/8817698 34188608
Zhao, Y., Tian, Y. & Feng, T. Sodium Houttuyfonate Ameliorates β-amyloid(1-42)-Induced Memory Impairment and Neuroinflammation through Inhibiting the NLRP3/GSDMD Pathway in Alzheimer’s Disease. Mediators Inflamm. 2021, 8817698 (2021).34188608
382. Bai Y N-salicyloyl tryptamine derivatives as potential therapeutic agents for Alzheimer’s disease with neuroprotective effects Bioorg. Chem. 2021 115 105255 10.1016/j.bioorg.2021.105255 34435574
Bai, Y. et al. N-salicyloyl tryptamine derivatives as potential therapeutic agents for Alzheimer’s disease with neuroprotective effects. Bioorg. Chem. 115, 105255 (2021).34435574
383. Shi Y-S 1,7-diphenyl-4-hepten-3-one mitigates Alzheimer’s-like pathology by inhibiting pyroptosis via activating the Nrf2 pathway. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2024 397 3065 3075 10.1007/s00210-023-02765-2
Shi, Y.-S. et al. 1,7-diphenyl-4-hepten-3-one mitigates Alzheimer’s-like pathology by inhibiting pyroptosis via activating the Nrf2 pathway. Naunyn-Schmiedeberg’s. Arch. Pharmacol. 397, 3065–3075 (2024).
384. Fu XX Telmisartan Alleviates Alzheimer’s Disease-Related Neuropathologies and Cognitive Impairments J. Alzheimers Dis. 2023 94 919 933 10.3233/JAD-230133 37355897
Fu, X. X. et al. Telmisartan Alleviates Alzheimer’s Disease-Related Neuropathologies and Cognitive Impairments. J. Alzheimers Dis. 94, 919–933 (2023).37355897
385. Chou V INPP5D regulates inflammasome activation in human microglia Nat. Commun. 2023 14 7552 10.1038/s41467-023-42819-w 38016942
Chou, V. et al. INPP5D regulates inflammasome activation in human microglia. Nat. Commun. 14, 7552 (2023).38016942
386. Flores J Noël A Fillion ML LeBlanc AC Therapeutic potential of Nlrp1 inflammasome, Caspase-1, or Caspase-6 against Alzheimer disease cognitive impairment Cell Death Differ. 2022 29 657 669 10.1038/s41418-021-00881-1 34625662
Flores, J., Noël, A., Fillion, M. L. & LeBlanc, A. C. Therapeutic potential of Nlrp1 inflammasome, Caspase-1, or Caspase-6 against Alzheimer disease cognitive impairment. Cell Death Differ. 29, 657–669 (2022).34625662
387. Zhang T Bushen Huoxue Acupuncture Inhibits NLRP1 Inflammasome-Mediated Neuronal Pyroptosis in SAMP8 Mouse Model of Alzheimer’s Disease Neuropsychiatr. Dis. Treat. 2021 17 339 346 10.2147/NDT.S279304 33574670
Zhang, T. et al. Bushen Huoxue Acupuncture Inhibits NLRP1 Inflammasome-Mediated Neuronal Pyroptosis in SAMP8 Mouse Model of Alzheimer’s Disease. Neuropsychiatr. Dis. Treat. 17, 339–346 (2021).33574670
388. Esmaeili-Mahani S Apelin-13 prevents hippocampal synaptic plasticity impairment in Parkinsonism rats J. Chem. Neuroanat. 2021 111 101884 10.1016/j.jchemneu.2020.101884 33161074
Esmaeili-Mahani, S. et al. Apelin-13 prevents hippocampal synaptic plasticity impairment in Parkinsonism rats. J. Chem. Neuroanat. 111, 101884 (2021).33161074
389. Ye X Caspase-1: A Promising Target for Preserving Blood-Brain Barrier Integrity in Acute Stroke Front Mol. Neurosci. 2022 15 856372 10.3389/fnmol.2022.856372 35370546
Ye, X. et al. Caspase-1: A Promising Target for Preserving Blood-Brain Barrier Integrity in Acute Stroke. Front Mol. Neurosci. 15, 856372 (2022).35370546
390. Zhang X Salidroside ameliorates Parkinson’s disease by inhibiting NLRP3-dependent pyroptosis Aging (Albany NY) 2020 12 9405 9426 10.18632/aging.103215 32432571
Zhang, X. et al. Salidroside ameliorates Parkinson’s disease by inhibiting NLRP3-dependent pyroptosis. Aging (Albany NY) 12, 9405–9426 (2020).32432571
391. Cai M Kaemperfol alleviates pyroptosis and microglia-mediated neuroinflammation in Parkinson’s disease via inhibiting p38MAPK/NF-κB signaling pathway Neurochem Int 2022 152 105221 10.1016/j.neuint.2021.105221 34780806
Cai, M. et al. Kaemperfol alleviates pyroptosis and microglia-mediated neuroinflammation in Parkinson’s disease via inhibiting p38MAPK/NF-κB signaling pathway. Neurochem Int 152, 105221 (2022).34780806
392. Ma X Prussian Blue Nanozyme as a Pyroptosis Inhibitor Alleviates Neurodegeneration Adv. Mater. 2022 34 e2106723 10.1002/adma.202106723 35143076
Ma, X. et al. Prussian Blue Nanozyme as a Pyroptosis Inhibitor Alleviates Neurodegeneration. Adv. Mater. 34, e2106723 (2022).35143076
393. Jiang Z β-Hydroxybutyrate alleviates pyroptosis in MPP(+)/MPTP-induced Parkinson’s disease models via inhibiting STAT3/NLRP3/GSDMD pathway Int Immunopharmacol. 2022 113 109451 10.1016/j.intimp.2022.109451 36423429
Jiang, Z. et al. β-Hydroxybutyrate alleviates pyroptosis in MPP(+)/MPTP-induced Parkinson’s disease models via inhibiting STAT3/NLRP3/GSDMD pathway. Int Immunopharmacol. 113, 109451 (2022).36423429
394. Huan P Qiji Shujiang granules alleviates dopaminergic neuronal injury of parkinson’s disease by inhibiting NLRP3/Caspase-1 pathway mediated pyroptosis Phytomedicine 2023 120 155019 10.1016/j.phymed.2023.155019 37657208
Huan, P. et al. Qiji Shujiang granules alleviates dopaminergic neuronal injury of parkinson’s disease by inhibiting NLRP3/Caspase-1 pathway mediated pyroptosis. Phytomedicine 120, 155019 (2023).37657208
395. Poltorak A Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene Science 1998 282 2085 2088 10.1126/science.282.5396.2085 9851930
Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085–2088 (1998).9851930
396. Hu JJ FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation Nat. Immunol. 2020 21 736 745 10.1038/s41590-020-0669-6 32367036
Hu, J. J. et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat. Immunol. 21, 736–745 (2020).32367036
397. Saitoh S Chaperones and transport proteins regulate TLR4 trafficking and activation Immunobiology 2009 214 594 600 10.1016/j.imbio.2008.11.012 19250701
Saitoh, S. Chaperones and transport proteins regulate TLR4 trafficking and activation. Immunobiology 214, 594–600 (2009).19250701
398. Bai Y Disulfiram blocks inflammatory TLR4 signaling by targeting MD-2 Proc. Natl Acad. Sci. USA 2023 120 e2306399120 10.1073/pnas.2306399120 37487070
Bai, Y. et al. Disulfiram blocks inflammatory TLR4 signaling by targeting MD-2. Proc. Natl Acad. Sci. USA 120, e2306399120 (2023).37487070
399. Zhao LR Willing A Enhancing endogenous capacity to repair a stroke-damaged brain: An evolving field for stroke research Prog. Neurobiol. 2018 163-164 5 26 10.1016/j.pneurobio.2018.01.004 29476785
Zhao, L. R. & Willing, A. Enhancing endogenous capacity to repair a stroke-damaged brain: An evolving field for stroke research. Prog. Neurobiol. 163-164, 5–26 (2018).29476785
400. Kong LL Pinocembrin attenuates hemorrhagic transformation after delayed t-PA treatment in thromboembolic stroke rats by regulating endogenous metabolites Acta Pharm. Sin. 2021 42 1223 1234 10.1038/s41401-021-00664-x
Kong, L. L. et al. Pinocembrin attenuates hemorrhagic transformation after delayed t-PA treatment in thromboembolic stroke rats by regulating endogenous metabolites. Acta Pharm. Sin. 42, 1223–1234 (2021).
401. Chen Y RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor Cell Mol. Immunol. 2021 18 1425 1436 10.1038/s41423-021-00683-y 33972740
Chen, Y. et al. RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor. Cell Mol. Immunol. 18, 1425–1436 (2021).33972740
402. Zhu H Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition Front Immunol. 2021 12 714943 10.3389/fimmu.2021.714943 34367186
Zhu, H. et al. Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition. Front Immunol. 12, 714943 (2021).34367186
403. Chen C Directly targeting ASC by lonidamine alleviates inflammasome-driven diseases J. Neuroinflammation 2022 19 315 10.1186/s12974-022-02682-w 36577999
Chen, C. et al. Directly targeting ASC by lonidamine alleviates inflammasome-driven diseases. J. Neuroinflammation 19, 315 (2022).36577999
404. Hu R Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke Int Immunopharmacol. 2022 113 109315 10.1016/j.intimp.2022.109315 36279668
Hu, R. et al. Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke. Int Immunopharmacol. 113, 109315 (2022).36279668
405. Jia Y Xue K Luo Y Liu C Thiolutin attenuates ischemic stroke injury via inhibition of NLRP3 inflammasome: an in vitro and in vivo study Exp. Brain Res 2023 241 839 849 10.1007/s00221-023-06566-0 36749359
Jia, Y., Xue, K., Luo, Y. & Liu, C. Thiolutin attenuates ischemic stroke injury via inhibition of NLRP3 inflammasome: an in vitro and in vivo study. Exp. Brain Res. 241, 839–849 (2023).36749359
406. Guo X Intranasal administration of β-1, 3-galactosyltransferase 2 confers neuroprotection against ischemic stroke by likely inhibiting oxidative stress and NLRP3 inflammasome activation Faseb j. 2022 36 e22542 10.1096/fj.202200456RR 36094000
Guo, X. et al. Intranasal administration of β-1, 3-galactosyltransferase 2 confers neuroprotection against ischemic stroke by likely inhibiting oxidative stress and NLRP3 inflammasome activation. Faseb j. 36, e22542 (2022).36094000
407. Guo, C. et al. Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis. ACS Chem. Neurosci. 8, 2194–2201 (2017).
408. Hou B Inhibition of the NLRP3-inflammasome prevents cognitive deficits in experimental autoimmune encephalomyelitis mice via the alteration of astrocyte phenotype Cell Death Dis. 2020 11 377 10.1038/s41419-020-2565-2 32415059
Hou, B. et al. Inhibition of the NLRP3-inflammasome prevents cognitive deficits in experimental autoimmune encephalomyelitis mice via the alteration of astrocyte phenotype. Cell Death Dis. 11, 377 (2020).32415059
409. Sánchez-Fernández A Skouras DB Dinarello CA López-Vales R OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis Front Immunol. 2019 10 2578 10.3389/fimmu.2019.02578 31736980
Sánchez-Fernández, A., Skouras, D. B., Dinarello, C. A. & López-Vales, R. OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis. Front Immunol. 10, 2578 (2019).31736980
410. Pan L Yanghe Pingchuan Granules Alleviate Airway Inflammation in Bronchial Asthma and Inhibit Pyroptosis by Blocking the TLR4/NF-κB/NRLP3 Signaling Pathway Mediators Inflamm. 2022 2022 6561048 10.1155/2022/6561048 36091667
Pan, L. et al. Yanghe Pingchuan Granules Alleviate Airway Inflammation in Bronchial Asthma and Inhibit Pyroptosis by Blocking the TLR4/NF-κB/NRLP3 Signaling Pathway. Mediators Inflamm. 2022, 6561048 (2022).36091667
411. Ambrus-Aikelin G JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders Sci. Rep. 2023 13 13524 10.1038/s41598-023-39805-z 37598239
Ambrus-Aikelin, G. et al. JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders. Sci. Rep. 13, 13524 (2023).37598239
412. Lv J Heme oxygenase-1 alleviates allergic airway inflammation by suppressing NF-κB-mediated pyroptosis of bronchial epithelial cells Faseb j. 2024 38 e23472 10.1096/fj.202300883RR 38329323
Lv, J. et al. Heme oxygenase-1 alleviates allergic airway inflammation by suppressing NF-κB-mediated pyroptosis of bronchial epithelial cells. Faseb j. 38, e23472 (2024).38329323
413. Yang J Protopine ameliorates OVA-induced asthma through modulatingTLR4/MyD88/NF-κB pathway and NLRP3 inflammasome-mediated pyroptosis Phytomedicine 2024 126 155410 10.1016/j.phymed.2024.155410 38367422
Yang, J. et al. Protopine ameliorates OVA-induced asthma through modulatingTLR4/MyD88/NF-κB pathway and NLRP3 inflammasome-mediated pyroptosis. Phytomedicine 126, 155410 (2024).38367422
414. Chen X Schisandrin B Attenuates Airway Inflammation and Airway Remodeling in Asthma by Inhibiting NLRP3 Inflammasome Activation and Reducing Pyroptosis Inflammation 2021 44 2217 2231 10.1007/s10753-021-01494-z 34143347
Chen, X. et al. Schisandrin B Attenuates Airway Inflammation and Airway Remodeling in Asthma by Inhibiting NLRP3 Inflammasome Activation and Reducing Pyroptosis. Inflammation 44, 2217–2231 (2021).34143347
415. Zeng J Schisandrin A regulates the Nrf2 signaling pathway and inhibits NLRP3 inflammasome activation to interfere with pyroptosis in a mouse model of COPD Eur. J. Med. Res 2023 28 217 10.1186/s40001-023-01190-8 37400851
Zeng, J. et al. Schisandrin A regulates the Nrf2 signaling pathway and inhibits NLRP3 inflammasome activation to interfere with pyroptosis in a mouse model of COPD. Eur. J. Med. Res. 28, 217 (2023).37400851
416. Tian, X. et al. -)-Epicatechin ameliorates cigarette smoke-induced lung inflammation via inhibiting ROS/NLRP3 inflammasome pathway in rats with COPD. Toxicol Appl Pharmacol. 429, 115674 (2021). .
417. Xu L Propofol modulates Nrf2/NLRP3 signaling to ameliorate cigarette smoke-induced damage in human bronchial epithelial cells Tissue Cell 2024 88 102341 10.1016/j.tice.2024.102341 38479189
Xu, L. et al. Propofol modulates Nrf2/NLRP3 signaling to ameliorate cigarette smoke-induced damage in human bronchial epithelial cells. Tissue Cell 88, 102341 (2024).38479189
418. Zhang C Halotherapy relieves chronic obstructive pulmonary disease by alleviating NLRP3 inflammasome-mediated pyroptosis Ann. Transl. Med 2022 10 1279 10.21037/atm-22-5632 36618788
Zhang, C. et al. Halotherapy relieves chronic obstructive pulmonary disease by alleviating NLRP3 inflammasome-mediated pyroptosis. Ann. Transl. Med. 10, 1279 (2022).36618788
419. Wu X Emodin Ameliorates Acute Pancreatitis-Associated Lung Injury Through Inhibiting the Alveolar Macrophages Pyroptosis Front Pharm. 2022 13 873053 10.3389/fphar.2022.873053
Wu, X. et al. Emodin Ameliorates Acute Pancreatitis-Associated Lung Injury Through Inhibiting the Alveolar Macrophages Pyroptosis. Front Pharm. 13, 873053 (2022).
420. Xu Q Emodin Alleviates Severe Acute Pancreatitis-Associated Acute Lung Injury by Inhibiting the Cold-Inducible RNA-Binding Protein (CIRP)-Mediated Activation of the NLRP3/IL-1β/CXCL1 Signaling Front Pharm. 2021 12 655372 10.3389/fphar.2021.655372
Xu, Q. et al. Emodin Alleviates Severe Acute Pancreatitis-Associated Acute Lung Injury by Inhibiting the Cold-Inducible RNA-Binding Protein (CIRP)-Mediated Activation of the NLRP3/IL-1β/CXCL1 Signaling. Front Pharm. 12, 655372 (2021).
421. Pu Z The effects and mechanisms of the anti-COVID-19 traditional Chinese medicine, Dehydroandrographolide from Andrographis paniculata (Burm.f.) Wall, on acute lung injury by the inhibition of NLRP3-mediated pyroptosis Phytomedicine 2023 114 154753 10.1016/j.phymed.2023.154753 37084628
Pu, Z. et al. The effects and mechanisms of the anti-COVID-19 traditional Chinese medicine, Dehydroandrographolide from Andrographis paniculata (Burm.f.) Wall, on acute lung injury by the inhibition of NLRP3-mediated pyroptosis. Phytomedicine 114, 154753 (2023).37084628
422. Zhang W Chicoric Acid Presented NLRP3-Mediated Pyroptosis through Mitochondrial Damage by PDPK1 Ubiquitination in an Acute Lung Injury Model Am. J. Chin. Med 2023 51 1431 1457 10.1142/S0192415X23500659 37530505
Zhang, W. et al. Chicoric Acid Presented NLRP3-Mediated Pyroptosis through Mitochondrial Damage by PDPK1 Ubiquitination in an Acute Lung Injury Model. Am. J. Chin. Med. 51, 1431–1457 (2023).37530505
423. Liu Y Tangeretin attenuates acute lung injury in septic mice by inhibiting ROS-mediated NLRP3 inflammasome activation via regulating PLK1/AMPK/DRP1 signaling axis Inflamm. Res 2024 73 47 63 10.1007/s00011-023-01819-8 38147126
Liu, Y. et al. Tangeretin attenuates acute lung injury in septic mice by inhibiting ROS-mediated NLRP3 inflammasome activation via regulating PLK1/AMPK/DRP1 signaling axis. Inflamm. Res 73, 47–63 (2024).38147126
424. Qiu H EuHD1 protects against inflammatory injury driven by NLRP3 inflammasome Int Immunopharmacol. 2023 115 109712 10.1016/j.intimp.2023.109712 37724954
Qiu, H. et al. EuHD1 protects against inflammatory injury driven by NLRP3 inflammasome. Int Immunopharmacol. 115, 109712 (2023).37724954
425. Ren M Ergolide covalently binds NLRP3 and inhibits NLRP3 inflammasome-mediated pyroptosis Int Immunopharmacol. 2023 120 110292 10.1016/j.intimp.2023.110292 37182452
Ren, M. et al. Ergolide covalently binds NLRP3 and inhibits NLRP3 inflammasome-mediated pyroptosis. Int Immunopharmacol. 120, 110292 (2023).37182452
426. Shao JJ Britannin as a novel NLRP3 inhibitor, suppresses inflammasome activation in macrophages and alleviates NLRP3-related diseases in mice Acta Pharm. Sin. 2024 45 803 814 10.1038/s41401-023-01212-5
Shao, J. J. et al. Britannin as a novel NLRP3 inhibitor, suppresses inflammasome activation in macrophages and alleviates NLRP3-related diseases in mice. Acta Pharm. Sin. 45, 803–814 (2024).
427. Zhang C Xuebijing alleviates LPS-induced acute lung injury by downregulating pro-inflammatory cytokine production and inhibiting gasdermin-E-mediated pyroptosis of alveolar epithelial cells Chin. J. Nat. Med 2023 21 576 588 37611976
Zhang, C. et al. Xuebijing alleviates LPS-induced acute lung injury by downregulating pro-inflammatory cytokine production and inhibiting gasdermin-E-mediated pyroptosis of alveolar epithelial cells. Chin. J. Nat. Med. 21, 576–588 (2023).37611976
428. Peukert K Tetracycline ameliorates silica-induced pulmonary inflammation and fibrosis via inhibition of caspase-1 Respir. Res 2022 23 21 10.1186/s12931-022-01937-7 35130879
Peukert, K. et al. Tetracycline ameliorates silica-induced pulmonary inflammation and fibrosis via inhibition of caspase-1. Respir. Res 23, 21 (2022).35130879
429. Amaral NB Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients Inflamm. Res 2023 72 895 899 10.1007/s00011-023-01718-y 36917217
Amaral, N. B. et al. Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients. Inflamm. Res. 72, 895–899 (2023).36917217
430. Zhang H CHIP protects against septic acute kidney injury by inhibiting NLRP3-mediated pyroptosis iScience 2023 26 107762 10.1016/j.isci.2023.107762 37692286
Zhang, H. et al. CHIP protects against septic acute kidney injury by inhibiting NLRP3-mediated pyroptosis. iScience 26, 107762 (2023).37692286
431. Zhu X αKlotho protein has therapeutic activity in contrast-induced acute kidney injury by limiting NLRP3 inflammasome-mediated pyroptosis and promoting autophagy Pharm. Res 2021 167 105531 10.1016/j.phrs.2021.105531
Zhu, X. et al. αKlotho protein has therapeutic activity in contrast-induced acute kidney injury by limiting NLRP3 inflammasome-mediated pyroptosis and promoting autophagy. Pharm. Res. 167, 105531 (2021).
432. Li X miR-30c-5p Alleviated Pyroptosis During Sepsis-Induced Acute Kidney Injury via Targeting TXNIP Inflammation 2021 44 217 228 10.1007/s10753-020-01323-9 32892306
Li, X. et al. miR-30c-5p Alleviated Pyroptosis During Sepsis-Induced Acute Kidney Injury via Targeting TXNIP. Inflammation 44, 217–228 (2021).32892306
433. Yang B Circ DENND4C inhibits pyroptosis and alleviates ischemia-reperfusion acute kidney injury by exosomes secreted from human urine-derived stem cells Chem. Biol. Interact. 2024 391 110922 10.1016/j.cbi.2024.110922 38412628
Yang, B. et al. Circ DENND4C inhibits pyroptosis and alleviates ischemia-reperfusion acute kidney injury by exosomes secreted from human urine-derived stem cells. Chem. Biol. Interact. 391, 110922 (2024).38412628
434. Luo X Carnosine alleviates cisplatin-induced acute kidney injury by targeting Caspase-1 regulated pyroptosis Biomed. Pharmacother. 2023 167 115563 10.1016/j.biopha.2023.115563 37742605
Luo, X. et al. Carnosine alleviates cisplatin-induced acute kidney injury by targeting Caspase-1 regulated pyroptosis. Biomed. Pharmacother. 167, 115563 (2023).37742605
435. Xiong J DUSP2-mediated inhibition of tubular epithelial cell pyroptosis confers nephroprotection in acute kidney injury Theranostics 2022 12 5069 5085 10.7150/thno.72291 35836796
Xiong, J. et al. DUSP2-mediated inhibition of tubular epithelial cell pyroptosis confers nephroprotection in acute kidney injury. Theranostics 12, 5069–5085 (2022).35836796
436. Kong X Loganin reduces diabetic kidney injury by inhibiting the activation of NLRP3 inflammasome-mediated pyroptosis Chem. Biol. Interact. 2023 382 110640 10.1016/j.cbi.2023.110640 37473909
Kong, X. et al. Loganin reduces diabetic kidney injury by inhibiting the activation of NLRP3 inflammasome-mediated pyroptosis. Chem. Biol. Interact. 382, 110640 (2023).37473909
437. Gao Y Ma Y Xie D Jiang H ManNAc protects against podocyte pyroptosis via inhibiting mitochondrial damage and ROS/NLRP3 signaling pathway in diabetic kidney injury model Int Immunopharmacol. 2022 107 108711 10.1016/j.intimp.2022.108711 35338958
Gao, Y., Ma, Y., Xie, D. & Jiang, H. ManNAc protects against podocyte pyroptosis via inhibiting mitochondrial damage and ROS/NLRP3 signaling pathway in diabetic kidney injury model. Int Immunopharmacol. 107, 108711 (2022).35338958
438. Li N Tangshen Formula Attenuates Diabetic Kidney Injury by Imparting Anti-pyroptotic Effects via the TXNIP-NLRP3-GSDMD Axis Front Pharm. 2020 11 623489 10.3389/fphar.2020.623489
Li, N. et al. Tangshen Formula Attenuates Diabetic Kidney Injury by Imparting Anti-pyroptotic Effects via the TXNIP-NLRP3-GSDMD Axis. Front Pharm. 11, 623489 (2020).
439. Rauf A Honokiol: A review of its pharmacological potential and therapeutic insights Phytomedicine 2021 90 153647 10.1016/j.phymed.2021.153647 34362632
Rauf, A. et al. Honokiol: A review of its pharmacological potential and therapeutic insights. Phytomedicine 90, 153647 (2021).34362632
440. Ma Q Honokiol suppresses the aberrant interactions between renal resident macrophages and tubular epithelial cells in lupus nephritis through the NLRP3/IL-33/ST2 axis Cell Death Dis. 2023 14 174 10.1038/s41419-023-05680-9 36859530
Ma, Q. et al. Honokiol suppresses the aberrant interactions between renal resident macrophages and tubular epithelial cells in lupus nephritis through the NLRP3/IL-33/ST2 axis. Cell Death Dis. 14, 174 (2023).36859530
441. Wei T Rational design, synthesis, and pharmacological characterisation of dicarbonyl curcuminoid analogues with improved stability against lung cancer via ROS and ER stress mediated cell apoptosis and pyroptosis J. Enzym. Inhib. Med. Chem 2022 37 2357 2369 10.1080/14756366.2022.2116015
Wei, T. et al. Rational design, synthesis, and pharmacological characterisation of dicarbonyl curcuminoid analogues with improved stability against lung cancer via ROS and ER stress mediated cell apoptosis and pyroptosis. J. Enzym. Inhib. Med. Chem. 37, 2357–2369 (2022).
442. Zhu J Salvianolic acid A regulates pyroptosis of endothelial cells via directly targeting PKM2 and ameliorates diabetic atherosclerosis Front Pharm. 2022 13 1009229 10.3389/fphar.2022.1009229
Zhu, J. et al. Salvianolic acid A regulates pyroptosis of endothelial cells via directly targeting PKM2 and ameliorates diabetic atherosclerosis. Front Pharm. 13, 1009229 (2022).
443. Weng X Apigenin inhibits macrophage pyroptosis through regulation of oxidative stress and the NF-κB pathway and ameliorates atherosclerosis Phytother. Res 2023 37 5300 5314 10.1002/ptr.7962 37526050
Weng, X. et al. Apigenin inhibits macrophage pyroptosis through regulation of oxidative stress and the NF-κB pathway and ameliorates atherosclerosis. Phytother. Res. 37, 5300–5314 (2023).37526050
444. Liu S LncRNA H19 Mitigates Oxidized Low-Density Lipoprotein Induced Pyroptosis via Caspase-1 in Raw 264.7 Cells Inflammation 2021 44 2407 2418 10.1007/s10753-021-01511-1 34341910
Liu, S. et al. LncRNA H19 Mitigates Oxidized Low-Density Lipoprotein Induced Pyroptosis via Caspase-1 in Raw 264.7 Cells. Inflammation 44, 2407–2418 (2021).34341910
445. Zhang BL Inhibition of GSDMD activation by Z-LLSD-FMK or Z-YVAD-FMK reduces vascular inflammation and atherosclerotic lesion development in ApoE(-/-) mice Front Pharm. 2023 14 1184588 10.3389/fphar.2023.1184588
Zhang, B. L. et al. Inhibition of GSDMD activation by Z-LLSD-FMK or Z-YVAD-FMK reduces vascular inflammation and atherosclerotic lesion development in ApoE(-/-) mice. Front Pharm. 14, 1184588 (2023).
446. Azumi J The Organogermanium Compound 3-(Trihydroxygermyl) Propanoic Acid (THGP) Suppresses Inflammasome Activation Via Complexation with ATP Int J. Mol. Sci. 2022 23 13364 10.3390/ijms232113364 36362152
Azumi, J. et al. The Organogermanium Compound 3-(Trihydroxygermyl) Propanoic Acid (THGP) Suppresses Inflammasome Activation Via Complexation with ATP. Int J. Mol. Sci. 23, 13364 (2022).36362152
447. Liu J Autophagy blockage promotes the pyroptosis of ox-LDL-treated macrophages by modulating the p62/Nrf2/ARE axis J. Physiol. Biochem 2021 77 419 429 10.1007/s13105-021-00811-2 33886081
Liu, J. et al. Autophagy blockage promotes the pyroptosis of ox-LDL-treated macrophages by modulating the p62/Nrf2/ARE axis. J. Physiol. Biochem. 77, 419–429 (2021).33886081
448. Yang ZJ Knockdown of the long non‑coding RNA MALAT1 ameliorates TNF‑α‑mediated endothelial cell pyroptosis via the miR‑30c‑5p/Cx43 axis Mol. Med. Rep 2023 27 90 10.3892/mmr.2023.12977 36896775
Yang, Z. J. et al. Knockdown of the long non‑coding RNA MALAT1 ameliorates TNF‑α‑mediated endothelial cell pyroptosis via the miR‑30c‑5p/Cx43 axis. Mol. Med. Rep. 27, 90 (2023).36896775
449. Li H Geniposide suppresses NLRP3 inflammasome-mediated pyroptosis via the AMPK signaling pathway to mitigate myocardial ischemia/reperfusion injury Chin. Med 2022 17 73 10.1186/s13020-022-00616-5 35715805
Li, H. et al. Geniposide suppresses NLRP3 inflammasome-mediated pyroptosis via the AMPK signaling pathway to mitigate myocardial ischemia/reperfusion injury. Chin. Med. 17, 73 (2022).35715805
450. Chai R Tanshinone IIA inhibits cardiomyocyte pyroptosis through TLR4/NF-κB p65 pathway after acute myocardial infarction Front Cell Dev. Biol. 2023 11 1252942 10.3389/fcell.2023.1252942 37766966
Chai, R. et al. Tanshinone IIA inhibits cardiomyocyte pyroptosis through TLR4/NF-κB p65 pathway after acute myocardial infarction. Front Cell Dev. Biol. 11, 1252942 (2023).37766966
451. Dong HQ Liproxstatin‑1 induces cell cycle arrest, apoptosis, and caspase‑3/GSDME‑dependent secondary pyroptosis in K562 cells Int J. Oncol. 2022 61 119 10.3892/ijo.2022.5409 36004469
Dong, H. Q. et al. Liproxstatin‑1 induces cell cycle arrest, apoptosis, and caspase‑3/GSDME‑dependent secondary pyroptosis in K562 cells. Int J. Oncol. 61, 119 (2022).36004469
452. Nie C Hydrogen gas inhalation ameliorates cardiac remodelling and fibrosis by regulating NLRP3 inflammasome in myocardial infarction rats J. Cell Mol. Med 2021 25 8997 9010 10.1111/jcmm.16863 34402164
Nie, C. et al. Hydrogen gas inhalation ameliorates cardiac remodelling and fibrosis by regulating NLRP3 inflammasome in myocardial infarction rats. J. Cell Mol. Med. 25, 8997–9010 (2021).34402164
453. Chai X Chlorogenic acid protects against myocardial ischemia-reperfusion injury in mice by inhibiting Lnc Neat1/NLRP3 inflammasome-mediated pyroptosis Sci. Rep. 2023 13 17803 10.1038/s41598-023-45017-2 37853132
Chai, X. et al. Chlorogenic acid protects against myocardial ischemia-reperfusion injury in mice by inhibiting Lnc Neat1/NLRP3 inflammasome-mediated pyroptosis. Sci. Rep. 13, 17803 (2023).37853132
454. Pan W Coenzyme Q10 mitigates macrophage mediated inflammation in heart following myocardial infarction via the NLRP3/IL1β pathway BMC Cardiovasc Disord. 2024 24 76 10.1186/s12872-024-03729-x 38281937
Pan, W. et al. Coenzyme Q10 mitigates macrophage mediated inflammation in heart following myocardial infarction via the NLRP3/IL1β pathway. BMC Cardiovasc Disord. 24, 76 (2024).38281937
455. Qin C Epigallocatechin gallate prevents cardiomyocytes from pyroptosis through lncRNA MEG3/TAF15/AIM2 axis in myocardial infarction Chin. Med 2023 18 160 10.1186/s13020-023-00856-z 38057891
Qin, C. et al. Epigallocatechin gallate prevents cardiomyocytes from pyroptosis through lncRNA MEG3/TAF15/AIM2 axis in myocardial infarction. Chin. Med. 18, 160 (2023).38057891
456. Yue R Mesenchymal stem cell-derived exosomal microRNA-182-5p alleviates myocardial ischemia/reperfusion injury by targeting GSDMD in mice Cell Death Discov. 2022 8 202 10.1038/s41420-022-00909-6 35422485
Yue, R. et al. Mesenchymal stem cell-derived exosomal microRNA-182-5p alleviates myocardial ischemia/reperfusion injury by targeting GSDMD in mice. Cell Death Discov. 8, 202 (2022).35422485
457. Lu Y Magnetic vagus nerve stimulation alleviates myocardial ischemia-reperfusion injury by the inhibition of pyroptosis through the M(2)AChR/OGDHL/ROS axis in rats J. Nanobiotechnology 2023 21 421 10.1186/s12951-023-02189-3 37957640
Lu, Y. et al. Magnetic vagus nerve stimulation alleviates myocardial ischemia-reperfusion injury by the inhibition of pyroptosis through the M(2)AChR/OGDHL/ROS axis in rats. J. Nanobiotechnology 21, 421 (2023).37957640
458. Elmadbouh I Singla DK BMP-7 Attenuates Inflammation-Induced Pyroptosis and Improves Cardiac Repair in Diabetic Cardiomyopathy Cells 2021 10 2640 10.3390/cells10102640 34685620
Elmadbouh, I. & Singla, D. K. BMP-7 Attenuates Inflammation-Induced Pyroptosis and Improves Cardiac Repair in Diabetic Cardiomyopathy. Cells 10, 2640 (2021).34685620
459. Yang F Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy Int J. Biol. Sci. 2019 15 1010 1019 10.7150/ijbs.29680 31182921
Yang, F. et al. Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy. Int J. Biol. Sci. 15, 1010–1019 (2019).31182921
460. Zhong C Berberine inhibits NLRP3 inflammasome activation by regulating mTOR/mtROS axis to alleviate diabetic cardiomyopathy Eur. J. Pharm. 2024 964 176253 10.1016/j.ejphar.2023.176253
Zhong, C. et al. Berberine inhibits NLRP3 inflammasome activation by regulating mTOR/mtROS axis to alleviate diabetic cardiomyopathy. Eur. J. Pharm. 964, 176253 (2024).
461. Abo-Saif MA Pomegranate peel extract protects against the development of diabetic cardiomyopathy in rats by inhibiting pyroptosis and downregulating LncRNA-MALAT1 Front Pharm. 2023 14 1166653 10.3389/fphar.2023.1166653
Abo-Saif, M. A. et al. Pomegranate peel extract protects against the development of diabetic cardiomyopathy in rats by inhibiting pyroptosis and downregulating LncRNA-MALAT1. Front Pharm. 14, 1166653 (2023).
462. Yan M The Chinese herbal medicine Fufang Zhenzhu Tiaozhi protects against diabetic cardiomyopathy by alleviating cardiac lipotoxicity-induced oxidative stress and NLRP3-dependent inflammasome activation Biomed. Pharmacother. 2022 148 112709 10.1016/j.biopha.2022.112709 35190353
Yan, M. et al. The Chinese herbal medicine Fufang Zhenzhu Tiaozhi protects against diabetic cardiomyopathy by alleviating cardiac lipotoxicity-induced oxidative stress and NLRP3-dependent inflammasome activation. Biomed. Pharmacother. 148, 112709 (2022).35190353
463. Lu L Irisin improves diabetic cardiomyopathy-induced cardiac remodeling by regulating GSDMD-mediated pyroptosis through MITOL/STING signaling Biomed. Pharmacother. 2024 171 116007 10.1016/j.biopha.2023.116007 38171238
Lu, L. et al. Irisin improves diabetic cardiomyopathy-induced cardiac remodeling by regulating GSDMD-mediated pyroptosis through MITOL/STING signaling. Biomed. Pharmacother. 171, 116007 (2024).38171238
464. Wei Z Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway Mediators Inflamm. 2023 2023 3906043 10.1155/2023/3906043 37101595
Wei, Z. et al. Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway. Mediators Inflamm. 2023, 3906043 (2023).37101595
465. Wei Z Quercetin Inhibits Pyroptosis in Diabetic Cardiomyopathy through the Nrf2 Pathway J. Diabetes Res 2022 2022 9723632 10.1155/2022/9723632 36624860
Wei, Z. et al. Quercetin Inhibits Pyroptosis in Diabetic Cardiomyopathy through the Nrf2 Pathway. J. Diabetes Res. 2022, 9723632 (2022).36624860
466. Sun S Puerarin Inhibits NLRP3-Caspase-1-GSDMD-Mediated Pyroptosis via P2X7 Receptor in Cardiomyocytes and Macrophages Int J. Mol. Sci. 2023 24 13169 10.3390/ijms241713169 37685976
Sun, S. et al. Puerarin Inhibits NLRP3-Caspase-1-GSDMD-Mediated Pyroptosis via P2X7 Receptor in Cardiomyocytes and Macrophages. Int J. Mol. Sci. 24, 13169 (2023).37685976
467. Xu K Self-adaptive pyroptosis-responsive nanoliposomes block pyroptosis in autoimmune inflammatory diseases Bioact. Mater. 2024 36 272 286 38496034
Xu, K. et al. Self-adaptive pyroptosis-responsive nanoliposomes block pyroptosis in autoimmune inflammatory diseases. Bioact. Mater. 36, 272–286 (2024).38496034
468. Zhao J PLGA-microspheres-carried circGMCL1 protects against Crohn’s colitis through alleviating NLRP3 inflammasome-induced pyroptosis by promoting autophagy Cell Death Dis. 2022 13 782 10.1038/s41419-022-05226-5 36088391
Zhao, J. et al. PLGA-microspheres-carried circGMCL1 protects against Crohn’s colitis through alleviating NLRP3 inflammasome-induced pyroptosis by promoting autophagy. Cell Death Dis. 13, 782 (2022).36088391
469. Cai X hucMSC-derived exosomes attenuate colitis by regulating macrophage pyroptosis via the miR-378a-5p/NLRP3 axis Stem Cell Res. Ther 2021 12 416 10.1186/s13287-021-02492-6 34294138
Cai, X. et al. hucMSC-derived exosomes attenuate colitis by regulating macrophage pyroptosis via the miR-378a-5p/NLRP3 axis. Stem Cell Res. Ther. 12, 416 (2021).34294138
470. Zhang D β-sitosterol alleviates dextran sulfate sodium-induced experimental colitis via inhibition of NLRP3/Caspase-1/GSDMD-mediated pyroptosis Front Pharm. 2023 14 1218477 10.3389/fphar.2023.1218477
Zhang, D. et al. β-sitosterol alleviates dextran sulfate sodium-induced experimental colitis via inhibition of NLRP3/Caspase-1/GSDMD-mediated pyroptosis. Front Pharm. 14, 1218477 (2023).
471. Ye Z Tou Nong powder obstructs ulcerative colitis through the regulation of NF-κB/NLRP3/Caspase-1/GSDMD inflammasome pyroptotic pathway J. Ethnopharmacol. 2023 317 116846 10.1016/j.jep.2023.116846 37356744
Ye, Z. et al. Tou Nong powder obstructs ulcerative colitis through the regulation of NF-κB/NLRP3/Caspase-1/GSDMD inflammasome pyroptotic pathway. J. Ethnopharmacol. 317, 116846 (2023).37356744
472. Yang W Necrosulfonamide ameliorates intestinal inflammation via inhibiting GSDMD-medicated pyroptosis and MLKL-mediated necroptosis Biochem. Pharm 2022 206 115338 10.1016/j.bcp.2022.115338 36347275
Yang, W. et al. Necrosulfonamide ameliorates intestinal inflammation via inhibiting GSDMD-medicated pyroptosis and MLKL-mediated necroptosis. Biochem. Pharm. 206, 115338 (2022).36347275
473. Ma X Munronoid I Ameliorates DSS-Induced Mouse Colitis by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis Via Modulation of NLRP3 Front Immunol. 2022 13 853194 10.3389/fimmu.2022.853194 35865528
Ma, X. et al. Munronoid I Ameliorates DSS-Induced Mouse Colitis by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis Via Modulation of NLRP3. Front Immunol. 13, 853194 (2022).35865528
474. Liu D Ginsenoside Rg3 Ameliorates DSS-Induced Colitis by Inhibiting NLRP3 Inflammasome Activation and Regulating Microbial Homeostasis J. Agric Food Chem. 2023 71 3472 3483 10.1021/acs.jafc.2c07766
Liu, D. et al. Ginsenoside Rg3 Ameliorates DSS-Induced Colitis by Inhibiting NLRP3 Inflammasome Activation and Regulating Microbial Homeostasis. J. Agric Food Chem. 71, 3472–3483 (2023).
475. Fan R Wedelolactone alleviates acute pancreatitis and associated lung injury via GPX4 mediated suppression of pyroptosis and ferroptosis Free Radic. Biol Med 2021 173 29 40 10.1016/j.freeradbiomed.2021.07.009 34246777
Fan, R. et al. Wedelolactone alleviates acute pancreatitis and associated lung injury via GPX4 mediated suppression of pyroptosis and ferroptosis. Free Radic. Biol Med. 173, 29–40 (2021).34246777
476. Li S Hair follicle-MSC-derived small extracellular vesicles as a novel remedy for acute pancreatitis J. Control Release 2022 352 1104 1115 10.1016/j.jconrel.2022.11.029 36402231
Li, S. et al. Hair follicle-MSC-derived small extracellular vesicles as a novel remedy for acute pancreatitis. J. Control Release 352, 1104–1115 (2022).36402231
477. Feng M Qingjie Huagong decoction inhibits pancreatic acinar cell pyroptosis by regulating circHipk3/miR-193a-5p/NLRP3 pathway Phytomedicine 2024 126 155265 10.1016/j.phymed.2023.155265 38422649
Feng, M. et al. Qingjie Huagong decoction inhibits pancreatic acinar cell pyroptosis by regulating circHipk3/miR-193a-5p/NLRP3 pathway. Phytomedicine 126, 155265 (2024).38422649
478. Wang X Baicalein alleviates pyroptosis and inflammation in hyperlipidemic pancreatitis by inhibiting NLRP3/Caspase-1 pathway through the miR-192-5p/TXNIP axis Int Immunopharmacol. 2021 101 108315 10.1016/j.intimp.2021.108315 34785144
Wang, X. et al. Baicalein alleviates pyroptosis and inflammation in hyperlipidemic pancreatitis by inhibiting NLRP3/Caspase-1 pathway through the miR-192-5p/TXNIP axis. Int Immunopharmacol. 101, 108315 (2021).34785144
479. Wu J Treatment of Severe Acute Pancreatitis and Related Lung Injury by Targeting Gasdermin D-Mediated Pyroptosis Front Cell Dev. Biol. 2021 9 780142 10.3389/fcell.2021.780142 34858995
Wu, J. et al. Treatment of Severe Acute Pancreatitis and Related Lung Injury by Targeting Gasdermin D-Mediated Pyroptosis. Front Cell Dev. Biol. 9, 780142 (2021).34858995
480. Huang ZW Sinapic Acid Alleviates Acute Pancreatitis in Association with Attenuation of Inflammation, Pyroptosis, and the AMPK/NF-κB Signaling Pathway Am. J. Chin. Med 2022 50 2185 2197 10.1142/S0192415X2250094X 36222121
Huang, Z. W. et al. Sinapic Acid Alleviates Acute Pancreatitis in Association with Attenuation of Inflammation, Pyroptosis, and the AMPK/NF-κB Signaling Pathway. Am. J. Chin. Med. 50, 2185–2197 (2022).36222121
481. Wang X Salidroside ameliorates severe acute pancreatitis-induced cell injury and pyroptosis by inactivating Akt/NF-κB and caspase-3/GSDME pathways Heliyon 2023 9 e13225 10.1016/j.heliyon.2023.e13225 36747537
Wang, X. et al. Salidroside ameliorates severe acute pancreatitis-induced cell injury and pyroptosis by inactivating Akt/NF-κB and caspase-3/GSDME pathways. Heliyon 9, e13225 (2023).36747537
482. Gong L CD44-Targeting Drug Delivery System of Exosomes Loading Forsythiaside A Combats Liver Fibrosis via Regulating NLRP3-Mediated Pyroptosis Adv. Health. Mater. 2023 12 e2202228 10.1002/adhm.202202228
Gong, L. et al. CD44-Targeting Drug Delivery System of Exosomes Loading Forsythiaside A Combats Liver Fibrosis via Regulating NLRP3-Mediated Pyroptosis. Adv. Health. Mater. 12, e2202228 (2023).
483. Chen P Stem Cells From Human Exfoliated Deciduous Teeth Alleviate Liver Cirrhosis via Inhibition of Gasdermin D-Executed Hepatocyte Pyroptosis Front Immunol. 2022 13 860225 10.3389/fimmu.2022.860225 35634294
Chen, P. et al. Stem Cells From Human Exfoliated Deciduous Teeth Alleviate Liver Cirrhosis via Inhibition of Gasdermin D-Executed Hepatocyte Pyroptosis. Front Immunol. 13, 860225 (2022).35634294
484. Cardoso-Lezama I Nicotinic acid attenuates experimental non-alcoholic steatohepatitis by inhibiting the NLRP3 inflammasome/pyroptosis pathway Biochem Pharm. 2023 216 115762 10.1016/j.bcp.2023.115762 37604293
Cardoso-Lezama, I. et al. Nicotinic acid attenuates experimental non-alcoholic steatohepatitis by inhibiting the NLRP3 inflammasome/pyroptosis pathway. Biochem Pharm. 216, 115762 (2023).37604293
485. Kim HY Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome Commun. Biol. 2021 4 824 10.1038/s42003-021-02345-1 34193972
Kim, H. Y. et al. Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome. Commun. Biol. 4, 824 (2021).34193972
486. Povero D Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis J. Pharm. Exp. Ther. 2023 386 242 258 10.1124/jpet.123.001639
Povero, D. et al. Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis. J. Pharm. Exp. Ther. 386, 242–258 (2023).
487. Zhang ZT Trilobatin alleviates non-alcoholic fatty liver disease in high-fat diet plus streptozotocin-induced diabetic mice by suppressing NLRP3 inflammasome activation Eur. J. Pharm. 2022 933 175291 10.1016/j.ejphar.2022.175291
Zhang, Z. T. et al. Trilobatin alleviates non-alcoholic fatty liver disease in high-fat diet plus streptozotocin-induced diabetic mice by suppressing NLRP3 inflammasome activation. Eur. J. Pharm. 933, 175291 (2022).
488. Wan Y Ursolic acid alleviates Kupffer cells pyroptosis in liver fibrosis by the NOX2/NLRP3 inflammasome signaling pathway Int Immunopharmacol. 2022 113 109321 10.1016/j.intimp.2022.109321 36252479
Wan, Y. et al. Ursolic acid alleviates Kupffer cells pyroptosis in liver fibrosis by the NOX2/NLRP3 inflammasome signaling pathway. Int Immunopharmacol. 113, 109321 (2022).36252479
489. Shiffman M Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease Aliment Pharm. Ther. 2019 49 64 73 10.1111/apt.15030
Shiffman, M. et al. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharm. Ther. 49, 64–73 (2019).
490. Wang Q A bioorthogonal system reveals antitumour immune function of pyroptosis Nature 2020 579 421 426 10.1038/s41586-020-2079-1 32188939
Wang, Q. et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature 579, 421–426 (2020).32188939
491. Yang L Intraepithelial mast cells drive gasdermin C-mediated type 2 immunity Immunity 2024 57 1056 1070.e1055 10.1016/j.immuni.2024.03.017 38614091
Yang, L. et al. Intraepithelial mast cells drive gasdermin C-mediated type 2 immunity. Immunity 57, 1056–1070.e1055 (2024).38614091
492. Wree A NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice Hepatology 2014 59 898 910 10.1002/hep.26592 23813842
Wree, A. et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 59, 898–910 (2014).23813842
493. Wu LM Atorvastatin inhibits pyroptosis through the lncRNA NEXN-AS1/NEXN pathway in human vascular endothelial cells Atherosclerosis 2020 293 26 34 10.1016/j.atherosclerosis.2019.11.033 31830726
Wu, L. M. et al. Atorvastatin inhibits pyroptosis through the lncRNA NEXN-AS1/NEXN pathway in human vascular endothelial cells. Atherosclerosis 293, 26–34 (2020).31830726
494. Ran, L. et al. UK5099 Inhibits the NLRP3 Inflammasome Independently of its Long-Established Target Mitochondrial Pyruvate Carrier. Adv Sci (Weinh), 11, e2307224 (2024).
495. Rathkey JK Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis Sci. Immunol. 2018 3 eaat2738 10.1126/sciimmunol.aat2738 30143556
Rathkey, J. K. et al. Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. Sci. Immunol. 3, eaat2738 (2018).30143556
496. Li Y Cleavage-independent activation of ancient eukaryotic gasdermins and structural mechanisms Science 2024 384 adm9190 10.1126/science.adm9190 38662913
Li, Y. et al. Cleavage-independent activation of ancient eukaryotic gasdermins and structural mechanisms. Science 384, adm9190 (2024).38662913
497. Roshanravan N Effects of oral butyrate and inulin supplementation on inflammation-induced pyroptosis pathway in type 2 diabetes: A randomized, double-blind, placebo-controlled trial Cytokine 2020 131 155101 10.1016/j.cyto.2020.155101 32315958
Roshanravan, N. et al. Effects of oral butyrate and inulin supplementation on inflammation-induced pyroptosis pathway in type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Cytokine 131, 155101 (2020).32315958
498. Faghfouri AH Regulation of NLRP3 inflammasome by zinc supplementation in Behçet’s disease patients: A double-blind, randomized placebo-controlled clinical trial Int Immunopharmacol. 2022 109 108825 10.1016/j.intimp.2022.108825 35561480
Faghfouri, A. H. et al. Regulation of NLRP3 inflammasome by zinc supplementation in Behçet’s disease patients: A double-blind, randomized placebo-controlled clinical trial. Int Immunopharmacol. 109, 108825 (2022).35561480
499. Klück V Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial Lancet Rheumatol. 2020 2 e270 e280 10.1016/S2665-9913(20)30065-5 33005902
Klück, V. et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2, e270–e280 (2020).33005902
500. Zhang Z Structural basis for thioredoxin-mediated suppression of NLRP1 inflammasome Nature 2023 622 188 194 10.1038/s41586-023-06532-4 37704723
Zhang, Z. et al. Structural basis for thioredoxin-mediated suppression of NLRP1 inflammasome. Nature 622, 188–194 (2023).37704723
501. Hochheiser IV Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3 Nature 2022 604 184 189 10.1038/s41586-022-04467-w 35114687
Hochheiser, I. V. et al. Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. Nature 604, 184–189 (2022).35114687
502. Xia S Gasdermin D pore structure reveals preferential release of mature interleukin-1 Nature 2021 593 607 611 10.1038/s41586-021-03478-3 33883744
Xia, S. et al. Gasdermin D pore structure reveals preferential release of mature interleukin-1. Nature 593, 607–611 (2021).33883744
503. Yan HHN Chan AS Lai FP Leung SY Organoid cultures for cancer modeling Cell Stem Cell 2023 30 917 937 10.1016/j.stem.2023.05.012 37315564
Yan, H. H. N., Chan, A. S., Lai, F. P. & Leung, S. Y. Organoid cultures for cancer modeling. Cell Stem Cell 30, 917–937 (2023).37315564
504. Zhou H NLRP3 Inflammasome Mediates Silica-induced Lung Epithelial Injury and Aberrant Regeneration in Lung Stem/Progenitor Cell-derived Organotypic Models Int J. Biol. Sci. 2023 19 1875 1893 10.7150/ijbs.80605 37063430
Zhou, H. et al. NLRP3 Inflammasome Mediates Silica-induced Lung Epithelial Injury and Aberrant Regeneration in Lung Stem/Progenitor Cell-derived Organotypic Models. Int J. Biol. Sci. 19, 1875–1893 (2023).37063430
505. Gao R The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction Int Immunopharmacol. 2019 74 105575 10.1016/j.intimp.2019.04.022 31299609
Gao, R. et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. Int Immunopharmacol. 74, 105575 (2019).31299609
506. van Hout GP The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction Eur. Heart J. 2017 38 828 836 27432019
van Hout, G. P. et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur. Heart J. 38, 828–836 (2017).27432019
